The shortest conclusion
Even ifthe connectome and cell type are known, the long-term dynamics are not yet determined. Current primary literature shows relatively consistently that at least nineteen types of maintenance-states remain. First, even within the same transcriptomic type, the morpho-electric phenotype and ion-channel expression vary widely, and AIS geometry and Na+ channel distribution can vary over a span of hours to days. Second, activity-dependent transcription, chromatin accessibility, and epigenetic state change which neurons are eligible for allocation, which late gene programs stabilize memory, and which plastic transitions remain available over hours to weeks. Third, post-transcriptional RNA-state changes which splice isoform, m6A-dependent translation / degradation route, and RNA-editing ratio operate on the same graph even when gene-level abundance looks similar. Fourth, phospho-signaling / second-messenger state changes which phosphosite, kinase/phosphatase balance, and signaling nanodomain are currently operative even when transcript and bulk protein abundance look similar. Fifth, neural circuits homeostatically adjust their firing rate and synaptic strength, not only maintaining current activity but also having a set point of where to return. Sixth, sleep/wake cycles create a temporal division of labor between synaptic scaling and firing-rate homeostasis. Seventh, sleep architecture and replay-coupling state determine whether slow oscillations, spindles, ripples, and consolidation-permissive NREM windows align strongly enough for reactivation and stabilization. Eighth, the myelin sheath and oligodendrocyte connections are involved not only in timing but also in axonal support. Ninth, local proteostasis and synaptic-tagging state determine which recently potentiated spines or dendritic branches capture plasticity-related proteins, how translation/degradation/autophagy remain balanced, and which late changes survive molecular turnover. Tenth, perisynaptic extracellular matrix / perineuronal-net state changes which plastic transitions, receptor-diffusion regimes, and stabilization paths remain available on the same graph. Eleventh, ionic milieu / chloride homeostasis changes inhibitory polarity, local gain, and state-transition dynamics through chloride set point, transporter state, and interstitial ion composition. Twelfth, thermal-state changes membrane kinetics, field-potential amplitude, and sequence timing even without rewiring. Thirteenth, neuromodulatory specificity changes which transmitter-linked gain regime, receptor-family occupancy context, and challenge-limited release route are actually operating even on the same structural scaffold. Fourteenth, local ATP supply, mitochondrial parking position, fission/fusion, and redox reserve constrain synaptic vesicle recycling, dendritic plasticity, and local translation. Fifteenth, cargo-transport / cytoskeletal trafficking state determines which receptors, endosomes, RNA cargoes, mitochondria, and presynaptic components actually reach the relevant branch, spine, or bouton on the required timescale. Sixteenth, neurovascular-unit / BBB / pericyte state determines which capillaries dilate, which endothelial/pericyte barrier and transport regime is active, and whether local plasticity unfolds under the same metabolic / barrier support conditions. Seventeenth, glial metabolism / substrate routing determines which fuel class, supplier cell, and transport route support the neuron under long-term-memory, starvation, intensive-learning, or glucose-limited regimes. Eighteenth, astrocyte ensemble / network state determines whether glia encode local transmitter context, participate in recall, stabilize memory across days, or reorganize fear-state representations. Nineteenth, clearance/immune support including meningeal lymphatic drainage, CSF-interstitial exchange, and microglia support synaptic physiology and multiday recovery. Therefore, this site treats the reconsolidation mechanism, including relative excitability, activity-dependent transcription / chromatin state, post-transcriptional RNA-state, phospho-signaling / second-messenger state, AIS / channel state, homeostatic set point, sleep-dependent renormalization, sleep architecture / replay-coupling state, myelin support, local proteostasis / synaptic-tagging state, cargo-transport / cytoskeletal trafficking state, perisynaptic ECM / PNN state, thermal-state, ionic milieu / chloride homeostasis, neuromodulation, bioenergetic / mitochondrial state, neurovascular-unit / BBB / pericyte state, glial metabolism / substrate routing, astrocyte ensemble, and clearance / immune support, as hidden states that remain outside the connectome.
Philosophy, legal systems, and copying issues are not discussed here. It addresses why wiring diagrams, cell types, and short-term activity matching alone are still an underspecification when reading WBE and long-term BCI.
19 maintenance-states to fix first
| maintenance-state | What's missing | Dangerous misreading | Currently handling |
|---|---|---|---|
| Intrinsic excitability / AIS / ion-channel configuration | Response laws of the cell to input, such as threshold, gain, afterhyperpolarization, burstiness, rebound, AIS length/position, and Na+ channel distribution. | If you have a cell-type label or a short activity record, you can almost determine the same input-output rules. | Leave as latent state unless accompanied by morpho-electric or patch/perturbation. |
| Activity-dependent transcription / chromatin / epigenetic state | Which neurons are primed for allocation, which late-response programs stabilize memory, which locus-specific plasticity rules are open over hours to weeks, and whether the measured object was accessibility, histone chemistry, DNA-methylation control, higher-order looping, or locus-specific editing rather than one generic epigenetic row. | If there is a cell-type atlas, a one-shot DEG list, or one epigenetic assay, the current plasticity-competent program is almost fixed too. | Treat static transcriptomic labels or single-object epigenetic assays as identity / object priors only; leave memory-stabilization programs as latent unless a time-stamped or causal route is shown. |
| Post-transcriptional RNA-state | Which splice isoform, m6A-dependent translation / degradation route, and RNA-editing ratio are currently operating in the relevant cells and compartments. | If gene-level transcript abundance looks similar, isoform choice, m6A-reader engagement, and RNA-editing state are almost fixed too. | Treat gene-level abundance as insufficient; keep isoform / m6A / editing controller explicit as latent unless directly measured, causally perturbed, or externally calibrated. |
| Phospho-signaling / second-messenger state | Which phosphosite occupancy pattern, kinase/phosphatase balance, and compartment-specific second-messenger nanodomain are currently operating in the relevant cells and compartments. | If transcript or bulk protein abundance looks similar, the active phospho-controller is almost fixed too. | Treat transcript / protein abundance as insufficient; keep phospho-signaling explicit as latent unless directly measured, causally perturbed, or externally calibrated. |
| Firing rate set point / recovery controller | Where the circuit returns after perturbation, with what time constant, and which compensatory path to use. | If the current average firing rates are similar, then the maintenance mechanism is also the same. | Longitudinal claims will be demoted if there is no fixed-model degradation and recovery log or set point indicator. |
| Renormalization of sleep / wake dependencies | When synaptic modeling, phosphoproteome, and network regimes are reset and accumulated. | If the activities during wakefulness and same-day decoding are similar, then the maintenance mechanism for the next day is also the same. | If sleep state or overnight recovery is lacking, cross-day stability is limited. |
| Sleep architecture / replay-coupling state | Whether slow oscillations, spindles, ripples, and consolidation-permissive NREM windows align strongly enough for replay and long-term stabilization. | If a night of sleep occurred, or a cue was delivered during sleep, then the consolidation mechanism was also already matched. | If architecture, event definition, or replay-coupling is unmeasured, overnight retention or TMR gain remains different from replay-consistent maintenance. |
| Myelin / oligodendrocyte support | Changes in conduction velocity, activity-dependent myelination, and axonal metabolic support. | If you set delay as a constant, timing and energy support are sufficient. | The absence of myelin/oligodendroglial state weakens timing-sensitive claims and long-term recovery claims. |
| Perisynaptic ECM / PNN state | Plasticity windows, receptor mobility, inhibitory stabilization, and resistance to memory erasure on the same local circuit. | If you know synapse count or weight, then the update rule and stabilization gate are basically fixed too. | If ECM / PNN state is unmeasured, adult plasticity and stabilization claims remain limited and should be written as latent state. |
| Ionic milieu / chloride homeostasis | Local chloride set point, KCC2/NKCC1 transporter state, extracellular K+ / Ca2+ / pH composition, and the sign / gain of inhibition on the same circuit. | If the graph, cell type, and nominal weights are similar, then inhibitory polarity, network state, and rhythm stability are also almost fixed. | If ionic / chloride state is unmeasured, perturbed, or externally calibrated, inhibitory sign, state-transition, and rhythm-stability claims remain limited and should be written as latent state. |
| thermal-state / tissue operating temperature | Regional tissue temperature, local heating burden, and temperature-dependent operating point that shape membrane kinetics, field-potential amplitude, and sequence timing. | If the graph, cell type, and delay proxy are the same, then temperature can be treated as a fixed background constant. | If thermal-state is unmeasured, externally calibrated, or left latent, field-potential amplitude, membrane-kinetic, and timing-sensitive claims remain limited. |
| Neuromodulatory specificity / transmitter context | Which transmitter-linked covariate, local transmitter signal, receptor-family prior, ligand occupancy state, or challenge-limited release proxy is actually operating in the named region and time window. | If the graph, cell type, and behavior regime are similar, then neuromodulatory gain, receptor occupancy context, and transmitter-specific routing are also almost fixed. | If neuromodulatory route is unmeasured, causally perturbed only indirectly, or left latent, transmitter-specific gain, occupancy, and release claims remain limited and should be written as latent or proxy-bounded. |
| bioenergetic / mitochondrial state | Local ATP supply, mitochondrial parking position, fission/fusion, ATP synthase relocation, and redox reserve. | If you look only at glial substrate-routing or macro metabolic support, you can wrongly read it as if it already represented the local energy constraints of neurons. | If there is no bioenergetic/mitochondrial state, reliability during repeated stimulation, dendritic plasticity, and energetic mechanism of local translation will remain as a latent state. |
| Cargo-transport / cytoskeletal trafficking state | Which receptors, endosomes, RNA granules, mitochondria, and presynaptic cargoes are delivered, paused, retained, or docked at the relevant branch, spine, or bouton. | If local translation or ATP support is known, then delivery to the correct compartment is also almost implied. | If cargo-delivery route is unmeasured, perturbed, or externally calibrated, compartment-specific stabilization, synaptogenesis, and branch-level maintenance remain latent. |
| Neurovascular-unit / BBB / pericyte state | Which capillaries dilate or constrict, which endothelial / pericyte barrier and transport regime is active, and whether local BBB permeability / transcytosis state currently supports or limits plasticity. | If vascular-state / CVR, resting perfusion, or one hemodynamic nuisance audit is known, then the underlying biological neurovascular controller is also basically fixed. | If neurovascular / BBB route is unmeasured, perturbed, or externally calibrated, local capillary support, barrier-state, and plasticity-support claims remain latent; human BBB routes are first read as macro permeability proxies. |
| Glial metabolism / substrate routing | Astrocyte-neuron lactate shuttle, glia-to-neuron ketone-body routing, glia-to-neuron fatty-acid transfer, and apoE / sortilin-dependent lipid delivery are distinct fuel-routing objects. | I read that if you track neuronal engrams, mitochondrial state, or one macro energetic proxy, you can almost determine the active glial fuel route too. | If you drop glial substrate-routing, limit the scope of plasticity, long-horizon fuel support, and memory-related maintenance claims. |
| clearance / immune support | Meningeal lymphatic drainage, CSF-interstitial transport, respiration- or sleep-conditioned CSF motion, tracer/model-based clearance variables, and microglia-linked synaptic support are distinct objects. | If one human glymphatic paper exists, local immune control and multiday maintenance are basically observed too. | If clearance transport and immune-effector evidence are not separated, multiday recovery, protein-clearance, and local maintenance-controller claims remain overstated; current human rows are first read as transport-side proxies. |
| Local proteostasis / synaptic tagging under turnover | Which tagged spine or branch captures plasticity-related proteins, how local translation/degradation/autophagy remain balanced, and which late changes survive molecular turnover. | If current weight or transcriptomic program is known, the late-stabilization route is basically fixed too. | If the tag/capture/proteostasis route is unmeasured, late stabilization and reconsolidation claims remain latent. |
Why cell type and short-term activity matching alone are not enough
1. Transcriptomic type does not completely fix morpho-electric phenotype
Gouwens et al. (2021) showed that transcriptomic cell types in the mouse motor cortex still vary continuously within morpho-electric space. This means that even if the cell-type label is known, the electrophysiological parameters are not uniquely determined. Furthermore, Schulz et al. (2006) showed that identified neurons can preserve function despite large differences in ion-channel mRNA and current levels. Therefore, even if cell-type labels are overlaid on the connectome, threshold and gain layers still remain separate variables.
2. Activity-dependent transcription / chromatin state is not the same as cell identity
The weak point that became clearer in this pass was that the site had become good at separating cell identity from intrinsic excitability, while still leaving the current transcriptional / chromatin program that makes memory allocation and stabilization possible too close to the cell-type bucket. That is too coarse. Santoni et al. (2024) showed that chromatin plasticity predetermines neuronal eligibility for memory-trace formation, Traunmüller et al. (2025) showed that novel-environment exposure drives temporally defined and region-specific chromatin-accessibility and gene-expression changes in hippocampus, Terceros et al. (2026) showed distinct thalamocortical transcriptional gates together with time-dependent causal requirements for memory stabilization over days to weeks, and Coda et al. (2025) showed that cell-type- and locus-specific epigenetic editing can bidirectionally regulate memory expression. Therefore, even if the connectome and the cell-type label are fixed, the current plasticity-competent transcriptional program and stabilization controller can still differ over hours to weeks.
Sun et al. (2024) provided a strong spatial-transcriptomic clue for long-term memory, but Mukamel & Yu (2025) argued that some memory-related DEG claims are sensitive to animal-level dependence correction, and Sun et al. (2025) replied that the analysis target differs. Therefore, on this site, a memory-related transcriptomic signature is treated as time-stamped clue / hypothesis-generating evidence unless temporal calibration, locus specificity, or causal perturbation is also shown.
The next correction sits inside the route itself. Traunmüller et al. (2025) is an accessibility-plus-expression map, Guan et al. (2009) is a histone-acetylation / HDAC control route, Gulmez Karaca et al. (2020) is an engram-specific DNA-methylation stabilization route, Bharadwaj et al. (2014) is a higher-order looping route, and Coda et al. (2025) is a locus-specific editing route. These papers do not share one direct observable, one persistence timescale, or one causal move. Therefore, on this site, saying only epigenetic evidence exists is still too coarse unless the molecular object itself is named.
The remaining weakness was that the site still let at least four different inferential objects collapse into one label such as "memory transcriptomics". The primary literature does not support that shortcut. Santoni et al. (2024) is about allocation eligibility, Traunmüller et al. (2025) is a time-resolved response map, Terceros et al. (2026) is a persistent stabilization cascade with time-dependent causal perturbation, and Coda et al. (2025) is locus-specific causal editability in a defined circuit. Sun et al. (2024) further showed that transcriptomic signatures can persist for weeks in a defined fear-memory paradigm, while Mukamel & Yu (2025), Sun et al. (2025), and Zimmerman et al. (2021) show why the experimental unit and DEG statistics can materially change what survives as evidence. Therefore, on this site, we now require a transcription / chromatin route card before a claim is promoted beyond a time-stamped clue.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the result supports allocation eligibility, acute/post-learning time course, persistent stabilization program, or locus-specific causal editability. | Different inferential objects collapse into one label such as memory transcriptomics. |
| Biological regime | Name species, sex, brain region / circuit, learning task, recall/reactivation state, and whether the design is observational or perturbational. | Evidence from one region and one task is silently promoted to a generic memory controller. |
| Time axis | Write baseline and every post-learning / post-recall sampling window, and state whether the assay is destructive cross-sectional sampling rather than longitudinal readout in the same cells. | An acute signature is overread as a persistent controller or a long-term trace. |
| Assay and direct observable | Name bulk RNA-seq, sc/snRNA-seq, sc/snATAC, spatial transcriptomics, ChIP-seq, or editing route, plus whether the direct observable is transcript abundance, chromatin accessibility, histone mark, or perturbation response. | Cell identity, current transcription, chromatin openness, and causal control are treated as if they were the same measurement. |
| Molecular object / persistence mode | Name whether the paper directly constrained chromatin accessibility, histone-acetylation / histone-methylation state, DNA-methylation program, higher-order looping / topology, or locus-specific editing, and state whether the claimed persistence is acute, hours-to-days, or weeks-long. | Epigenetic evidence becomes a catch-all label, and accessibility, chemical marks, methylome rewrites, and loop topology are overread as interchangeable proofs of the same controller. |
| Experimental unit / dependence control | Report animal-level n, batch structure, whether cells from the same animal were treated as subsamples, and how pseudoreplication or animal-level dependence was handled. | False-positive differential signals can be mistaken for memory-specific programs. |
| Causal leverage | Write whether the paper only observed a signature, perturbed regulators, or edited a named locus, and which behavioral phase was affected. | Observational signatures are promoted to necessary or sufficient mechanisms. |
| Abstention boundary | Fix in one line which state variables remain latent, especially same-subject in vivo continuity, whole-brain coverage, and non-destructive time-resolved readout. | A destructive, region-bounded assay is overread as current whole-brain state identification. |
Current human routes on this site do not provide a comparable in vivo whole-brain readout of current chromatin accessibility, histone-mark state, DNA-methylation program, or higher-order chromatin topology. The strongest cited routes remain mouse in vivo allocation or stabilization work, destructive single-nucleus multiomics, postmortem tissue, or locus-specific perturbations in defined circuits such as Santoni et al. (2024), Traunmüller et al. (2025), Bharadwaj et al. (2014), Coda et al. (2025), and Terceros et al. (2026). Therefore, on this site, transcription / chromatin state remains a local hidden state in living humans unless it is externally calibrated or causally perturbed in a narrower preparation.
3. Post-transcriptional RNA-state is not the same as gene-level transcript abundance
The remaining weakness after separating cell identity from current transcription / chromatin state was that the site still left post-transcriptional RNA-state too close to gene-level transcript abundance. That was too coarse. Wang et al. (2015) showed that a neuron-specific LSD1 splice isoform regulates memory formation, Dai et al. (2019) showed that presynaptic neurexin alternative splicing changes postsynaptic receptor balance and contextual memory, Shi et al. (2018) showed that the m6A reader YTHDF1 facilitates hippocampus-dependent learning and memory, Li et al. (2025) showed that inhibiting YTHDF2-mediated m6A mRNA degradation enhances protein synthesis and memory, and Peterson et al. (2025) showed that ADAR2-mediated GluA2 RNA editing contributes to homeostatic synaptic plasticity. Therefore, even if the connectome, cell-type label, and gene-level abundance are similar, the operative RNA-state that helps set receptor composition, plasticity route, and memory-relevant stabilization can still differ.
Current human in vivo routes on this site do not directly reveal isoform choice, m6A-reader engagement, or RNA-editing ratio across the whole living brain. Specialized long-read atlas work such as Joglekar et al. (2024) is important evidence that brain splicing programs are rich and cell-type-specific, but it is still an atlas-building / ex vivo observability route rather than a comparable in vivo whole-brain human measurement. Therefore, on this site, post-transcriptional RNA-state remains a local hidden state in humans unless it is externally calibrated or causally perturbed in a narrower preparation.
The remaining weakness on this page was that it still let several different inferential objects collapse into one label such as post-transcriptional RNA evidence. The primary literature does not support that shortcut. Wang et al. (2015) is about an alternative-splice isoform that changes downstream chromatin / transcriptional control, Dai et al. (2019) is about presynaptic alternative splicing that shifts postsynaptic NMDA versus AMPA receptor balance, Shi et al. (2018) is about neuronal-stimulus-dependent m6A translation through YTHDF1, Li et al. (2025) is about YTHDF2-mediated m6A degradation constraining protein synthesis and memory, Peterson et al. (2025) is about ADAR2-mediated RNA editing controlling homeostatic AMPAR composition, and Joglekar et al. (2024) is an isoform atlas / observability-ceiling route. Therefore, this site now requires a post-transcriptional RNA route card before a claim is promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the result supports alternative-splice controller logic, m6A-dependent translation, m6A-dependent degradation / stabilization, RNA-editing controller logic, or an atlas / observability map. | Mechanistically different papers collapse into one vague label such as RNA-state evidence. |
| RNA control axis | Name the actual RNA-side controller: splice isoform / exon choice, m6A writer / eraser / reader route, editing enzyme and edited site, or long-read isoform survey axis. | The word post-transcriptional hides whether the paper is really about recoding, translation, degradation, or isoform allocation. |
| Biological regime | Name species, sex, brain region / circuit, cell class, developmental stage, behavioral phase, and whether the preparation is culture, slice, awake animal, fixed tissue, or human ex vivo sample. | A local route in one circuit or age window is silently promoted to a generic brain-wide memory controller. |
| Time axis / state dependence | Write baseline and every post-learning / post-stimulation / post-recall window, and state whether the assay is an endpoint snapshot or a repeated readout across the relevant state change. | An acute RNA response is overread as a persistent maintenance controller or a long-term trace. |
| Assay and direct observable | Name the direct RNA observable explicitly, such as isoform ratio, exon inclusion, m6A-marked transcript binding / occupancy, editing fraction, or isoform-resolved long-read map, and separate it from downstream electrophysiology or behavior. | Gene-level abundance, bulk RNA summaries, and downstream physiology are treated as if they directly measured the operative RNA-state. |
| Downstream functional object | State whether the RNA route is claimed to alter chromatin / transcriptional control, receptor composition, protein synthesis, mRNA decay, homeostatic scaling, or only an observability ceiling. | Hybrid papers such as splice-dependent chromatin control and editing-dependent receptor recoding are misread as if they fixed the same latent variable. |
| Causal leverage | Write whether the paper only observed an RNA pattern, perturbed the reader / writer / editor, edited a named site, rescued a knockout, or re-expressed a controller, and which physiological or behavioral output changed. | Correlated RNA signatures are promoted to necessary or sufficient controllers without intervention support. |
| Human observability ceiling | State whether the strongest human-facing evidence is an ex vivo long-read atlas, a targeted human tissue sample, or no human route at all, and do not blur that with living-human in vivo measurement. | Atlas-building or hippocampus-limited evidence is overread as current whole-brain human RNA-state identification. |
| Abstention boundary | Fix in one line which state variables remain latent, especially same-subject whole-brain continuity, compartment-specific RNA localization, live cell-type-specific readout, and non-destructive human coverage. | A local mechanistic paper or atlas is overread as if the current living-brain RNA controller were nearly solved. |
The need is multi-axis. Wang et al. (2015) is not just an RNA paper; it is an alternative-splice isoform whose downstream object is activity-dependent transcriptional elongation. Dai et al. (2019) is not about a generic memory trace either; it is about presynaptic neurexin splice choice differentially controlling postsynaptic receptor responses without synapse-density change. Shi et al. (2018) and Li et al. (2025) are both m6A papers, but one is about stimulus-dependent translation via YTHDF1 whereas the other is about mRNA degradation via YTHDF2. Peterson et al. (2025) is different again because it is about RNA editing of a named receptor subunit during homeostatic synaptic scaling. Finally, Joglekar et al. (2024) shows that isoform diversity varies strongly across cell type, region, development, and species, but that remains an atlas ceiling, not a living-human whole-brain readout. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for current human whole-brain RNA-state identification without a route-card audit.
4. Phospho-signaling / second-messenger state is not the same as transcript or protein abundance
The remaining weakness after separating post-transcriptional RNA-state from gene-level transcript abundance was that the site still left phospho-signaling / second-messenger state too close to transcriptomics, proteomics, or nominal weights. That was too coarse. Giese et al. (1998) showed that CaMKII Thr286 autophosphorylation is required for LTP and learning, Lee et al. (2003) showed that distinct AMPA-receptor phosphorylation sites regulate bidirectional synaptic plasticity, Havekes et al. (2016) showed that compartment-targeted PDE4A5 signaling can impair hippocampal LTP and long-term memory without a global cAMP claim, Vierra et al. (2023) showed that ER-plasma membrane junctions create Ca2+-activated PKA signaling nanodomains in neurons, Altas et al. (2024) showed that region-specific phosphorylation redirects neuroligin-3 localization between excitatory and inhibitory synapses in mouse and human brain samples, and Rodriguez et al. (2025) showed that a single HDAC3 phosphosite mutation bidirectionally modulates LTP and long-term memory in adult and aging mice. Therefore, even if the connectome, cell-type label, gene-level abundance, and bulk protein abundance are similar, the operative phospho-controller that helps set plasticity expression and memory-relevant signaling can still differ.
Current human in vivo routes on this site do not directly reveal phosphosite occupancy, kinase/phosphatase balance, or compartment-specific signaling nanodomains across the whole living brain. Ex vivo atlas work such as Biswas et al. (2023) is important evidence that the human brain phosphoproteome is region-structured, but it is still an atlas-building / ex vivo observability route rather than a comparable in vivo whole-brain human measurement. Therefore, on this site, phospho-signaling / second-messenger state remains a local hidden state in humans unless it is externally calibrated or causally perturbed in a narrower preparation.
The remaining weakness on this page was that it still let several different inferential objects collapse into one label such as phospho-signaling evidence. The primary literature does not support that shortcut. Lee et al. (2003) and Tomita et al. (2005) are about phosphosite-specific gating of bidirectional synaptic plasticity, Havekes et al. (2016) and Vierra et al. (2023) are about compartmentalized second-messenger routing, Altas et al. (2024) is region-specific phosphorylation with synapse-type relocalization in mouse and human samples, Rodriguez et al. (2025) is a single-site phospho-mutant causal memory intervention, and Biswas et al. (2023) is a human ex vivo phosphoproteome atlas. Therefore, this site now requires a phospho-signaling route card before a claim is promoted beyond a phosphosite clue, a local signalosome intervention, or a region-structured atlas readout.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the result supports phosphosite-specific plasticity gating, kinase/phosphatase controller logic, compartmentalized second-messenger routing, region-structured phosphoproteome atlas, or phospho-mutant causal intervention. | Endpoint phosphoproteomics, live signaling, and causal phosphosite edits collapse into one vague label such as phospho evidence. |
| Biological regime | Name species, sex, brain region / circuit, cell class, synapse class, behavioral phase, and whether the preparation is slice, culture, fixed tissue, awake animal, or human ex vivo sample. | Evidence from one preparation is silently promoted to a generic brain-wide phospho-controller. |
| Time axis | Write baseline and every post-learning / post-stimulation / post-recall sampling window, and state whether the assay is an endpoint snapshot or a time-resolved reporter. | An acute phosphosite change is overread as a persistent maintenance controller or vice versa. |
| Assay and direct observable | Name phospho-specific immunoblot / staining, phosphoproteomics, FRET or biosensor imaging, kinase / phosphatase manipulation, or phospho-mimic / phospho-null replacement, and write the direct observable explicitly. | Protein abundance, phosphosite occupancy, second-messenger concentration, and causal leverage are treated as if they were the same measurement. |
| Spatial / compartment scope | Specify whether the result resolves tissue region, cell type, synapse class, dendritic compartment, ER-plasma membrane junction, or another nanodomain / signalosome anchor. | A region-level atlas is overread as if it fixed the operative local signaling nanodomain in the relevant cells. |
| Causal leverage | Write whether the paper only observed a phospho pattern, perturbed a kinase / phosphatase pathway, or used a named phospho-mutant or targeted localization intervention, and which physiological or behavioral output changed. | Correlated phosphosite changes are promoted to necessary or sufficient controllers without intervention support. |
| Abstention boundary | Fix in one line which state variables remain latent, especially same-subject whole-brain in vivo continuity, phosphatase balance outside the assayed compartment, and human live-readout availability. | Region-bounded or ex vivo evidence is overread as current whole-brain phospho-state identification. |
5. Sometimes what is maintained is not the “current value” but the “return destination”
Turrigiano et al. (1998) showed that neocortical neurons bidirectionally scale quantal amplitude in response to chronic activity blockade or increase. Furthermore, O'Leary et al. (2014) showed that the relationship among activity set point, cell type, and compensation can be explained with a simple biophysical model of activity-dependent ion-channel expression. Hengen et al. (2016) showed that individual neurons return to a precise firing-rate set point in vivo. What matters here is that not only the activity value as a snapshot, but also the controller state that determines where the system returns after perturbation, remains a separate variable.
6. Intrinsic excitability is not one line item: allocation, AIS state, and recovery control separate
The weakness that needed deeper treatment here was that if we write intrinsic excitability as one latent state, memory allocation by relative excitability, gain adjustment by AIS geometry / Na+ channel distribution, and homeostatic recovery control start to look like one evidence layer. They are not. Grubb & Burrone (2010) showed activity-dependent AIS relocation, Kuba et al. (2010) showed presynaptic-activity-dependent regulation of AIS Na+ channel distribution, Jamann et al. (2021) showed rapid homeostatic AIS scaling in mouse barrel cortex, Fréal et al. (2023) showed that sodium-channel endocytosis drives AIS plasticity, and Benoit et al. (2025) showed AIS dynamics during associative fear learning. Therefore, even if the same connectome and the same cell type are known, threshold, gain, spike-initiation rules, and recovery behavior over hours to days can still remain latent.
When reading input-output rules for WBE or long-term BCI, do not collapse intrinsic excitability into one number or one “missing variable.” Relative excitability for allocation, AIS / channel state, and homeostatic recovery control should be audited separately, or at least given separate abstention reasons.
The remaining weakness on this page was that intrinsic-excitability evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Yiu et al. (2014) and Hadzibegovic et al. (2025) are about allocation / early engram-excitability routes. Grubb & Burrone (2010), Kuba et al. (2010), Jamann et al. (2021), Fréal et al. (2023), and Benoit et al. (2025) are about AIS / ion-channel-state routes. O'Leary et al. (2014) and Hengen et al. (2016) are about homeostatic set-point / recovery-control routes. Tallman et al. (2025) adds a human hippocampal single-unit allocation-linked route in epilepsy patients, while Huber et al. (2013), Kuhn et al. (2016), Khatri et al. (2025), Zrenner et al. (2018), and Fehér et al. (2026) remain noninvasive living-human perturbation-conditioned proxy routes. Therefore, this site now requires an intrinsic excitability / homeostatic-set-point route card before a claim is promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about allocation / engram-selection bias, AIS / ion-channel-state plasticity, homeostatic set-point / recovery control, or a living-human perturbation-conditioned proxy. | Different inferential objects collapse into one phrase such as excitability evidence supports memory and stability. |
| Physiological locus | Name the cell class, region, and structural or assay locus actually constrained: for example engram neurons, AIS geometry / Na+ channel distribution, population firing-rate return, or TMS-evoked / PAS-conditioned human cortex. | A local controller or cell-class-specific rule is silently promoted to a generic whole-brain excitability readout. |
| Direct observable | Write whether the paper directly measures spike threshold / gain, AIS position / length, channel distribution, firing-rate return trajectory, plasticity efficacy, or only a perturbation-conditioned behavioral / electrophysiological outcome. | A proxy for response to perturbation is overread as direct measurement of the responsible controller. |
| Time axis / intervention window | Fix whether the claim concerns pre-learning allocation, minutes-to-hours AIS reconfiguration, hours-to-days homeostatic recovery, or a momentary wake / sleep / EEG-state-gated assay window. | Fast permissive changes, slow return dynamics, and transient assay-state dependence are treated as one timescale. |
| Human evidence class / proxy class | When human evidence is cited, state whether it is a clinical single-unit / local allocation route, a sleep-history recalibration proxy, a state-gated perturbation proxy, or another bounded assay, and say which controller remains latent. | Human local-unit evidence and living-human perturbation-conditioned evidence are silently promoted to one interchangeable route and then overread as direct AIS / channel or cell-specific recovery-controller readout. |
| Abstention boundary | Fix in one line what remains latent, especially cell-specific controller identity, branch- or ensemble-specific allocation rules, whole-brain in vivo AIS / channel readout, and cross-species bridge assumptions. | The paper is overread as if current intrinsic-excitability state had been directly identified in a living human brain. |
Benoit et al. (2025) showed that AIS structure itself changes during associative fear learning, while Hadzibegovic et al. (2025) showed that early intrinsic-excitability plasticity in neocortical engram neurons regulates later memory formation and precision. Hengen et al. (2016) then showed that firing-rate homeostasis depends on sleep/wake regime rather than being a single static property. On the human side, Tallman et al. (2025) showed that remembered episodic memories in the hippocampus are associated with sparse codes when encoding involved a relative increase in firing, but also stated that firing is only an indirect index of excitability. Khatri et al. (2025) and Zrenner et al. (2018) showed in humans that EEG-defined or personalized brain states modulate TMS outcomes, but their direct observables remain bounded corticospinal or plasticity-assay responses. Therefore, the word excitability does not yet tell us whether the paper constrained allocation bias, AIS microstructure, recovery control, a local human clinical-unit route, or only a perturbation-conditioned human proxy.
7. sleep / wake cycles rewire synapse and network regimes
The weakness of the current site was that it focused maintenance-state too much on excitability and molecular turnover, while underemphasizing that sleep supplies the time axis of renormalization itself. Torrado Pacheco et al. (2021) showed that firing rates elevated during wake return toward downward homeostasis during sleep. de Vivo et al. (2017) showed ultrastructural synaptic scaling across the wake/sleep cycle, Diering et al. (2017) showed Homer1a-dependent excitatory-synapse scaling-down during sleep, Noya et al. (2019) showed that the forebrain synaptic proteome is driven by sleep, Xu et al. (2024) showed that sleep restores a better cortical computational regime, and Koukaroudi et al. (2024) showed that sleep deprivation reduces excitatory-synapse diversity in cortex and hippocampus. Therefore, same-day activity matching cannot be read as maintenance-state matching. Without sleep history, overnight recovery logs, and any explicit account of sleep architecture, next-day stability and post-learning re-equilibration remain separate questions.
Ngo et al. (2013) showed in humans that slow-oscillation stimulation only improves memory when phase-locked to the right part of the ongoing rhythm, Maingret et al. (2016) showed in rats that timed coupling of hippocampal ripples to cortical delta/spindle events boosts next-day memory, and Latchoumane et al. (2017) showed in mice that in-phase spindle induction promotes hippocampus-dependent memory whereas out-of-phase manipulation does not. On the human side, Whitmore et al. (2022) showed that TMR benefit depends on ample and undisturbed N3 sleep, Baxter et al. (2023) showed that strong oscillatory effects can coexist with no additional memory gain when stimulation disrupts sleep, Schreiner et al. (2021) showed that endogenous reactivation is clocked by SO-spindle complexes, Schreiner et al. (2023) showed that respiration-linked SO-spindle coupling is related to reactivation strength, Geva-Sagiv et al. (2023) showed that enhancing hippocampal-prefrontal synchrony during sleep improves memory, Schreiner et al. (2024) linked spindle-locked ripples to human memory reactivation, Whitmore et al. (2024) showed that sleep-disruption effects differ for week-old versus recently formed memories, and Deng et al. (2025) showed that even within NREM the consolidation window is time-structured. Therefore, on this site, sleep duration/history and sleep architecture / replay-coupling are treated as separate maintenance-state variables, and even inside sleep architecture the site now separates sleep continuity, physiology gating, and memory-age dependence.
The remaining weakness on this page was that it still let several different inferential objects collapse into one label such as sleep replay evidence. The primary literature does not support that shortcut. Ngo et al. (2013) is a phase-locked auditory intervention in healthy humans, Baxter et al. (2023) is a sleep-integrity boundary because oscillatory gains did not become extra memory gain, Whitmore et al. (2022) is an undisturbed-N3 boundary, Schreiner et al. (2021) is endogenous scalp-EEG decoding around aggregated SO-spindle events, Schreiner et al. (2023) is a respiration-linked physiology gate, Geva-Sagiv et al. (2023) is an intracranial closed-loop synchrony intervention, Schreiner et al. (2024) is human ripple-linked iEEG evidence, Whitmore et al. (2024) shows a memory-age dependence of sleep-disruption effects, Duan et al. (2025) shows item-level strengthening versus decay under TMR, Shin et al. (2025) shows difficulty-selective benefit under personalized TMR, and Deng et al. (2025) shows a time-structured intracellular NREM window. Therefore, this site now requires a sleep replay route card before overnight retention, oscillation gain, TMR benefit, or ripple-linked evidence is promoted beyond a stage-, continuity-, physiology-, or memory-subset-conditioned claim.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family / memory target | State whether the paper supports endogenous reactivation, cue-driven strengthening, closed-loop synchrony intervention, item-selective preservation / decay, challenging-memory rescue, or a cellular timing window. | Different inferential objects collapse into one phrase such as sleep replay supports memory. |
| Preparation / spatial access | Name healthy-human scalp EEG, human intracranial EEG / DBS, rodent LFP / optogenetics, or another preparation, plus the brain regions actually measured or stimulated. | Local or patient-specific evidence is silently promoted to generic whole-brain human mechanism evidence. |
| State and event definition | Write sleep stage, SO/spindle/ripple detector or coupling metric, whether the events were endogenous or cue-evoked, and any cue-free baseline or non-event comparison. | NREM sleep or sleep happened replaces the actual oscillatory regime that the claim depends on. |
| Timing / control policy | Report phase target, cue spacing or dose policy, mixed-phase / sham / off-window controls, refractory-period handling, and the exact time window in which the effect is claimed. | A cue delivered during sleep is overread as phase-specific or mechanism-specific causal evidence. |
| Sleep-integrity / disturbance burden | Report arousal markers, cue-evoked awakenings or stage transitions, spindle suppression when relevant, sound-calibration policy, and any cue-free or disturbance-matched comparison. | A successful cue or oscillation change is overread as if the intervention left the sleep process intact. |
| NREM substate / physiology gate | Name whether the claim depends only on a stage label or on an additional physiology gate such as respiration-linked coupling, ripple-linked windows, intracellular timing windows, or another named NREM substate marker. | N2 or N3 silently stands in for a finer physiological regime that the paper actually depended on. |
| Direct observable / analysis unit | Name whether the readout is oscillation gain, average retention, item-level strengthening versus decay, scalp decoding, ripple rate, hippocampal-cortical coupling, or another neural/behavioral observable. | Across-item variability and the difference between oscillation gain, aggregate score gain, and replay-specific evidence disappear. |
| Difficulty / prior-strength / memory-age regime | State whether the protocol targeted all items, cued subsets, weak memories, high-difficulty memories, recent memories, week-old memories, or another selection rule. | Selective benefits or disruption effects are silently promoted to uniform overnight consolidation across items and memory ages. |
| Abstention boundary | Fix in one line what remains latent, especially ripple ground truth in scalp EEG, patient-to-healthy generalization, item-level coverage, sleep-disruption dependence, and the difference between cue efficacy, oscillation gain, and endogenous mechanism. | Proxy-rich or intervention-rich results are promoted to complete replay-mechanism evidence. |
Baxter et al. (2023) showed that strong SO / spindle changes can coexist with no added motor-memory gain when sleep continuity is disturbed, Whitmore et al. (2022) showed that TMR benefit scales with uninterrupted N3 and falls with cue-related disruption, Schreiner et al. (2021) explicitly reported modest decoding levels, aggregation across SO-spindle events, and limited scalp access to ripples, Schreiner et al. (2023) showed that respiration-linked coupling is itself relevant to reactivation strength, Whitmore et al. (2024) showed that disruption does not carry the same consequence for week-old memories as for recent ones, Duan et al. (2025) showed that the same TMR session can produce both strengthening and decaying items with different coupling dynamics, and Shin et al. (2025) further showed that behavioral benefit and SW-spindle coupling can concentrate in the challenging-memory regime rather than appearing uniformly across all items. Therefore, on this site, average overnight improvement or a generic TMR sentence is not enough: the claim must disclose which event class, which sleep-integrity regime, which physiology gate, and which memory subset or age produced the reported effect.
8. Myelin and oligodendrocytes are timing and support variables
The earlier version mentioned delay and myelin, but still left myelin plasticity and oligodendrocyte support too close to a fixed delay constant. That was too coarse. Gibson et al. (2014) showed that neuronal activity promotes oligodendrogenesis and adaptive myelination, and McKenzie et al. (2014) showed that active central myelination is required for motor-skill learning. Seidl et al. (2015), Dutta et al. (2018), Cohen et al. (2020), Micheva et al. (2021), and Dubey et al. (2022) further show that node / internode geometry, periaxonal coupling, and PV-axon myelination can tune conduction timing and synchrony rather than acting like one fixed scalar delay. Xin et al. (2024) then showed that adolescent oligodendrogenesis can act as a functional brake on adult visual-cortex plasticity, while Della-Flora Nunes et al. (2025) showed that neuronal recovery after demyelination does not require complete restoration of healthy myelin levels. Together with Looser et al. (2024), these papers show that even with the same wiring and the same cell type, timing, synchrony, plasticity windows, and recoverability can still differ if the myelin / oligodendroglial state differs. A model that absorbs delay into a fixed constant must state explicitly which timing-sensitive, plasticity-sensitive, and recovery-sensitive behaviors are discarded in that approximation.
Human myelin MRI is also not one thing. Arshad et al. (2017) showed that myelin water fraction and calibrated T1w/T2w can both be reliable while T1w/T2w still has low criterion validity as a subcortical myelin index. Hagiwara et al. (2018) showed stronger white-matter agreement between SyMRI and MTsat than between either route and T1w/T2w. Baadsvik et al. (2024) then pushed myelin-bilayer mapping in vivo, but only in two healthy volunteers on high-performance hardware. Chen et al. (2025) showed that conventional quantitative MT remains orientation-dependent whereas MPF-SL kept head-orientation differences below 2% in vivo. Galbusera et al. (2025) then showed that qT1, but not MWF or MTR, separated demyelinated from remyelinated cortical lesions in a postmortem MRI design. Colaes et al. (2026) then showed that T1w/FLAIR has only weak associations with MWF and is safer to read as a broader tissue-health-sensitive ratio rather than a myelin-specific one. Therefore, this site reads current human myelin MRI as a quantity-defined proxy family rather than one generic myelin meter: inter-bilayer water, MT-family macromolecular contrast, bilayer-sensitive ultrashort-T2 contrast, qT1 remyelination sensitivity, and T1w/FLAIR tissue-health-sensitive ratios are not the same inferential object.
The remaining weakness on this page was that myelin evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Gibson et al. (2014) and McKenzie et al. (2014) are about activity-dependent oligodendrogenesis and learning. Seidl et al. (2015), Dutta et al. (2018), Cohen et al. (2020), Micheva et al. (2021), and Dubey et al. (2022) are about node / internode / periaxonal timing-state control. Xin et al. (2024) is about developmental myelination acting as a brake on adult plasticity. Della-Flora Nunes et al. (2025) is about how much remyelination is needed for functional recovery and explicitly shows that functional recovery does not require complete restoration of healthy myelin levels. On the human side, Arshad et al. (2017) showed that calibrated T1w/T2w should not be treated as interchangeable with MWF, Hagiwara et al. (2018) showed that SyMRI and MTsat align more strongly with one another than with T1w/T2w, Baadsvik et al. (2024) demonstrated a bilayer-sensitive proof-of-principle in two healthy volunteers, Chen et al. (2025) showed that orientation dependence is itself a route variable for conventional MT, Galbusera et al. (2025) showed that qT1 but not MWF or MTR tracked cortical remyelination in a histology-linked design, and Genc et al. (2025) still required external histopathological confirmation. Therefore, on this site, myelin / oligodendrocyte claims now require a route card before they are promoted beyond a local, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about activity-dependent oligodendrogenesis / learning, timing-state microgeometry, plasticity-brake function, remyelination-to-function recovery, or a human macro-proxy route. | Different inferential objects collapse into one phrase such as myelin evidence supports timing and learning. |
| Biological regime | Name species, developmental stage, healthy versus demyelinated or injured preparation, circuit / brain region, and whether the study is local, tract-scale, or whole-brain. | Adolescent visual-cortex plasticity, adult motor learning, demyelination recovery, and living-human MRI are silently promoted into one generic statement about brain-wide myelin function. |
| Direct observable / structural unit | Write whether the direct observable is new oligodendrocyte generation, myelin sheath / bilayer contrast, nodal gap length, internode geometry, periaxonal structure, tract-scale transmission speed, or another explicitly measured object. | myelin changed replaces the actual scale of evidence, and proxy rows are overread as if they had already measured the timing controller itself. |
| Functional target | Name the dependent variable that the claim is about, such as skill learning, deprived-eye response, phase / synchrony precision, VEP latency, single-neuron latency, or axonal-health support. | The site silently shifts from one dependent variable to another, for example from learning success to timing-complete reconstruction. |
| Recovery / completeness boundary | State whether healthy oligodendrocyte or myelin levels were actually restored, whether function recovered under partial remyelination, and whether the paper shows prevention, compensation, or full state restoration. | Any functional rescue is overread as proof that the healthy myelin-state was completely reconstructed. |
| Human quantity type / measurement model | For human evidence, disclose whether the route is tract-speed estimation, myelin-water fraction, MT / MTsat / qMT / MPF-family contrast, bilayer-sensitive ultrashort-T2 mapping, qT1 remyelination-sensitive readout, T1w/FLAIR tissue-health-sensitive ratio, diffusion-microstructure modelling with ex vivo gene-expression alignment, or another proxy class, together with hardware burden, orientation dependence, spatial scale, modelling assumptions, and whether the safe reading remains broader than myelin-specific contrast. | A human myelin paper is treated as if it had directly measured one interchangeable myelin object, per-axon conduction timing, oligodendrocyte support state, or a plasticity gate without a proxy audit. |
| Abstention boundary | Fix in one line what remains latent, especially per-axon conduction delay, node / internode / periaxonal microgeometry in humans, oligodendrocyte-axon metabolic support, local plasticity gating, and same-subject whole-brain controller identification. | Macro proxy or partial-recovery evidence is promoted to timing-complete, plasticity-complete, or maintenance-complete language. |
The need is two-sided. On the recovery side, Della-Flora Nunes et al. (2025) explicitly showed that visual neuronal recovery can return before myelin is fully restored to healthy levels, so functional rescue and myelin-state completion are not the same claim. On the human observability side, Arshad et al. (2017) showed that reliability does not guarantee myelin validity for T1w/T2w, Hagiwara et al. (2018) showed stronger agreement between SyMRI and MTsat than with T1w/T2w, Chen et al. (2025) showed that orientation dependence remains a route variable for conventional MT, Galbusera et al. (2025) showed that qT1 but not MWF or MTR separated cortical remyelination states, Genc et al. (2025) still required histopathological confirmation, and Baadsvik et al. (2024) remained a two-volunteer specialized proof-of-principle. Therefore, this site does not let a human myelin row inherit timing-complete or plasticity-complete language, and it does not let remyelination-linked recovery silently stand in for restored healthy myelin-state.
9. Perisynaptic ECM / PNN state is not passive packaging around synapses
The weakness I found in the current site was that although I separated synapses, timing, and glia, I still left the extracellular matrix around synapses and inhibitory neurons too implicit. That was too weak. Pizzorusso et al. (2002) showed that digesting chondroitin-sulfate proteoglycans can reopen ocular-dominance plasticity in adult visual cortex. Frischknecht et al. (2009) showed that brain extracellular matrix constrains AMPA-receptor lateral mobility and short-term synaptic plasticity. Gogolla et al. (2009) showed that perineuronal nets protect fear memories from erasure. More recently, Chelini et al. (2024) showed that focal peri-synaptic matrix clusters contribute to activity-dependent plasticity and memory in mice, and Jabłońska et al. (2024) showed that extracellular-matrix integrity regulates hippocampal GABAergic plasticity. What we can say directly from this is that even with the same connectome and the same nominal synapses, the plasticity gate, receptor-diffusion regime, and stabilization path can still differ if ECM / PNN state differs.
Human evidence for ECM / PNN state is still much weaker than the animal causal literature. Boonen et al. (2022) showed extracellular-matrix reorganization in human hippocampal sclerosis tissue, which is useful evidence that the matrix layer is biologically real in human disease tissue. But this remains ex vivo pathology, not an in vivo whole-brain readout of current ECM / PNN state. Therefore, on this site, human ECM evidence is treated as support for the existence of another layer, not as a direct measurement of ongoing plasticity gates.
The remaining weakness on this page was that ECM / PNN evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Pizzorusso et al. (2002) is about enzymatic reopening of adult cortical plasticity windows. Frischknecht et al. (2009) is about receptor lateral mobility and short-term plasticity under intact matrix constraints. Nguyen et al. (2020) is about microglia-driven ECM engulfment that promotes synapse remodeling and memory consolidation. Alexander et al. (2025) is about cell-type-specific aggrecan loss that dissociates CA2 social / reversal memory from PV-cell contextual fear memory. Mehak et al. (2025) is about age-linked CA2 PNN accumulation and ChABC rescue of recognition memory plus theta oscillations. Lehner et al. (2024) and Banovac et al. (2025) raise human relevance, but only as ex vivo hippocampal or postmortem cortical histology. Therefore, on this site, ECM / PNN claims now require a route card before they are promoted beyond a narrow, explicitly named ceiling.
| ECM / PNN route-card field | What must be stated | What goes wrong without it |
|---|---|---|
| Claim family | State whether the paper is about reopening a plasticity window, constraining receptor mobility, microglia- or protease-mediated matrix remodeling, cell-type-specific memory support, age / pathology-associated matrix shift, or human ex vivo mapping. | One positive ECM result is silently promoted to ECM controls memory in general. |
| Matrix object and cell population | Name the actual matrix object and target population, such as CSPG digestion, aggrecan loss, brevican / lectican remodeling, peri-synaptic matrix clusters, CA2 pyramidal-cell PNNs, PV-cell PNNs, or postmortem WFA / VCAN / NCAN classes. | The site accidentally treats every ECM paper as if it measured one interchangeable brain-wide matrix variable. |
| Direct observable | Write the direct readout: PNN density or intensity, receptor lateral mobility, matrix-cluster abundance, ECM engulfment / proteolysis, oscillatory readout, synapse-density change, or histological morphology / laminar distribution. | A behavioral or electrophysiological effect is overread as direct ground truth of the current ECM controller. |
| Controller / perturbation route | State which controller or intervention was actually used, such as ChABC digestion, conditional aggrecan deletion, IL-33 / microglial ECM engulfment, ageing comparison, epilepsy pathology, or non-interventional postmortem mapping. | Direct perturbation, developmental change, disease association, and descriptive histology are mixed together. |
| Functional target | Name the dependent variable explicitly: ocular-dominance plasticity, AMPAR mobility, social novelty memory, reversal learning, contextual fear memory, recognition memory, theta rhythmicity, or GABAergic plasticity. | A paper that constrains one task or circuit phenomenon is promoted to a generic statement that ECM solved plasticity or stabilization. |
| Recovery / completeness boundary | State whether the result shows reopening, rescue under an aged or pathological condition, preservation against erasure, or complete restoration of a healthy matrix state. | Any rescue after ECM manipulation is overread as proof that the healthy ECM / PNN state was fully reconstructed. |
| Human observability / external calibration | Disclose whether the human route is epilepsy pathology, postmortem cortical histology, or another ex vivo assay, and state explicitly that an in vivo whole-brain readout of current ECM / PNN gate state is still absent here. | Human histology is silently promoted to same-subject, time-varying, whole-brain ECM-state observability. |
| Abstention boundary | Write which variables remain latent, especially current whole-brain matrix state, same-subject longitudinal ECM change, local plasticity-gate identity outside the measured circuit, and any human-compatible controller readout. | The site accidentally treats ECM evidence exists as equivalent to ECM-complete or maintenance-complete state capture. |
This route card forces the reader to separate what matrix object changed, which cells carried that matrix, which intervention or controller was used, and whether the result was rescue, stabilization, or direct observation. Without that separation, ChABC reopening, CA2-specific aggrecan deletion, microglial ECM engulfment, ageing rescue, epilepsy histology, and postmortem cortical mapping can all sound like the same kind of progress even though they reduce different uncertainty terms and stop at very different claim ceilings.
10. Ionic milieu / chloride homeostasis is not background chemistry
The current site had become good at separating intrinsic excitability, ECM / PNN, myelin, and glial support, while still leaving chloride set point and interstitial ion composition in the background. That was too weak. Glykys et al. (2014) showed that local impermeant anions help establish neuronal chloride concentration, Heubl et al. (2017) showed that GABAA-receptor-mediated synaptic inhibition rapidly tunes KCC2 activity via the Cl-sensitive WNK1 kinase, Ding et al. (2016) showed that changing interstitial K+, Ca2+, Mg2+, and H+ is sufficient to shift cortical activity and sleep/wake state, and Huberfeld et al. (2007) showed perturbed chloride homeostasis together with depolarizing GABAergic signaling in human temporal-lobe epilepsy. More recently, Simonnet et al. (2023) showed that silencing KCC2 in mouse dorsal hippocampus compromises spatial/contextual memory and alters hippocampal rhythmogenesis, and Nakamura et al. (2019) showed that KCC2 overexpression enhances dendritic-spine plasticity and motor learning. Therefore, even with the same connectome, cell type, and nominal synaptic weights, inhibitory sign, network gain, rhythm stability, and part of memory-relevant plasticity can still differ if ionic milieu / chloride homeostasis differs.
Human ionic evidence is still a coarse observability class, but it is no longer safe to read it as one unnamed row. Qian et al. (2012) demonstrated mm-class tissue-sodium mapping in healthy human brain. Fleysher et al. (2013) combined single-quantum and triple-quantum-filtered imaging to derive ISMF / ISC / ISVF from a compartment model. Rodriguez et al. (2022) reported repeatable normalized sodium density-weighted quantification in simultaneous 1H / 23Na MRI. Azilinon et al. (2023) showed that TSC and the short-component fraction f can diverge across epileptogenic and noninvolved tissue, so not all sodium-derived rows move together. Qian et al. (2025) separated mono- and bi-T2 sodium signals from multi-TE single-quantum acquisition. These are different quantity types with different compartment assumptions, SNR burdens, and interpretive ceilings. They still do not tell us cell-specific chloride concentration, KCC2 / NKCC1 state, extracellular K+ or Ca2+ microdomains, or local EGABA. Therefore, on this site, human sodium imaging is treated as a quantity-defined macro ionic proxy family, not as one interchangeable ionic-state meter or direct ground truth of current chloride homeostasis.
The remaining weakness on this page was that ionic evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Glykys et al. (2014) is about local chloride set point established by impermeant anions. Heubl et al. (2017) is about activity-dependent KCC2 membrane regulation via Cl-sensitive WNK1 signaling. Ding et al. (2016) and Forsberg et al. (2022) are about interstitial / CSF ion composition linked to sleep-wake state. Byvaltsev et al. (2023) is about perisynaptic K+ clearance by reverse-mode KCC2 shaping glutamatergic transmission and LTP. Alfonsa et al. (2025) is about sleep-wake-history-related shifts in EGABAA and plasticity induction. Huberfeld et al. (2007) is a human pathology route with depolarizing GABA and altered KCC2 expression. The human sodium row is itself split: Qian et al. (2012) is tissue-sodium mapping, Fleysher et al. (2013) is SQ+TQF-derived ISMF / ISC / ISVF, Rodriguez et al. (2022) is a repeatable normalized sodium density-weighted route, Azilinon et al. (2023) shows that TSC and short-component fraction f can diverge, and Qian et al. (2025) is mono-/bi-T2 signal separation. Therefore, on this site, ionic / chloride claims now require a route card before they are promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the result supports chloride-set-point / EGABAA tuning, transporter-state regulation, interstitial-ion state switching, perisynaptic K+ clearance, human pathology route, or quantity-defined human macro ionic proxy. | Local inhibitory control, sleep-wake state transition, glutamatergic K+ clearance, pathology tissue, and macro sodium / CSF proxy results collapse into one label such as ionic evidence. |
| Biological regime / spatial scale | Name species, region, cell class or compartment, and whether the claim is about a dendritic spine / perisynaptic microdomain, a cortical network state, a hippocampal memory circuit, pathology tissue, CSF, or whole-brain sodium imaging. | A local microdomain mechanism or pathology-specific route is silently promoted to a generic whole-brain ionic controller. |
| Direct ionic observable | Write the direct readout: intracellular chloride concentration, EGABAA, KCC2 / NKCC1 / WNK1 state, extracellular K+ / Ca2+ / Mg2+ / H+ composition, tissue-sodium class, or CSF ion concentration. | A paper that measured one ionic object is overread as if it had fixed the entire chloride / ionic state. |
| Perturbation / controller route | State which controller or intervention was actually used, such as cotransporter block / overexpression, GABAA-receptor manipulation, sleep deprivation or sleep / wake history, extracellular-ion substitution, or a proxy-only imaging acquisition. | Direct mechanism, state-conditioned intervention, pathology observation, and proxy-only readout are mixed together. |
| Functional target | Name the target phenomenon explicitly: inhibitory polarity, residual depolarization, LTP induction, rhythm stability, sleep-wake transition, seizure-like activity, or memory formation. | A result that only constrains one target is promoted to a generic statement that ionic state solved plasticity or maintenance. |
| Human observability / external calibration | State whether the human route is pathology tissue, a CSF ion assay, a sodium MRI proxy, or another externally calibrated ionic measurement, and what local chloride variables still require external calibration. | Healthy-human CSF or sodium measurements are silently promoted to direct readout of local chloride homeostasis. |
| Human quantity type / compartment model | If the human route is sodium-based, state whether the quantity is tissue sodium concentration (TSC), normalized sodium density-weighted, SQ+TQF-derived ISMF / ISC / ISVF, mono-/bi-T2 separated signal, short-component fraction, or another named sodium quantity, together with the compartment model, calibration assumptions, and acquisition burden. | A result derived under one sodium quantity type is silently promoted to a generic readout of intracellular sodium, chloride state, or whole-brain ionic homeostasis. |
| Abstention boundary | Write which local variables remain latent, such as cell-specific chloride concentration, transporter balance, perisynaptic K+ handling, concentration-versus-volume-fraction ambiguity, intra- versus extracellular sodium partition in routine practice, and local inhibitory reversal potential. | The site accidentally treats ionic evidence exists as equivalent to ionic-complete or maintenance-complete state capture. |
This route card forces the reader to state whether the paper measured a local ionic variable, manipulated an ionic controller, observed a pathology-specific failure mode, or merely reported a macro human proxy. Without that separation, sodium MRI, CSF assays, KCC2 manipulations, and sleep-history-dependent EGABAA shifts can all sound like the same kind of progress even though they reduce different uncertainty terms and stop at different claim ceilings.
11. thermal-state is not a background constant
The site had become good at separating timing-state, ionic state, and bioenergetic state, while still leaving brain temperature too implicit, as if it were already controlled once wiring and delay were discussed. That was too weak. Hardingham & Larkman (1998), Van Hook (2020), and Volgushev et al. (2000) show that synaptic reliability, membrane properties, and spike output can all change with thermal operating point. Moser et al. (1993) showed that dentate field excitatory potentials can scale linearly with brain temperature and mask learning-specific changes. Long & Fee (2008) and Reig et al. (2010) showed that cooling or warming can move sequence timing and cortical rhythm regime. Therefore, even with the same connectome, cell type, nominal weights, and myelin proxy, release reliability, membrane kinetics, field-potential amplitude, and sequence timing can still differ if thermal-state differs.
Healthy-human thermal evidence is also not one thing. Rzechorzek et al. (2022) established a 4D map of brain temperature and daily thermal rhythms. Rogala et al. (2024) linked task-related temperature change to working-memory performance and BOLD responses in explicitly sampled voxels. Tan et al. (2025) measured healthy-adult frontal-lobe temperature with 1H-MRS thermometry and reported an age-related decrease in brain temperature together with a brain-body temperature gradient. But the human lane is no longer purely passive thermometry. Tan et al. (2024) used exertional or passive hyperthermia with MRI-based brain thermometry to show motor-cortex temperature rise together with suppressed cortical motor activity and poorer executive function, and Inoue et al. (2025) used intraoperative focal brain cooling with a multimodality probe to show temperature-dependent non-linear neurovascular modulation in 13 patients with refractory epilepsy. These are important advances, but they still remain bounded macro or perturbation-conditioned thermal routes, not direct readouts of cell-specific microtemperature, synapse-specific heating burden, or a local thermal controller. On this site, human thermometry and human thermal perturbation therefore support the existence of another layer without being promoted to local thermal-state ground truth.
The remaining weakness on this page was that thermal evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Hardingham & Larkman (1998) and Van Hook (2020) are about temperature-dependent synaptic / membrane operating point. Moser et al. (1993) is about field-potential confounding by brain temperature. Long & Fee (2008) and Reig et al. (2010) are about sequence-timing / rhythm-regime perturbation under cooling or warming. Owen et al. (2019) and Boorman et al. (2023) show that device- or preparation-linked heating/cooling can distort neural and neurovascular readouts. Lazopulo et al. (2025) is a brain-state proxy route. Rzechorzek et al. (2022), Rogala et al. (2024), and Tan et al. (2025) are human passive / task-linked macro thermometry routes. Tan et al. (2024) is a human systemic heat-perturbation route, and Inoue et al. (2025) is a human intraoperative focal-cooling / neurovascular route. Therefore, this site now requires a thermal route card before a claim is promoted beyond a local, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about cellular / synaptic operating point, field-potential confound, sequence / rhythm perturbation, device- or preparation-linked heating artifact, brain-state proxy, human passive / task-linked macro thermometry, or a human perturbation-conditioned thermal route. | Local cooling, electrophysiology confounds, optogenetic heating, human MRS thermometry, and human heat- or focal-cooling studies collapse into one phrase such as thermal evidence shows the relevant state. |
| Direct thermal observable | Name the actual thermal object: tissue temperature, cortical-surface setpoint, implanted thermistor readout, MRS-derived temperature estimate, or a temperature-modulated neural / vascular response. | The site stops distinguishing between directly measured temperature and a downstream neural or hemodynamic effect that only co-varies with temperature. |
| Spatial / preparation regime | Fix whether the result comes from acute slice, local cortical surface, implanted in vivo probe, named human MRS voxel, or whole-brain macro map. | A local slice mechanism or a frontal-voxel human measurement is silently promoted to whole-brain thermal-state observability. |
| Driver / perturbation route | Disclose whether temperature changed through local cooling, bath warming, laser / device heating, anesthesia / preparation effects, endogenous state transitions, systemic heat exposure, intraoperative focal cooling, or only passive observation. | The paper is overread as if the temperature route were controlled and interpretable when the driver itself remained ambiguous. |
| Time window | Name whether the route concerns subsecond-to-seconds kinetics, trial-averaged field potentials, minutes-long stimulation, task-block change, sleep-state transitions, or circadian / daily rhythm. | A diurnal human map is silently rephrased as current local thermal-state, or a short stimulation artifact is silently promoted to long-horizon maintenance evidence. |
| Functional target | State whether the dependent claim is synaptic reliability, spike generation, rhythm regime, sequence timing, neurovascular transfer, task association, or state tracking. | A result that supports one target is promoted to a generic statement that temperature-complete neural state was obtained. |
| Human proxy class / acquisition burden | If the route is human, write whether it is passive macro thermometry, task-linked thermal mapping, a systemic heat-perturbation route, an intraoperative focal-cooling route, or another bounded proxy, together with voxel coverage, acquisition burden, and whether the route is whole-brain or local. | Human thermometry or human thermal perturbation is silently promoted to cell-specific thermal controller readout or routine field-ready whole-brain thermal surveillance. |
| Abstention boundary | Write which local variables remained latent, especially microtemperature gradients, synapse-specific heating burden, cell-type-specific thermal sensitivity, and the controller that produced the observed temperature change. | The site accidentally treats brain temperature was measured as equivalent to local thermal-state completeness. |
This route card forces the reader to state whether the paper uses temperature as a controller, a confound, a proxy, a macro human measurement, or a bounded human perturbation route. Without that separation, a local cooling paper, an optogenetic-heating warning, a neurovascular temperature study, a severe-heat MRI paper, an intraoperative focal-cooling paper, and an MRS thermometry paper can all sound like the same kind of progress even though they answer different questions and stop at different claim ceilings.
12. Neuromodulatory specificity is not one measurement rung
This page had already taught readers not to collapse neuromodulation into one word, but it still left a site-level weakness: the maintenance-state page named neuromodulation as a hidden variable while giving it no dedicated route card of its own. That was too weak. Reimer et al. (2016) showed that pupil fluctuations track both adrenergic and cholinergic cortical activity rather than a single transmitter. Lohani et al. (2022) showed that cortical cholinergic signals are spatially heterogeneous across behavioral states. Neyhart et al. (2024) showed that local cortical acetylcholine depends on both cholinergic axon activity and local clearance kinetics. On the human side, Hansen et al. (2022) and Goulas et al. (2021) constrain regional receptor / transporter architecture, Wong et al. (2013) constrains selected receptor target engagement by an administered ligand, and Koepp et al. (1998), Lippert et al. (2019), plus Erritzoe et al. (2020) constrain challenge-limited dopamine or serotonin release proxies. Therefore, even if the same connectome, cell type, and behavioral epoch are held fixed, current gain regime, receptor occupancy context, and transmitter-linked release state can still differ.
Current human neuromodulatory evidence already comes in several layers, not one stack. A receptor / transporter atlas is a regional chemoarchitectural prior. Occupancy PET is a ligand- and dose-limited target-engagement proxy. Challenge-linked displacement PET is a receptor- and time-window-limited release proxy. None of those rows is promoted on this site to direct ground truth of the instantaneous whole-brain transmitter field, cell-specific downstream effect, or receptor-family-complete modulatory state.
The remaining weakness on this page was that neuromodulatory evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Reimer et al. (2016) is about a mixed arousal proxy. Lohani et al. (2022) and Neyhart et al. (2024) are about local cholinergic dynamics with explicit spatial and clearance constraints. Hansen et al. (2022) and Goulas et al. (2021) are about regional receptor / transporter atlas structure. Wong et al. (2013) is about occupancy of a selected D2 receptor target under an administered drug. Koepp et al. (1998), Lippert et al. (2019), and Erritzoe et al. (2020) are about challenge-linked displacement / release proxies within bounded windows. Therefore, this site now requires a neuromodulatory route card before a claim is promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about mixed arousal proxy, local transmitter sensor, receptor / transporter atlas, occupancy PET, or challenge-linked displacement / release-sensitive PET. | Pupil / HRV, local ACh imaging, regional receptor maps, occupancy studies, and release-proxy PET all collapse into one phrase such as neuromodulatory evidence shows current transmitter state. |
| Transmitter axis / receptor family | Name the transmitter system, receptor or transporter family, and whether the route is transmitter-mixed, receptor-selective, or still indirect. | The site silently promotes a selected receptor-family result to whole-brain all-transmitter or receptor-family-complete language. |
| Direct observable | Fix the actual object: pupil / HRV covariation, local extracellular transmitter signal, axon activity, atlas density, ligand occupancy, or challenge-linked binding change. | Regional prior, ligand engagement, and endogenous release proxy are treated as if they were the same measurement. |
| Driver / challenge route | Disclose whether the result depends on spontaneous behavior, named task state, pharmacological challenge, administered ligand plus dose, or no perturbation at all. | The paper is overread as if the transmitter route were directly observed without stating what actually drove the inferred change. |
| Quantification route / time window | Name whether the route is a continuous local sensor, group atlas, occupancy model, or displacement PET design, together with scan window, kinetic or simplified model, and arterial-versus-reference burden when relevant. | Minutes-scale challenge windows or cohort-level atlases are silently promoted to ongoing current-state readout. |
| Spatial scope / calibrator role | Fix whether the evidence is local cortex, a bounded ROI, or a regional whole-brain prior, and state what hidden-state family it safely calibrates on this site. | A local cholinergic measurement or atlas prior is silently promoted to whole-brain transmitter-field or cell-specific downstream-effect ground truth. |
| Abstention boundary | Write what remains latent, especially instantaneous whole-brain transmitter field, unsampled receptor families, laminar / cell-specific downstream effect, and stable cross-task neuromodulatory identity outside the measured window. | The site accidentally treats neuromodulatory evidence exists as equivalent to neuromodulation-complete internal-state capture. |
This route card forces the reader to separate coarse arousal covariate, local transmitter calibration, regional receptor prior, exogenous target engagement, and challenge-limited endogenous release proxy. Without that separation, the site can slide from a neuromodulatory paper exists to the current transmitter state was measured even though the cited papers do not justify that promotion.
13. bioenergetic / mitochondrial state is not another name for glial support
The weakness that became clearer here was that while I wrote about myelin / oligodendroglial support and astrocyte / metabolic support, I did not isolate neuronal local ATP supply and mitochondrial arrangement as independent maintenance-states. Rangaraju et al. (2014) showed that activity-driven local ATP synthesis is required for presynaptic function, Underwood et al. (2023) showed that fear training increases presynaptic mitochondrial respiration and that Drp1-linked enhancement is required for contextual memory, Rangaraju et al. (2019) showed that spatially stable mitochondrial compartments fuel local translation during plasticity, Divakaruni et al. (2018) showed that rapid dendritic mitochondrial fission is required for LTP induction, Bapat et al. (2024) showed that stabilized dendritic mitochondria locally support synaptic plasticity, Hu et al. (2025) showed polarized ATP synthase in synaptic mitochondria in response to learning and plasticity signals, and Vishwanath et al. (2026) showed that mitochondrial Ca2+ efflux can tune neuronal metabolism and long-term memory across species. Therefore, even with the same connectome, the same cell type, and the same astrocyte support, repeated-burst reliability, local plasticity support, and memory-relevant metabolic control can still change if the local neuronal bioenergetic state differs.
Ren et al. (2015) measured resting ATP synthesis, metabolite concentration, and pH using 31P-MRS in healthy human brains, Ren et al. (2017) measured MT-based PCr→γ-ATP and Pi→γ-ATP exchange flux under a 5-pool model, Guo et al. (2024) mapped whole-brain intracellular NAD content at 7 T, Kaiser et al. (2026) detected visual-task NAD+ dynamics in a functionally localized occipital voxel, Karkouri et al. (2026) quantified absolute deuterated-metabolite concentrations with a dedicated DMI quantification pipeline, and Li et al. (2025) quantified whole-brain glucose transport and metabolic-rate terms using dynamic deuterium magnetic resonance spectroscopic imaging. Even the deuterium routes are not route-free: Ahmadian et al. (2025) showed that human brain DMI signal changes materially with the administered [6,6'-2H2]glucose dose, and Bøgh et al. (2024) showed that repeatability at 3 T depends on a named acquisition and time-point regime. However, these are still macro energetic proxies of different quantity types and do not directly tell us which synapse neighborhood mitochondria are staying at, which dendritic branch lacks ATP reserve, or which local redox controller is limiting plasticity right now. Therefore, on this site, while acknowledging energetic imaging in humans as an important advance, we do not refer to direct readout of cell-specific bioenergetic / mitochondrial state.
The remaining weakness on this page was that bioenergetic evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Rangaraju et al. (2014) and Underwood et al. (2023) are about presynaptic ATP-linked energetic support / respiration for transmission and memory formation. Rangaraju et al. (2019), Divakaruni et al. (2018), and Bapat et al. (2024) are about dendritic positioning, fission, and local plasticity support. Hu et al. (2025) is about synaptic ATP-synthase nano-organization under learning-like conditions. Vishwanath et al. (2026) is about mitochondrial Ca2+-efflux tuning as a metabolic control lever for long-term memory across species. Human observability already splits further: Ren et al. (2015) is a resting metabolite / pH balance route, Ren et al. (2017) is an MT exchange-flux route, Guo et al. (2024) is a whole-brain NAD-content route, Kaiser et al. (2026) is a task-evoked 31P fMRS NAD+ route, Karkouri et al. (2026) is a deuterium absolute-quantification route, and Li et al. (2025) is a deuterium kinetic-rate route. Ahmadian et al. (2025) and Bøgh et al. (2024) then show that even deuterium visibility and repeatability remain dose-, time-point-, and protocol-conditioned. Therefore, this site now requires a bioenergetic / mitochondrial route card before a claim is promoted beyond a local, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the result supports presynaptic ATP-demand support, dendritic plasticity support, organelle micro-organization, metabolic-tuning intervention, human 31P metabolite / pH balance, human 31P MT exchange-flux, human 31P NAD-content mapping, human 31P functional NAD-dynamics, human deuterium metabolite-mapping / absolute-quantification, or human deuterium kinetic-rate imaging. | Acute synaptic support, local plasticity mechanism, memory enhancement, and human proxy imaging collapse into one label such as energetic evidence. |
| Biological regime / compartment | Name species, brain region, memory or plasticity paradigm, and whether the claim is presynaptic, dendritic, somatic, or whole-brain. | A dendritic-slice mechanism or a rodent memory intervention is silently promoted to a generic whole-brain energetic controller. |
| Direct energetic observable | Write the direct readout: ATP synthesis, oxygen-consumption / respiration, mitochondrial position or stability, fission / fusion event rate, ATP-synthase nanocluster distribution, Ca2+-efflux kinetics, or macro metabolic-rate map. | A paper that measured one energetic object is overread as if it had measured all local mitochondrial state variables. |
| Controller / perturbation route | State which controller or intervention was actually manipulated or assumed, such as Drp1, VAP stabilization, Letm1-mediated Ca2+ efflux, a spectral / exchange fit for resting 31P, a 5-pool MT model for 31P exchange flux, an NAD fitting route, an absolute-quantification pipeline for deuterium metabolite mapping, or a kinetic model applied to dynamic DMRSI. | The claim ceases to distinguish between direct mechanism, model-conditioned inference, and proxy-only readout. |
| Quantity type / model burden | Separate static structural organization, resting metabolite / pH balance, acute respiration / ATP-linked flux, 31P MT exchange-flux, NAD content or task-evoked NAD dynamics, deuterium absolute metabolite mapping, and whole-brain macro rate imaging, and disclose any spectral, dose / time-point, repeatability, kinetic, or compartment model burden. | Static mitochondrial organization is overread as ATP turnover truth, or a macro imaging estimate is overread as branch-local energetic state. |
| Functional target | Name the target phenomenon explicitly: vesicle cycling, repeated-burst reliability, LTP induction, local translation, recall, or long-term memory formation. | A result that only constrains one function target is promoted to a generic statement that `bioenergetics solved memory maintenance`. |
| Human observability / external calibration | State whether the human route is a 31P metabolite / pH balance, 31P MT exchange-flux, 31P NAD-content mapping, 31P functional NAD-dynamics, deuterium metabolite-mapping / absolute-quantification, or deuterium kinetic-rate proxy, which dose / time-point / repeatability regime conditions the route, and what local mitochondrial variables still require external calibration. | A 31P or deuterium route is silently promoted to branch-local mitochondrial-state ground truth. |
| Abstention boundary | Write which local variables remain latent, such as branch-specific ATP reserve, synapse-neighbor mitochondrial residence, fission/fusion controller state, redox reserve, or cell-specific Ca2+-efflux control. | The site accidentally treats `energetic evidence exists` as equivalent to energetic-complete or maintenance-complete state capture. |
The need is two-sided. On the mechanism side, Underwood et al. (2023) and Vishwanath et al. (2026) show that changing mitochondrial respiration or Ca2+-efflux control can alter memory without turning bioenergetics into one generic support row. On the human-observability side, Ren et al. (2015) constrains resting metabolite / pH balance, Ren et al. (2017) constrains 31P MT exchange flux, Guo et al. (2024) constrains whole-brain intracellular NAD content, Kaiser et al. (2026) constrains task-evoked NAD+ dynamics, Karkouri et al. (2026) constrains absolute deuterated-metabolite mapping, and Li et al. (2025) remains a deuterium kinetic-rate route. Ahmadian et al. (2025) and Bøgh et al. (2024) further show that deuterium visibility and repeatability are not route-free but remain tied to a named dose, time point, and protocol. This site therefore does not let a human energetic image inherit branch-local mitochondrial-state language.
14. Cargo-transport / cytoskeletal trafficking is not implied by proteostasis or ATP
The site had become good at separating local proteostasis from bioenergetics, while still leaving the delivery route itself too implicit. That was too weak. Park et al. (2006) showed that recycling-endosome exocytosis is required for LTP-associated spine growth, and Correia et al. (2008) showed myosin-Va-dependent translocation of GluR1 from dendritic shaft to spine during LTP. Maas et al. (2009) showed that synaptic activation rewrites microtubules supporting postsynaptic cargo transport, Uchida et al. (2014) showed that learning-phase microtubule stability controls KIF5-mediated GluA2 localization and memory, and Wong et al. (2024) showed that synaptic activity confines endogenous GluA1 vesicles near stimulated dendritic regions rather than making `cargo reached the correct spine` a solved generic statement. Zhao et al. (2020) showed that KIF5B depletion impairs dendritic transport, synaptic plasticity, and memory, Nakayama et al. (2017) showed that RNG105 / Caprin1-dependent dendritic mRNA localization is essential for long-term memory formation, Swarnkar et al. (2021) linked KIF5C-mediated transport to structural plasticity and long-term memory by constraining local translation, Liau et al. (2023) showed that a synaptic Gas5 isoform regulates activity-dependent trafficking and clustering of RNA granules and fear-extinction memory, Espadas et al. (2024) showed that the lncRNA SLAMR is transported along dendrites via KIF5C, recruited to synapses upon stimulation, and required for contextual-fear memory consolidation, de Queiroz et al. (2025) showed that axonal RNA localization is required for long-term but not short-term memory in a mature in vivo memory circuit, and Aiken & Holzbaur (2024) showed that local axonal microtubule patterning controls presynaptic cargo pausing and delivery. Therefore, even with the same connectome, the same weight estimate, the same local translation program, and the same ATP support, which cargo reaches which compartment, stays there, and remains available on the relevant timescale can still differ.
Current human in vivo routes still do not directly reveal branch- or bouton-specific cargo pausing, motor engagement, or microtubule traffic state. Narrow human-neuron preparations such as the induced-neuron axon system in Aiken & Holzbaur (2024) strengthen the mechanism side, but they do not erase the living-human whole-brain observability gap. This is an inference from the measurement classes available on the site, not a direct transport measurement. Therefore, on this site, cargo-transport / cytoskeletal trafficking remains a local hidden state in humans unless it is externally calibrated or causally perturbed in a narrower preparation.
The remaining weakness on this page was that cargo evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Park et al. (2006) and Correia et al. (2008) are about postsynaptic AMPAR / recycling-endosome delivery during LTP. Maas et al. (2009), Uchida et al. (2014), and Wong et al. (2024) are about transport-path state, namely microtubule remodeling, learning-phase-dependent microtubule stability, and activity-dependent vesicle confinement near the stimulated dendritic region. Nakayama et al. (2017), Liau et al. (2023), and Espadas et al. (2024) are about dendritic / synaptic RNA-granule organization and spine-targeted RNA support. de Queiroz et al. (2025) is about a distinct axonal RNA localization route in a mature in vivo memory circuit. Aiken & Holzbaur (2024) is about presynaptic cargo delivery and retention patterned by local axonal microtubule dynamics. Therefore, on this site, cargo-transport claims now require a route card before they are promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about postsynaptic receptor delivery, activity-dependent vesicle confinement / reservoir formation, learning-dependent microtubule-state gating, dendritic / synaptic RNA-granule organization, axonal RNA localization / presynaptic mRNA targeting, or presynaptic cargo retention / synaptogenesis. | Different inferential objects collapse into one phrase such as transport evidence shows compartment delivery is solved. |
| Cargo object | Name the actual cargo: AMPAR-containing vesicle, recycling endosome, GluA2-related receptor cargo, RNA granule / localized mRNA, synaptic-vesicle precursor, mitochondrion, or another explicitly followed object. | cargo becomes a generic word and one tracked object is silently promoted to all receptor, organelle, or RNA classes. |
| Compartment scope | Write whether the route is dendritic shaft, stimulated spine neighborhood, axonal branch, bouton, or presynaptic terminal, and whether the relevant unit is one spine, one branch, or a larger compartment. | Dendritic transport, spine entry, axonal delivery, and bouton retention are treated as if they had the same spatial ceiling. |
| Transport phase / state variable | Fix whether the result addresses long-range transport, local pausing / confinement, docking, exocytosis, retention, recycling, or translation-coupled capture. | A paper that only constrains one phase is promoted to a generic statement that the whole delivery route is known. |
| Trigger / time window | Name the regime that drives the route, such as seconds-to-minutes LTP induction, post-learning hours, multiday consolidation, development, or degeneration / ageing. | Learning-phase transport gates, acute plasticity delivery, and long-term memory consolidation are silently fused into one transport timeline. |
| Direct observable / assay | State whether the paper directly tracked cargo motion, measured microtubule state, quantified synaptosome-localized RNAs, imaged cargo reservoirs, or inferred transport only indirectly from endpoint receptor levels or behavior. | transport changed replaces the actual measurement, and endpoint memory phenotypes are overread as if they had directly revealed the delivery process. |
| Driver / perturbation route | Write whether the paper uses motor-protein depletion, microtubule stabilization or destabilization, actin perturbation, localization-element mutation, RNA-binding-protein mutation, or no causal perturbation at all. | The site silently shifts from correlational localization language to controller-identification language without a disclosed intervention route. |
| Human observability / transfer ceiling | For human-facing claims, disclose whether the strongest evidence is only a cultured human-neuron preparation, an ex vivo route, or no human route at all, and which living-human in vivo observables remain unavailable. | A narrow human preparation is promoted to living-human whole-brain cargo-state ground truth without an observability audit. |
| Abstention boundary | Fix what remains latent, especially arbitrary cargo identity across the whole neuron, same-subject living-human branch / bouton delivery, motor engagement at unmeasured compartments, and whether transport actually reached the functionally decisive synapse. | The site accidentally treats transport evidence exists as equivalent to cargo-complete or maintenance-complete state capture. |
The need is multi-axis. On the postsynaptic side, Park et al. (2006) and Correia et al. (2008) are about AMPAR / recycling-endosome delivery during LTP, not presynaptic cargo patterning. On the transport-path side, Uchida et al. (2014) shows that learning-phase microtubule stability changes memory through KIF5-dependent GluA2 localization, while Wong et al. (2024) shows local confinement of endogenous GluA1 vesicles near active synapses rather than proving that direct spine exocytosis is the universal rule. On the dendritic / synaptic RNA side, Nakayama et al. (2017) shows dendritic mRNA localization is required for long-term memory, Liau et al. (2023) shows activity-dependent trafficking and clustering of RNA granules at the synapse, and Espadas et al. (2024) shows KIF5C-dependent dendritic transport and synaptic recruitment of a memory-relevant lncRNA. On the axonal RNA side, de Queiroz et al. (2025) shows that presynaptic mRNA targeting is required for long-term memory in a mature in vivo circuit. On the presynaptic side, Aiken & Holzbaur (2024) is about bouton-oriented cargo delivery shaped by axonal microtubule dynamics in a human-neuron preparation, not a living-human whole-brain route. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for human whole-brain cargo-state identification without a route-card audit.
15. neurovascular-unit / BBB / pericyte state is not the same as vascular-state / CVR audit
The weak point that became clear here was that the site had become better at auditing measurement-side vascular transfer limits for BOLD and fNIRS, while still leaving maintenance-side neurovascular-unit / BBB / pericyte state undernamed. That is too coarse. Bell et al. (2010) showed that adult pericyte loss drives hypoperfusion, BBB breakdown, age-dependent neurodegeneration, and learning / memory impairment, and Kisler et al. (2020) showed that acute cortical pericyte ablation rapidly weakens stimulus-evoked CBF responses without requiring neuronal dysfunction. More recently, Pandey et al. (2023) showed that neuronal activity drives Igf2 expression from hippocampal pericytes and that pericyte-specific Igf2 loss impairs long-term memory, Swissa et al. (2024) showed that prolonged physiological stimulation can induce focal BBB modulation associated with cortical plasticity in rats and humans, and Mai-Morente et al. (2025) showed that pericyte pannexin1 controls capillary diameter and supports memory performance. Therefore, even if a vascular-state / CVR audit is passed for a hemodynamic measurement stack, the biological neurovascular controller that maintains capillary support, BBB transport, and plasticity-relevant barrier state can still remain different.
Current human evidence is narrower than the rodent causal literature, and even the human rung is not one boundary or one quantity type. Padrela et al. (2025) used multi-echo ASL to estimate BBB water-exchange time across 209 healthy adults, but the apparent gray-matter age effect disappeared after correcting for CBF and ATT, making it unsafe to read Tex as a flow-free barrier scalar. Morgan et al. (2024) then compared DP-ASL and ME-ASL in the same cohort and found significantly different BBB water-exchange values plus inconsistent age dependence, making it unsafe to treat ASL-derived Kw as one interchangeable permeability meter without naming the exact method and fitting route. Mouse work by Ohene et al. (2019) further showed that multi-TE ASL exchange time is sensitive to AQP4 loss at the blood-brain interface, making it unsafe on this site to read the ASL-side quantity as route-free endothelial leakiness. Padrela et al. (2026) then showed lower Tex in SCD, MCI, and moderate WMH burden while amyloid-status differences did not survive age / sex adjustment, making it unsafe to treat Tex as an amyloid-specific BBB meter. By contrast, Chung et al. (2025) developed a high-temporal-resolution dynamic PET method to estimate a tracer-specific BBB permeability-surface-area product across three radiotracers and showed lower FDG BBB PS in healthy aging, while also leaving human ground-truth PS unresolved. A separate human route family sits at the blood-CSF barrier / choroid plexus: Zhao et al. (2020) quantified apparent choroid-plexus blood flow in 7 healthy volunteers and explicitly noted that its long T1 may reflect water transport from arterial blood to CSF; Petitclerc et al. (2021) then used ultra-long-TE ASL in 12 healthy subjects to map a blood-to-CSF water-exchange time on the order of 60 s; Anderson et al. (2022) quantified a choroid-plexus water-efflux rate constant with DCE-MRI in 11 cognitively impaired and 28 cognitively normal older adults, while showing that kco and Ktrans are not interchangeable; Wu et al. (2026) reported a REXI-derived apparent kBCSFB with scan-rescan ICC = 0.84 in 6 healthy volunteers and a 34% decrease in middle-aged versus young adults; and Petitclerc et al. (2026) explicitly modeled Kbl→GM and Kbl→CSF in one human ASL acquisition and found the highest blood-to-CSF exchange in the choroid plexus. A third barrier-side human route now also sits in paired fluids rather than transport imaging: Farinas et al. (2025) used paired CSF and plasma proteomics from 2,171 individuals to derive individualized CSF/plasma ratios for 2,304 proteins; the paper treats those ratios as a paired-fluid protein-balance readout and explicitly notes that ratio shifts can reflect transport, synthesis, or degradation across compartments. These are stronger than saying no human barrier-related route exists, but they still do not directly identify which pericyte, which endothelial transport controller, which choroid-plexus epithelial transporter, or which local capillary recruitment state supported a specific memory or circuit. Therefore, on this site, current human BBB MRI / PET, blood-CSF-barrier / choroid-plexus MRI, and paired-fluid CSF/plasma proteomics are read as distinct proxy families, not as cell-specific neurovascular-unit ground truth.
The remaining weakness on this page was subtler than the 2026-03-26 family split. Even after separating rodent controller biology from human proxy routes, human barrier evidence could still be read as if it were one generic permeability meter. The primary literature does not support that shortcut. Padrela et al. (2025) is a human BBB water-exchange MRI route, but its gray-matter age effect disappears after CBF and ATT correction, so even the ASL-side quantity is not independent of vascular transport context. Morgan et al. (2024) showed that DP-ASL and ME-ASL can return markedly different BBB water-exchange values and inconsistent age dependence even within the same cohort, so ASL-derived BBB water transport itself is not yet one settled quantity family. Mouse work by Ohene et al. (2019) showed that the same multi-TE ASL exchange-time family is sensitive to AQP4 loss at the blood-brain interface, which means the ASL-side BBB signal cannot be treated here as a route-free generic leakiness scalar. Padrela et al. (2026) then showed lower Tex in SCD / MCI and moderate WMH burden while amyloid-group differences did not survive age / sex adjustment, so the same ASL-side quantity is not an amyloid-specific BBB meter either. Chung et al. (2025) is a human PET kinetic permeability route whose reported PS depends on the tracer-specific transport mechanism and kinetic model across three radiotracers, not a generic BBB leakiness scalar, and the paper explicitly leaves human ground-truth PS unresolved. A distinct human BCSFB / choroid-plexus route family also exists: Zhao et al. (2020) is a choroid-plexus perfusion route whose long T1 is interpreted as compatible with blood-to-CSF water transfer; Petitclerc et al. (2021) is a human blood-to-CSF water-transport route; Anderson et al. (2022) is a human choroid-plexus DCE water-cycling route; Wu et al. (2026) is a REXI-based apparent BCSFB exchange route; and Petitclerc et al. (2026) is a simultaneous BBB-plus-BCSFB ASL route that explicitly estimates both Kbl→GM and Kbl→CSF. A third human barrier-side route is not transport imaging at all: Farinas et al. (2025) is a paired-fluid CSF/plasma proteomic-balance route whose individualized protein ratios can reflect barrier transport, but also synthesis or degradation in either compartment, so it is not a generic permeability scalar either. Those routes do not cross the same boundary, use the same carrier class, or share one model family or validation ceiling. Therefore, on this site, neurovascular / BBB claims now require a route card that names the human quantity type, crossed boundary, dominant transport interpretation, and validation ceiling explicitly before they are promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about pericyte loss / hypoperfusion, acute neurovascular uncoupling, pericyte-to-neuron memory signaling, activity-dependent BBB modulation, capillary-diameter controller biology, human BBB water exchange, human PET permeability modeling, a human blood-CSF barrier / choroid-plexus perfusion / blood-to-CSF transport route, or a human paired-fluid CSF/plasma protein-balance route. | Different inferential objects collapse into one phrase such as vascular evidence shows the maintenance state was measured. |
| Biological locus / controller | Name whether the claim centers on pericytes, endothelium, BBB transcytosis / permeability, capillary tone, choroid-plexus epithelium / blood-CSF barrier transport, a brain-barrier-system balance between paired fluids, or a mixed neurovascular-unit route. | A measurement-side vascular nuisance audit gets silently promoted to a biological controller-identification claim. |
| Direct observable / route object | Write whether the direct observable is capillary diameter, CBF response, BBB water-exchange time / rate, tracer-specific permeability-surface-area product, choroid-plexus perfusion, blood-to-CSF water-exchange time / rate, DCE water-efflux rate, REXI-derived apparent kBCSFB, paired CSF/plasma protein ratio, leakage / contrast-agent escape, transcript / protein in vascular cells, or another explicitly measured object. | neurovascular state changed replaces the actual observable, and a macro water-exchange or transport proxy is overread as if it had directly measured the responsible pericyte or endothelial controller. |
| Driver / perturbation route | State whether the paper uses pericyte ablation, pericyte-specific gene knockout, sensory stimulation, receptor blockade, pharmacology, or no causal intervention at all. | The site silently shifts from correlation or proxy language to controller-identification language without a disclosed intervention route. |
| Human quantity type / transport regime | For human evidence, disclose whether the route estimates ASL-derived BBB water-exchange time / rate, tracer-specific PET PS under a named tracer and kinetic model, choroid-plexus perfusion, blood-to-CSF water-exchange time / rate, DCE choroid-plexus water efflux, REXI-derived apparent kBCSFB, paired CSF/plasma protein ratios, contrast-agent leakage, or another named transport quantity, and state whether the route is about water exchange, facilitated transport, free diffusion, paired-fluid balance, or non-specific leakage. | A human BBB paper is treated as if all BBB-related assays measured one interchangeable permeability scalar rather than different transport objects with different model assumptions. |
| Carrier / boundary crossed | State whether the measured carrier is water, a named PET radiotracer, an exogenous contrast agent, an endogenous protein measured in both CSF and plasma, or another explicitly named analyte, and whether the relevant route is blood-to-tissue exchange, blood-to-CSF / choroid-plexus transfer, paired-fluid barrier-system balance, tissue-to-blood escape, luminal transport, or another named boundary crossing. | Water exchange, tracer-specific influx, contrast leakage, and molecular transport collapse into one word such as permeability even though they do not share one biological object. |
| Interface sensitivity / dominant transport interpretation | State whether the route is being interpreted as AQP4-sensitive water transport at the blood-brain interface, tracer-specific luminal-to-tissue transport under a named PET model, blood-to-CSF transport at the choroid plexus / ventricular interface, paired-fluid protein balance with explicit source/sink ambiguity, contrast-agent leakage, or another explicitly named mechanism class. Ohene et al. (2019) shows why multi-TE ASL exchange time cannot be treated here as a route-free generic leakiness scalar, Padrela et al. (2026) shows why lower Tex in SCD / MCI and moderate WMH burden is not equivalent to amyloid-specificity, Petitclerc et al. (2026) shows why BBB and BCSFB water exchange should not be collapsed into one transport object, and Farinas et al. (2025) show why paired CSF/plasma ratios cannot be read as barrier transport alone. | ASL Tex / Kw or PET PS gets silently rephrased as one generic BBB-permeability meter and then overextended to amyloid-specific or controller-specific claims that the data did not establish. |
| Human measurement / model burden | Disclose field strength, acquisition family, fitting / kinetic model, validation status, and repeatability ceiling. Morgan et al. (2024) makes this explicit for BBB water-exchange MRI by showing method-dependent Kw estimates, Chung et al. (2025) makes it explicit for PET by noting the current lack of human ground-truth PS values, Wu et al. (2026) makes it explicit for BCSFB exchange by reporting scan-rescan repeatability but also a small-sample ceiling, and Farinas et al. (2025) makes it explicit for paired-fluid proteomics by requiring two-fluid assay harmonization, ratio construction, and interpretation that depends on both compartments. | A human BBB paper is treated as if it had directly measured local pericyte/endothelial controller state without a proxy / model audit or without separating route-local precision from biological meaning. |
| Validation / repeatability ceiling | Disclose whether the route has cross-method agreement, route-internal repeatability, or only a model-conditioned estimate with unresolved human ground truth. Morgan et al. (2024), Chung et al. (2025), Wu et al. (2026), and Farinas et al. (2025) show why this cannot be assumed: a large cohort does not erase route-specific ambiguity about what generated the measured ratio. | A paper with a precise-looking scalar is overread as a settled biological quantity even when method-family disagreement or absent ground truth still dominates the uncertainty. |
| Functional target | Name the dependent variable the claim is actually about, such as capillary dilation, BBB transport, synaptic plasticity, long-term memory, or age-linked macro permeability shift. | The site silently jumps from one target to another, for example from BBB permeability or capillary tone to general memory-maintenance completeness. |
| Abstention boundary | Fix in one line what remains latent, especially cell-specific controller identity in humans, choroid-plexus epithelial transporter identity, CSF-production controller identity, whether a paired-fluid protein-ratio shift was driven by transport versus synthesis or degradation, synapse-specific maintenance logic, arbitrary memory content, and same-subject whole-brain neurovascular-unit completeness. | Macro proxy or local rodent causal evidence is promoted to human whole-brain controller ground truth. |
The need is multi-axis. On the pericyte-deficiency side, Bell et al. (2010) and Kisler et al. (2020) show that capillary support and neurovascular coupling can fail before one can claim a shared neuronal state failure. On the signaling side, Pandey et al. (2023) shows that a pericyte-derived molecular signal can matter for long-term memory, which is not the same inferential object as capillary perfusion. On the plasticity side, Swissa et al. (2024) links activity-dependent BBB modulation to cortical plasticity, which is not the same object as chronic BBB breakdown. On the controller side, Mai-Morente et al. (2025) isolates a pericyte Panx1 route for capillary-diameter control with memory consequences. On the human observability side, Padrela et al. (2025) measures BBB water exchange but loses its gray-matter age effect after CBF / ATT correction, Morgan et al. (2024) shows that even ASL-derived BBB water-exchange estimates are method-dependent and still need independent validation, Ohene et al. (2019) shows that multi-TE ASL exchange time is sensitive to AQP4 loss at the blood-brain interface, Padrela et al. (2026) shows that lower Tex tracks early cognitive / cerebrovascular burden more clearly than amyloid status, and Chung et al. (2025) estimates tracer-specific BBB permeability across three radiotracers under kinetic-model assumptions while explicitly stopping short of human ground truth. A different human route family is already visible at the blood-CSF barrier: Zhao et al. (2020) measures choroid-plexus perfusion with an ASL model that explicitly allows signal from generated CSF, Petitclerc et al. (2021) maps blood-to-CSF exchange in 12 healthy subjects, Anderson et al. (2022) separates kco from Ktrans at the choroid plexus in older adults, Wu et al. (2026) reports scan-rescan repeatability for apparent kBCSFB, and Petitclerc et al. (2026) explicitly estimates both Kbl→GM and Kbl→CSF in one acquisition while arguing that BBB and BCSFB water exchange are governed by barriers with distinct physiology. A third human barrier-side route is already visible in paired fluids: Farinas et al. (2025) quantify individualized CSF/plasma ratios for 2,304 proteins across 2,171 individuals, but the direct observable is a paired-fluid protein balance whose interpretation explicitly remains compatible with transport, synthesis, or degradation changes. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for a direct human whole-brain pericyte / endothelial / choroid-plexus-epithelial controller readout without a route-card audit.
16. Glial metabolism / substrate routing is not the same as neuronal mitochondrial control or astrocyte ensemble state
The remaining weakness after splitting neuronal bioenergetics from astrocyte ensemble-state was that the site still let glial fuel supply sound like generic background support. The primary literature does not support that shortcut. Suzuki et al. (2011) showed that astrocyte-neuron lactate transport is required for long-term memory formation. Silva et al. (2022) showed that under starvation glia synthesize ketone bodies locally to sustain memory. Pavlowsky et al. (2025) then showed that memory after intensive massed learning depends on neuronal fatty-acid oxidation while cortex glia supply the lipids. Greda et al. (2025) further showed that apoE3 / sortilin-dependent lipid delivery enables neurons to use long-chain fatty acids as metabolic fuel when glucose is limited. Those are not the same inferential object as local mitochondrial positioning, and they are not the same inferential object as minute-scale astrocyte-network encoding or learning-associated astrocyte ensembles. Therefore, even if neuronal mitochondrial arrangement and astrocyte ensemble identity were both held fixed, the active glial supplier, fuel class, and transport route can still differ in ways that change memory-relevant energy support.
Current living-human evidence is still much weaker here than on the rodent mechanism side. Human 1H-MRSI, 31P-MRS, deuterium routes, and astrocyte-related PET can constrain macro biochemical organization, macro energetic balance or rate terms, or target-defined astrocyte-related proxy classes, but they do not directly tell us which glial cell supplied which fuel, whether the operative route was lactate-, ketone-, or lipid-based, or which neuron-specific uptake controller was active in vivo. Therefore, on this site, glial substrate-routing remains a hidden maintenance-state family in humans unless it is externally calibrated or causally perturbed in a narrower preparation.
The remaining weakness on this page was that glial metabolic-support evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Suzuki et al. (2011) is about a lactate-shuttle support route. Silva et al. (2022) is about a glia-to-neuron ketone-body route under starvation. Pavlowsky et al. (2025) is about glia-to-neuron fatty-acid flux during intensive learning. Greda et al. (2025) is about apoE / sortilin-dependent neuronal lipid uptake and fuel-choice gating. Therefore, this site now requires a glial metabolism / substrate-routing route card before a claim is promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about lactate-shuttle support, ketone-body routing under nutrient stress, glia-to-neuron fatty-acid flux during learning, lipoprotein-mediated neuronal lipid uptake / fuel-choice gating, or only a macro human energetic proxy. | Lactate, ketone, fatty-acid, and lipoprotein-uptake routes collapse into one phrase such as glial metabolic support. |
| Glial source and neuronal sink | Name the supplier glial population, the recipient neuronal population or compartment, and whether the route is cortex glia, astrocyte, microglia-conditioned lipoprotein delivery, or another explicitly named supplier class. | A source-specific route is silently promoted to a generic whole-brain glial support controller. |
| Fuel object / carrier | Write the actual transferred substrate explicitly: lactate, ketone body, fatty acid, apoE-bound lipid, or another named carrier. | The site hides which energetic object was actually routed and overreads one substrate class as if all alternative fuel routes had been fixed. |
| Regime trigger / time window | State whether the route is tied to long-term-memory formation, starvation, intensive massed learning, glucose limitation, ageing-like hypometabolism, or another explicitly named metabolic regime and timescale. | A starvation route, a cramming-like learning route, and a glucose-limited fuel-choice route are silently fused into one universal baseline mechanism. |
| Direct observable / assay | State whether the paper directly measured substrate transfer, transporter dependence, ATP change, behavioral memory output, lipid-droplet dynamics, neuronal respiration, or only an indirect endpoint. | glial support changed replaces the actual measurement, and behavior is overread as if the substrate route itself had been observed directly. |
| Transport / controller route | Name the actual transport or controller axis, such as lactate transporters, ketone-body synthesis / export, CPT1-dependent fatty-acid oxidation, or apoE / sortilin / PPARα-linked lipid uptake and fuel switching. | The site silently shifts from route-conditioned support language to generic controller-identification language without naming what actually moved the fuel. |
| Human observability / external calibration | For human-facing claims, disclose whether the strongest evidence is only a macro energetic proxy, a target-defined astrocyte-related proxy, an ex vivo lipid signal, or no direct living-human substrate-routing route at all, and state what still requires external calibration. | A macro human energetic image or astrocyte PET route is silently promoted to direct glia-to-neuron fuel-routing ground truth. |
| Abstention boundary | Fix in one line what remains latent, especially supplier-cell identity in vivo, fuel-class choice at the relevant synapse or circuit, same-subject whole-brain routing state, and the relation between glial supply and neuronal mitochondrial usage. | The site accidentally treats glial metabolic-support evidence exists as equivalent to substrate-routing-complete or maintenance-complete state capture. |
The need is multi-axis. On the lactate side, Suzuki et al. (2011) links astrocyte-neuron lactate transport to long-term memory formation, but that does not show ketone-body or lipid routing. On the starvation side, Silva et al. (2022) links glial ketone-body synthesis to memory support, which is not the same inferential object as a baseline lactate shuttle. On the intensive-learning side, Pavlowsky et al. (2025) shows a glia-to-neuron fatty-acid route that supports memory after massed training, which is again not the same object as starvation ketone support. On the mammalian fuel-choice side, Greda et al. (2025) shows that apoE3 / sortilin-dependent lipid uptake can enable neuronal use of long-chain fatty acids under glucose limitation, which is stronger than a generic lipid-support sentence but still not a direct whole-brain human route. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for direct living-human glial substrate-routing identification without a route-card audit.
17. Astrocyte ensemble / network state is not the same as glial substrate routing
Reading maintenance-state too neuron-centrically makes it easy to misread local transmitter integration and recall-state glia as background noise. Cahill et al. (2024) showed that local neurotransmitter inputs are encoded into broad cortical astrocyte network states over minutes. Furthermore, Williamson et al. (2025) showed that a learning-associated astrocyte ensemble forms near engram neurons in hippocampus, that ensemble reactivation promotes recall, and astrocyte-specific NFIA deletion suppresses recall. Dewa et al. (2025) showed that an emotional-memory-associated astrocytic ensemble contributes to multiday stabilization across repeated recall while integrating noradrenergic input and local engram signal, and Bukalo et al. (2026) showed that basolateral-amygdala astrocytes reorganize during fear retrieval / extinction and that astrocyte Ca2+ signaling supports amygdala-prefrontal representations. Therefore, it is dangerous to treat astrocyte-state as interchangeable with either glial substrate routing or neuronal mitochondrial support; the astrocyte ensemble itself remains a state variable in long-term memory. At the same time, the strongest causal evidence still centers on rodent hippocampus and amygdala, so these results should not be rephrased as direct readout of arbitrary human content or whole-brain maintenance-state.
Current human evidence is narrower than the rodent causal literature and is already split not only by molecular target, but also by tracer family, route role, quantification route, and cohort / covariate regime. Villemagne et al. (2022) characterized 18F-SMBT-1 PET as an MAO-B-selective reactive-astrogliosis proxy with pharmacological blockade, and Villemagne et al. (2022) then measured reactive astrogliosis across the Alzheimer disease spectrum within that tracer family. Hiraoka et al. (2025) then showed that even within the SMBT-1 MAO-B route, brain-side quantification depends on the named route burden, because scan window and reference-region choices were explicitly tested against kinetic modeling rather than assumed away. Mesfin et al. (2026) then separated a whole-body biodistribution route in six healthy humans over 5.5 h, with strong late gallbladder and intestinal accumulation, so even within the same tracer family the paper may be about systemic tracer burden rather than regional brain astrogliosis burden. Matsuoka et al. (2026) then showed that the separate 11C-SL25.1188 MAO-B tracer family in Alzheimer disease still depends on its own simplified arterial-free quantification route rather than inheriting SMBT-1 assumptions. Tyacke et al. (2018) characterized 11C-BU99008 PET as an imidazoline2 binding-site (I2BS) route with idazoxan competition and no blockade by isocarboxazid, so it is not the same molecular target as MAO-B PET. Livingston et al. (2022) then showed a regionally dynamic BU99008 pattern in cognitively impaired individuals, with higher uptake in Aβ-positive MCI than in AD across several cortices. Best et al. (2026) further showed with SL25.1188 human MAO-B PET in alcohol use disorder that mean binding was not generally elevated and shifted with AUD severity plus daily cigarette use, so even within an MAO-B route the tracer family, cohort regime, and covariates can materially change the reading. Jaisa-Aad et al. (2024) further showed postmortem that cortical MAO-B is mainly astrocytic but varies across AD/ADRD classes. Therefore, on this site, current human astrocyte PET is read as a target-defined, tracer-family-separated, route-role-separated, quantification-defined, and disease-/covariate-conditioned astrocyte-related proxy class, not as one generic human astrocyte-state meter and not as human whole-brain astrocyte-state ground truth.
Sun et al. (2024) suggested peri-engram neuron-astrocyte interaction and nominated Igfbp2 as a long-term-memory candidate, but Mukamel & Yu (2025) argued that some DEG claims are sensitive to animal-level dependence correction, and Sun et al. (2025) replied that the target of inference differs. Therefore, on this site, transcriptomic neuron-astrocyte evidence is treated as clue / hypothesis-generating evidence, while the causal weight of glia is read mainly from intervention studies such as Williamson et al. (2025), Dewa et al. (2025), and Bukalo et al. (2026).
The remaining weakness on this page was that astrocyte evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Cahill et al. (2024) is about minute-scale cortical astrocyte-network encoding of local neurotransmitter input. Williamson et al. (2025) is about learning-associated hippocampal astrocyte ensembles and recall. Dewa et al. (2025) is about multiday astrocytic stabilization of emotional memory. Bukalo et al. (2026) is about amygdala astrocyte Ca2+ signaling and fear-memory representations. Villemagne et al. (2022) is a human MAO-B astrocyte-related PET route linked to reactive astrogliosis, whereas Tyacke et al. (2018) is a human I2BS PET route. Livingston et al. (2022) then showed that BU99008 uptake can vary by region and impairment stage rather than moving as one monotone astrocyte scalar. Therefore, on this site, astrocyte claims now require a route card before they are promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about minute-scale astrocyte-network encoding, learning-associated recall ensemble, multiday stabilization ensemble, fear-state representation, or human astrocyte-related PET proxy. | Ensemble encoding, recall-state astrocytes, multiday stabilization, fear-state representations, and target-defined PET proxies collapse into one phrase such as astrocyte evidence shows memory state is measured. |
| Biological regime | Name species, brain region, task regime, healthy versus pathology context, and whether the relevant timescale is minutes, same-day recall, or multiday stabilization. | Cortical transmitter encoding, hippocampal recall, amygdala fear representation, and human PET all get silently promoted into one generic astrocyte claim. |
| Direct astrocyte observable | Write whether the direct observable is astrocyte Ca2+ dynamics, network-state readout, ensemble labeling, PET tracer binding, or another explicitly measured astrocyte-related object. | astrocyte state changed replaces the actual measurement, and a tracer proxy is overread as if it had directly measured ensemble identity or memory-specific astrocyte configuration. |
| Driver / perturbation route | State whether the paper uses transporter blockade, local transmitter manipulation, ensemble reactivation, gene deletion, astrocyte Ca2+ intervention, pharmacological blocking for PET selectivity, or no causal manipulation at all. | The site silently shifts from correlational astrocyte language to controller-identification language without a disclosed perturbation route. |
| Functional target | Name the dependent variable the claim is actually about, such as long-term memory formation, recall, multiday stabilization, fear-memory representation, or reactive-astrogliosis burden. | The site silently jumps from one target to another, for example from recall support or PET tracer binding to general maintenance completeness. |
| Human target / quantity type / tracer burden | For human evidence, disclose whether the route is MAO-B PET, I2BS PET, another explicitly named target, a whole-body biodistribution / tracer-burden route, only a macro energetic / support proxy, or no human astrocyte-related route at all, together with route role such as first-in-human target validation, AD-spectrum disease context, brain quantification, or whole-body biodistribution, blocking / competition evidence, quantification route such as validated scan window / reference region or kinetic model, disease or cohort regime, and material covariates such as smoking or recent substance exposure. | Different molecular targets, route roles, quantification routes, and stage- or covariate-dependent directions collapse into astrocyte PET, and a tracer-defined reactive-astrogliosis, I2BS, or systemic tracer-burden paper is overread as one generic astrocyte-state meter. |
| Abstention boundary | Fix in one line what remains latent, especially arbitrary memory content, whole-brain human astrocyte-ensemble identity, cell-specific neuron-astrocyte controller assignment, and same-subject human maintenance-state completeness. | Rodent causal evidence or human tracer evidence is promoted to human whole-brain memory-readout or state-complete maintenance language. |
The need is multi-axis. On the network-state side, Cahill et al. (2024) shows minute-scale cortical astrocyte-network encoding, which is not the same inferential object as recall or multiday stabilization. On the memory-ensemble side, Williamson et al. (2025) and Dewa et al. (2025) move from ensemble identity to recall and multiday stabilization, while Bukalo et al. (2026) is about fear-memory representations in a specific amygdala circuit. On the human side, Villemagne et al. (2022) established a first-in-human MAO-B SMBT-1 route, Villemagne et al. (2022) measured reactive astrogliosis across the Alzheimer disease spectrum within that tracer family, Hiraoka et al. (2025) showed that SMBT-1 brain quantification still depends on a named scan window / reference-region route relative to kinetic modeling, Mesfin et al. (2026) measured whole-body biodistribution over 5.5 h in six healthy humans and showed strong late gallbladder / intestinal burden, which constrains tracer distribution and dosimetry rather than regional brain astrogliosis burden, Matsuoka et al. (2026) showed that SL25.1188 in Alzheimer disease depends on its own simplified arterial-free quantification route, Tyacke et al. (2018) measures an I2BS route, Livingston et al. (2022) shows region- and stage-dependent BU99008 behavior, Best et al. (2026) shows that SL25.1188 MAO-B binding in another human disease regime shifts with severity and daily cigarette use rather than moving as one monotone scalar, and Jaisa-Aad et al. (2024) shows that MAO-B expression itself varies across AD/ADRD classes. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for human whole-brain astrocyte-state identification without a route-card audit.
18. clearance / immune support is not passive cleanup
The weak point that became clear here was that while I wrote about astrocyte / metabolic support in detail, I did not sufficiently isolate meningeal lymphatics, CSF-interstitial exchange, microglia, and clearance / immune support as an independent maintenance-state. Louveau et al. (2015) demonstrated structural and functional CNS lymphatic vessels, Ahn et al. (2019) showed that skull-base meningeal lymphatic vessels drain cerebrospinal fluid, and Kim et al. (2025) showed that the meningeal-lymphatics-microglia axis regulates synaptic physiology. The human lane is now split as well. Biechele et al. (2023) showed why TSPO is not a universal human activation-state meter, Wijesinghe et al. (2025) validated TSPO PET as a microglial biomarker in PSP, Horti et al. (2022) plus Ogata et al. (2025) established first-in-human CSF1R PET routes, and Yan et al. (2025) quantified COX-2 in healthy human brain. Fultz et al. (2019) then showed coupled macroscopic CSF oscillations during human NREM sleep, Kim, Huang, & Liu (2025) demonstrated a noninvasive MRI route for parenchyma-CSF water exchange, Eide & Ringstad (2021) showed that sleep deprivation impairs molecular clearance in humans, Eide et al. (2023) showed that intrathecal-tracer glymphatic markers and pharmacokinetic CSF-to-blood clearance capacity can track different plasma biomarker changes, Hirschler et al. (2025) measured region-specific CSF-mobility drivers with MRI, Lim et al. (2025) measured respiration-conditioned CSF net flow in awake humans while noting that plane-specific 2D PC-MRI net flow does not by itself represent whole-brain bulk circulation, Yoo et al. (2025) added an exercise-conditioned intravenous-contrast route for putative glymphatic influx and parasagittal meningeal-lymphatic flow, and Dagum et al. (2026) showed glymphatic-route transport of amyloid-beta and tau from brain to plasma in humans. Therefore, clearance / immune support is not just a metaphor for cleanup, but a measurable multiday support-state. At the same time, current human gains now split between transport-side observables and target-defined neuroimmune PET rather than remaining transport-only: these human results are still not direct readouts of local synaptic weight, cell-specific immune control, or moment-to-moment neural truth, and they do not all measure the same human quantity or target. On this site, clearance / immune support is therefore treated as a distinct slow support-state, while human evidence is first read as a split between a macro clearance-transport proxy family and target-defined neuroimmune PET routes.
Fultz et al. (2019) is a human fast-fMRI plus EEG route for macroscopic CSF oscillation during NREM sleep, not a solute-specific clearance assay. Kim, Huang, & Liu (2025) is a noninvasive MRI route for parenchyma-CSF water exchange in 6 young and 6 older healthy participants, not a protein-specific efflux readout. Hirschler et al. (2025) is a 7T MRI technical report on CSF mobility, and the authors explicitly interpret their quantity as mobility rather than net flow or direct solute clearance. Lim et al. (2025) is an awake-state 2D PC-MRI route for plane-specific CSF net flow and displacement under breathing manipulations, and the authors explicitly note that this metric does not by itself represent whole-brain bulk circulation. Yoo et al. (2025) adds an exercise-conditioned intravenous-contrast route for putative glymphatic influx and parasagittal meningeal-lymphatic flow in 16 long-term exercisers, with manual ROI steps and an explicit small-sample / healthy-young limitation. Eide et al. (2023) combines intrathecal gadobutrol, contrast MRI, and a population pharmacokinetic model, and shows that plasma Aβ40/42 and pTau181 can track different human clearance markers. Dagum et al. (2026) is an important advance that combines randomized crossover and plasma biomarkers, but it still relies on an investigational device, a multicompartment model, and a relatively small amyloid-positive subset. A second human lane is target-defined neuroimmune PET: Biechele et al. (2023) and Wijesinghe et al. (2025) constrain a TSPO disease-context / validation-bounded route, Horti et al. (2022) and Ogata et al. (2025) constrain CSF1R route-setting PET, and Yan et al. (2025) constrains an enzyme-defined COX-2 route. Therefore, this site treats the transport-side rows and the target-defined PET rows as different provisional human support proxies rather than one human glymphatic or immune scalar, and does not promote any of them to ground truth of cell-specific immune control or local synaptic maintenance.
The remaining weakness on this page was that clearance / immune evidence could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Louveau et al. (2015) and Ahn et al. (2019) are about meningeal-lymphatic structure and drainage anatomy. Da Mesquita et al. (2021) is about ageing / AD-like consequence and immunotherapy modulation when lymphatic function is impaired. Kim et al. (2025) is about a meningeal-lymphatics-microglia route that regulates synaptic physiology. Biechele et al. (2023) and Wijesinghe et al. (2025) constrain a TSPO disease-context / validation-bounded route. Horti et al. (2022) and Ogata et al. (2025) constrain first-in-human CSF1R PET routes. Yan et al. (2025) constrains an enzyme-defined COX-2 route. Fultz et al. (2019) is a human macroscopic CSF-oscillation route. Kim, Huang, & Liu (2025) is a human parenchyma-CSF water-exchange route. Hablitz et al. (2019) and Eide & Ringstad (2021) constrain physiology-linked clearance dynamics. Lim et al. (2025) is a human respiration-conditioned net-flow MRI route. Yoo et al. (2025) is an exercise-conditioned intravenous-contrast route for putative glymphatic influx and parasagittal meningeal-lymphatic flow. Eide et al. (2023) is a human intrathecal-tracer plus CSF-to-blood clearance-capacity route. Hirschler et al. (2025) is a human CSF-mobility MRI route. Dagum et al. (2026) is a model-based human biomarker-efflux route. Therefore, on this site, clearance / immune claims now require a route card before they are promoted beyond a narrow, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about drainage anatomy, disease / ageing lymphatic dysfunction, microglia-mediated synaptic maintenance, TSPO disease-context / validation-bounded PET, CSF1R route-setting PET, COX-2 enzyme-defined PET, sleep / physiology-linked mobility, human macroscopic CSF oscillation, human parenchyma-CSF water exchange, human respiration-conditioned net-flow MRI, human CSF-mobility imaging, intrathecal tracer retention / CSF-to-blood clearance, or human biomarker-efflux modeling. | Different inferential objects collapse into one phrase such as clearance evidence shows maintenance is measured. |
| Transport-side vs effector-side vs target-defined PET split | State whether the paper constrains fluid transport / drainage / efflux, an immune effector / synaptic controller, a target-defined neuroimmune PET route, or an explicitly demonstrated bridge between them. | A human transport proxy or target-defined PET route is overread as if it had already identified the responsible microglial controller, astrocyte-microglia interaction, or affected synapse. |
| Biological regime | Name species, healthy versus disease context, sleep / anesthesia / wake manipulation, local versus whole-brain preparation, and whether the paper studies normal support, pathology aggravation, or therapeutic rescue. | Mouse meningeal ablation, AD-like disease modulation, healthy-human sleep deprivation, and healthy-human MRI are silently promoted into one generic statement about clearance. |
| Direct observable / route object | Write whether the direct observable is lymphatic vessel anatomy, tracer movement, CSF mobility, protein concentration change, target-defined PET binding / blockade-sensitive signal, microglial transcriptional state, synaptic physiology, or another explicitly measured object. | clearance changed or immune PET changed replaces the actual observable, and a mobility or PET proxy is overread as if it had directly measured local immune control or synaptic maintenance. |
| Driver / perturbation route | State whether the paper manipulates lymphatic integrity, vascular / vasomotion state, sleep deprivation, microglial signaling, pharmacology, or nothing causal at all. | The site silently shifts from correlational support-state language to controller-identification or causal-maintenance language without a disclosed intervention route. |
| Human route object / quantity type | For human evidence, state whether the route measures macroscopic CSF oscillation, parenchyma-CSF water exchange, respiration-conditioned plane-specific net flow, CSF mobility in SAS / PVS, intrathecal tracer retention, CSF-to-blood clearance capacity, model-based brain-to-plasma biomarker efflux, TSPO disease-context / validation-bounded binding, CSF1R route-setting binding, or COX-2 enzyme-defined binding. | Different human routes are silently treated as one generic glymphatic measurement or immune PET even though they constrain different quantities or targets. |
| Carrier / analyte / target class and boundary crossed | For human evidence, state whether the route follows water, gadolinium contrast, endogenous protein biomarkers such as Aβ / tau, TSPO, CSF1R, COX-2, or another named carrier / analyte / target, and whether the relevant boundary is parenchyma-to-CSF exchange, SAS / PVS mobility, parasagittal mLV flow, CSF-to-blood transfer, or another explicitly named compartment transition, while also stating when a target-defined PET route does not cross a transport boundary at all. | Water mobility, contrast influx, intrathecal retention, brain-to-plasma biomarker efflux, and target-defined PET binding are silently treated as one generic glymphatic quantity even though they do not cross the same boundary, track the same carrier, or measure the same target class. |
| Physiology-driver audit | Report which physiology-linked driver was measured or manipulated, such as slow-wave EEG, BOLD / blood-volume oscillation, heart rate / HRV, respiration, breathing training / breathing depth, vasomotion, arterial compliance, sleep deprivation, or a device-derived parenchymal-resistance proxy. | A physiology-linked mover of the route is misread as the clearance object itself, and autonomic / vascular variation is silently promoted to direct support-state measurement. |
| Intervention naturalness / regime | State whether the route reflects natural sleep, acute sleep deprivation, wake-state breathing manipulation, long-term exercise training, intrathecal contrast administration, or device-assisted overnight modeling, and say whether the paper estimates a baseline state or an intervention-conditioned change. | An intervention-conditioned or contrast-dependent route is overread as if it were a route-free baseline measure of human clearance capacity. |
| Human measurement / model burden | For human evidence, disclose field strength, sequence family or tracer route, whether the route depends on motion-sensitizing gradients, MT labeling, intrathecal contrast, population pharmacokinetics, a multicompartment model, arterial input, reference-tissue modeling, or pharmacological blockade, plus cohort size, acquisition burden, and model assumptions. | A human clearance paper or neuroimmune PET paper is treated as if it had directly measured glymphatic flux, local microglial state, or cell-specific immune control without a proxy / model audit. |
| Validation / repeatability ceiling | Disclose whether the route has route-internal reliability, manual ROI burden, cross-method support, explicit small-sample limitations, disease-context validation, post-mortem alignment, pharmacological-blockade support, or only a model-conditioned fit without direct human flux or immune-controller ground truth. Yoo et al. (2025), Biechele et al. (2023), and Dagum et al. (2026) make these ceilings explicit in different ways. | A paper with a strong physiological or target-validation story is overread as if the transport or PET estimate were already a settled quantitative ground truth rather than a route-conditioned proxy. |
| Functional target | Name the dependent variable the claim is actually about, such as macromolecule drainage, amyloid burden, immunotherapy response, synaptic physiology, cognitive deficit, or multiday recovery support. | The site silently jumps from one target to another, for example from amyloid-handling or MRI mobility to general memory-maintenance completeness. |
| Abstention boundary | Fix in one line what remains latent, especially cell-specific immune controller, responsible synapse, local astrocyte-microglia coordination, instantaneous neural state, and same-subject whole-brain support-state identification. | Macro proxy, disease-model modulation, or biomarker-efflux evidence is promoted to local maintenance-controller or moment-to-moment neural-readout language. |
The need is multi-axis. On the anatomy side, Louveau et al. (2015) and Ahn et al. (2019) establish drainage routes, but they do not by themselves identify the immune effector. On the disease-modulation side, Da Mesquita et al. (2021) links impaired meningeal lymphatics to worse microglial inflammatory response and poorer anti-Aβ immunotherapy outcome, which is stronger than a purely anatomical statement but still not a general human readout. On the human physiology side, Fultz et al. (2019) shows coupled slow-wave, hemodynamic, and CSF oscillations during NREM sleep, which is a macroscopic route for CSF motion rather than a direct protein-clearance assay. Kim, Huang, & Liu (2025) measures parenchyma-CSF water exchange, which is closer to exchange than oscillation but still not protein-specific efflux. Hirschler et al. (2025) measures CSF mobility and explicitly stops short of claiming net flow direction. Yoo et al. (2025) measures exercise-conditioned putative glymphatic influx and parasagittal mLV flow using intravenous contrast plus IR-ALADDIN, which is useful but not a route-free natural-sleep baseline and not a direct endogenous-solute assay. Eide et al. (2023) shows that CSF-to-blood clearance capacity, intrathecal tracer retention, and plasma biomarker changes need not collapse onto one human marker because Aβ40/42 and pTau181 tracked different routes. Dagum et al. (2026) then infers brain-to-plasma biomarker clearance with an investigational device and multicompartment model, while also relying on dimensionality reduction to manage the regressor burden in a relatively small amyloid-positive subgroup. Therefore, this site does not let these rows inherit one another's claim ceiling, and it does not let any of them stand in for local synaptic maintenance or cell-specific immune control without a route-card audit.
19. Local proteostasis / synaptic tagging under molecular turnover is another state layer
The weak point that became clearer in this pass was that the site separated current synaptic state from transcriptional / chromatin state, while still leaving the branch-local route that decides which potentiated synapse captures plasticity-related proteins and survives turnover too implicit. That is too coarse. Frey & Morris (1997) proposed synaptic tagging as the condition that allows late LTP to capture plasticity-related proteins, Shires et al. (2012) demonstrated synaptic tagging and capture in the living rat, and Govindarajan et al. (2011) showed that the dendritic branch is a preferred integrative unit for protein-synthesis-dependent LTP. Furthermore, Fonseca et al. (2006) showed that maintenance of late LTP depends on a balance between protein synthesis and proteasome-dependent degradation, Pandey et al. (2021) linked local autophagy-coupled translation to long-term memory formation, Chang et al. (2024) showed that secretory autophagy is a distinct route for activity-induced synaptic remodeling, Thomas et al. (2025) showed that actin / spine geometry can persist on the timescale of the synaptic tag, Lee et al. (2022) showed that synaptic memory can survive molecular turnover by active state transfer, and Parker et al. (2025) showed that proteasome augmentation can mitigate age-related spatial learning and memory decline in mice. Therefore, even if the connectome, a weight estimate, and a one-shot transcriptomic measurement are given, which synapses remain capture-ready, which local proteostasis route is operative, and which late changes persist under turnover can still remain latent.
The current human routes on this site, such as SV2A PET, MRSI, 31P-MRS / deuterium metabolite mapping / deuterium kinetic imaging / sodium MRI, myelin maps, TMS-EEG, and CSF proxies, do not directly tell us which spine or dendritic branch carried the tag, captured the plasticity-related proteins, or ran the relevant translation/degradation/autophagy program. This is an inference from the measurement classes summarized below. Therefore, on this site, local proteostasis / synaptic tagging remains a local hidden state in humans unless it is externally calibrated or causally perturbed.
The remaining weakness on this page was that it still let several different inferential objects collapse into one label such as proteostasis evidence. The primary literature does not support that shortcut. Frey & Morris (1997) and Shires et al. (2012) are about tag / capture eligibility. Govindarajan et al. (2011) is about dendritic branch-level integration of protein-synthesis-dependent LTP. Fonseca et al. (2006) and Parker et al. (2025) are about synthesis-degradation or proteasome-capacity balance with memory consequences. Pandey et al. (2021) and Chang et al. (2024) are about autophagy-linked plasticity routes. Lee et al. (2022) and Thomas et al. (2025) are about turnover-resistant persistence or a candidate tag substrate. Therefore, this site now requires a local proteostasis / synaptic-tagging route card before a claim is promoted beyond a tag-setting clue, a branch-level integration result, an autophagy / proteasome perturbation, or a turnover-resistance mechanism.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper supports tag / capture eligibility, branch-level integration, synthesis-degradation balance, autophagy-linked remodeling, turnover-resistant persistence, or a proteasome-capacity intervention. | Different inferential objects collapse into one phrase such as proteostasis evidence supports memory stability. |
| Biological regime / integrative unit | Name species, brain region, synapse or branch class, behavioral phase, and whether the relevant unit is the synapse, dendritic branch, neuron, or whole preparation. | A branch-local mechanism or aging-intervention result is silently promoted to a generic whole-brain late-stabilization controller. |
| Direct observable / assay | Write the actual readout explicitly: tag/capture protocol, branch-restricted LTP, proteasome activity / assembly, autophagosome-autolysosome route, secretory-autophagy marker, stable actin fraction, spine geometry persistence, or another named observable. | proteostasis changed replaces the actual measured object, and assay-specific ceilings disappear. |
| Turnover / time window | State whether the claim is about minutes-to-hours late LTP, reconsolidation after retrieval, multiday persistence, ageing-related decline, or another explicitly named turnover window. | An acute stabilization effect is overread as a durable turnover-resistant controller, or a chronic intervention is overread as an acute tag readout. |
| Controller / perturbation route | Name what was actually manipulated or assumed, such as protein synthesis blockade, proteasome modulation, autophagy pathway component, secretory-autophagy release factor, or active-state-transfer mechanism. | The site ceases to distinguish direct mechanism, pathway perturbation, and inferred persistence under turnover. |
| Functional target | Name the dependent variable the claim is about, such as late LTP maintenance, spine remodeling, reconsolidation, contextual fear memory, spatial learning, or age-related cognitive decline. | A result that constrains one target is promoted to a generic statement that proteostasis solved long-term memory maintenance. |
| Human observability / external calibration | State whether any human route is direct or whether current evidence remains an externally calibrated or proxy-only ceiling. | Regional human proxies or animal causal evidence are silently promoted to branch-local human proteostasis readout. |
| Abstention boundary | Fix in one line what remains latent, especially tagged branch identity, PRP capture map, local ribosome / proteasome / autophagy state, same-subject whole-brain continuity, and responsible controller beyond the assayed pathway. | The site accidentally treats proteostasis evidence exists as equivalent to late-stabilization-complete or maintenance-complete state capture. |
The need is multi-axis. On the local-integration side, Govindarajan et al. (2011) shows that the relevant unit can be the dendritic branch rather than the whole neuron. On the pathway side, Chang et al. (2024) shows that activity-induced remodeling is not exhausted by degradative autophagy because secretory autophagy can be selectively required. On the intervention side, Parker et al. (2025) shows that changing proteasome capacity can alter learning and memory in aged mice, which is stronger than a correlational proteostasis sentence but still not a direct tag readout. On the human-observability side, current routes on this site still do not resolve tagged branches, PRP capture, local ribosome / proteasome / autophagy state, or same-subject whole-brain late-stabilization controllers. Therefore, this site does not let proteostasis evidence exists stand in for late-stabilization completeness.
20. Relative excitability influences future memory allocation
Yiu et al. (2014) showed that relative neuronal excitability before learning influences which neurons are more likely to be incorporated into a memory trace. Additionally, Hadzibegovic et al. (2025) show that early intrinsic excitability plasticity of neocortical engram neurons regulates memory formation and precision. Therefore, even if the connectome is the same, future learning paths and memory allocation can change if the excitability landscape is different.
2026-03 Addendum: Human maintenance-state observability is layered, not direct
The reason this section needed a second pass is that “human evidence is starting to appear” was still too undifferentiated. Human maintenance-state evidence does not come as one direct readout. Instead, current primary literature pushes different layers upward: structural scaffold, regional synaptic-density proxy, regional receptor / transporter atlas prior, ligand-limited occupancy proxy, challenge-limited displacement / release proxy, macro-biochemical scaffold, macro energetic proxy, quantity-defined macro ionic proxy family, macro thermal / perturbation-conditioned thermal proxy family, quantity-defined macro-myelin proxy family, macro BBB water-exchange / tracer-specific transport proxy family, macro blood-CSF barrier / choroid-plexus transport proxy family, target-defined astrocyte-related proxy, perturbation-conditioned plasticity proxy, and macro clearance-transport proxy family. Meanwhile, current transcriptional / chromatin state, current post-transcriptional RNA-state, current phospho-signaling / second-messenger state, current ECM / PNN gate state, current chloride homeostasis, branch-local proteostasis / tag-capture route, and current cell-specific immune-controller state still do not have a comparable in vivo whole-brain human route. Therefore, even on the human side, maintenance-state must be read as layered evidence, not as a nearly direct state-complete snapshot.
| What I began to see in human | Directly visible layer | Still latent layer | Safe site reading |
|---|---|---|---|
| human nanoscale ultrastructure Shapson-Coe et al. |
Ultrastructure, cell/synapse arrangement, and local structure scaffold of fixed human cortex fragments. | Current weight, sleep history, recovery controller, neuromodulatory context, and glial slow-state. | Structural scaffold enhancement of fixed tissue, not a state-complete snapshot. |
| human synaptic-density PET Finnema et al., Naganawa et al., Johansen et al. |
Regional presynaptic vesicle density based on SV2A binding and atlas-level synaptic-density distribution. | Current synaptic efficacy, release probability, postsynaptic receptor occupancy, silent-synapse recruitment, excitatory / inhibitory composition, and trial-level fluctuation. | Regional synaptic-density proxy, not moment-to-moment transmission ground truth. |
| human receptor / transporter atlas Hansen et al., Goulas et al. |
Group-average regional chemoarchitectural prior across named receptor and transporter systems. | Current receptor occupancy, task-time endogenous release, cell-specific downstream effect, and the individual's present transmitter field. | Regional neuromodulatory prior, not an individual's current neuromodulatory state. |
| human occupancy PET Wong et al. |
Target engagement of a selected receptor family under an administered ligand and bounded quantification model. | Endogenous transmitter release, unsampled receptor families, laminar or cell-specific effect, and stable state outside the dosing window. | Ligand- and dose-limited target-engagement proxy, not whole-brain transmitter-state ground truth. |
| human displacement / release-sensitive PET Koepp et al., Lippert et al., Erritzoe et al. |
Challenge-linked binding change for a selected tracer / receptor family over a bounded scan window, used as a proxy for endogenous release. | Complete transmitter field, unsampled receptor families, downstream consequence, and stable neuromodulatory identity outside the challenge window. | Challenge-limited release proxy, not continuous whole-brain neuromodulatory readout. |
| human metabolic connectome Lucchetti et al. |
Gray-matter parcel similarity graph built from five 1H-MRSI metabolite profiles (tCr / tNAA / Glx / Ins / Cho). | Axonal edge-level connectivity, current glucose metabolic rates / ATP turnover, cell-specific metabolic routing, astrocyte ensemble, local transmitter state, and synapse-specific maintenance. | Macro-biochemical similarity scaffold or covariate, not local maintenance-state ground truth. |
| human 31P metabolite / pH balance Ren et al. |
Resting ATP synthesis, phosphorus-metabolite concentrations, and intra- / extracellular pH under 31P-MRS. | Branch-specific ATP reserve, task-evoked metabolic switching, cell-specific mitochondrial positioning, and synapse-specific fatigue risk. | Macro metabolite / pH proxy, not local mitochondrial-state ground truth. |
| human 31P MT exchange-flux Ren et al. |
Model-conditioned PCr→ATP and Pi→ATP exchange-flux estimates under band-inversion / magnetization-transfer spectroscopy. | Route-free ATP-turnover truth, cell-specific energetic routing, local redox reserve, and branch-specific mitochondrial control. | Model-conditioned macro exchange-flux proxy, not direct local controller readout. |
| human 31P NAD-content mapping Guo et al. |
Whole-brain intracellular NAD-content mapping at macro resolution under specialized 31P-MRSI processing. | Task-locked local NAD dynamics, branch-specific mitochondrial status, and cell-specific redox-controller identity. | Macro NAD-content proxy, not a dynamic or local mitochondrial-state readout. |
| human localized functional 31P NAD-dynamics Kaiser et al. |
Task-evoked NAD+ changes in a functionally localized spectroscopy voxel under prior localization and block design. | Whole-brain NAD distribution, task-general energetic state, route-free controller identity, and branch-specific mitochondrial positioning. | Localized task-linked NAD-dynamics proxy, not whole-brain or route-general energetic ground truth. |
| human deuterium metabolite-mapping / absolute quantification Karkouri et al. |
Absolute deuterated-metabolite concentrations plus calibration-dependent companion rate estimates under a dedicated deuterium acquisition and quantification pipeline. | Route-free kinetic-rate truth, generic dose invariance, branch-local mitochondrial reserve, and synapse-specific fatigue risk. | Macro deuterated-metabolite burden proxy, not route-free kinetic or local mitochondrial ground truth. |
| human deuterium kinetic-rate imaging Li et al. |
Blood-input and kinetic-model-dependent glucose-transport / metabolic-rate maps from dynamic deuterium MRSI. | Absolute route-free metabolite burden, generic dose invariance, branch-specific mitochondrial positioning, and local controller identity. | Model-conditioned macro kinetic-rate proxy, not local mitochondrial-state ground truth. |
| human sodium MRI / ionic proxy Qian et al. |
mm-class tissue sodium mapping in vivo plus newer mono- / bi-T2 sodium separation under specialized sodium MRI acquisition. | Cell-specific chloride concentration, KCC2 / NKCC1 balance, extracellular K+ / Ca2+ / pH microdomains, local inhibitory reversal potential, and routine identification of intra- versus extracellular sodium partition. | Macro ionic proxy, not direct readout of current chloride homeostasis. |
| human CSF ionic assay Forsberg et al. |
Healthy-human CSF potassium, calcium, and magnesium measurements across wakefulness, sleep, and sleep deprivation. | Which local microdomain, which cell class, which chloride transporter, and which synapse-level inhibitory controller produced the bulk change. | CSF-level ionic / circadian proxy, not local chloride or EGABA ground truth. |
| human passive / task-linked macro thermometry Rzechorzek et al., Rogala et al., Tan et al. (2025) |
Regional brain temperature rhythms, frontal-lobe spectroscopy temperatures, and task-linked macro thermal changes measured with MRS thermometry. | Cell-specific microtemperature, synapse-specific heating burden, and local thermal control around the same circuit. | Bounded macro thermal proxy, not direct readout of local thermal-state. |
| human perturbation-conditioned thermal routes Tan et al. (2024), Inoue et al. (2025) |
Measured brain-temperature changes together with bounded motor, executive, perfusion, or neurovascular responses under severe heat exposure or intraoperative focal cooling. | Cell-specific microtemperature, route-general local thermal-controller identity, routine whole-brain coverage, and same-subject transfer outside the perturbation regime. | Perturbation-conditioned human thermal proxy, not direct readout of local thermal-state. |
| human myelin MRI quantity-type split Arshad et al., Hagiwara et al., Baadsvik et al., Chen et al., Galbusera et al., Colaes et al. |
Different human MRI routes constrain different objects: myelin-water, MT-family macromolecular contrast, bilayer-sensitive ultrashort-T2 contrast, qT1 remyelination sensitivity, and T1w/FLAIR tissue-health-sensitive ratios, each with route-specific orientation, hardware, or specificity burden. | Single-axon conduction delay, activity-dependent myelination, oligodendrocyte-axon metabolic support, and a cell-specific timing controller. | Quantity-defined macro-myelin proxy family, not one interchangeable timing-state meter. |
| human BBB water-exchange / tracer-specific transport proxy Padrela et al., Morgan et al., Chung et al. |
Macro BBB water-exchange or tracer-specific permeability-surface-area route under explicit ASL or dynamic PET kinetic models, with method dependence still unresolved even within ASL-based Kw estimates. | Cell-specific pericyte / endothelial controller identity, local capillary recruitment state, barrier-state at a tagged synapse, and arbitrary memory-content support. | Macro BBB water-transport / tracer-transport proxy, not direct neurovascular-unit controller ground truth. |
| human blood-CSF barrier / choroid-plexus transport proxy Zhao et al., Petitclerc et al., Anderson et al., Wu et al. |
Apparent choroid-plexus perfusion, blood-to-CSF water-exchange time, choroid-plexus water-efflux rate, or apparent kBCSFB under ASL, DCE-MRI, or REXI measurement models. | Route-free CSF-production truth, whole-brain solute-clearance capacity, choroid-plexus epithelial transporter identity, BBB / pericyte controller identity outside the CP, and local synaptic maintenance. | Route-conditioned BCSFB / choroid-plexus transport proxy family, not generic BBB truth or generic clearance truth. |
| human clinical single-unit allocation route Tallman et al. |
Hippocampal single-unit recordings in epilepsy patients showing that remembered items with a relative increase in firing at encoding are selectively associated with sparse episodic-memory coding at retrieval. | Pre-existing intrinsic excitability versus learning-induced excitability, AIS / channel state, synaptic-drive contribution, and whole-brain controller coverage. | Local clinical-unit allocation-related readout, not a whole-brain excitability map or direct controller measurement. |
| human sleep-homeostasis / plasticity proxy Huber et al., Kuhn et al., Fehér et al. |
A macro perturbational proxy that changes TMS-EEG excitability and PAS induction plasticity depending on wake / sleep / nap. | Which cell type, synapse, glia, or controller was responsible for the change. | Perturbation-conditioned maintenance proxy, not direct identification of the responsible controller. |
| human state-gated perturbation proxy Zrenner et al., Khatri et al. |
A state-conditioned causal proxy in which EEG-defined or personalized whole-brain CST states influence TMS-induced plasticity efficacy or corticospinal responses. | AIS geometry, channel distribution, cell-specific allocation state, and long-horizon recovery controllers. | State-conditioned causal proxy, not direct measurement of the excitability mechanism itself. |
| human astrocyte-related PET proxy Villemagne et al. (SMBT-1 first-in-human / AD-spectrum), Tyacke et al., Livingston et al. |
A target-defined regional MAO-B or I2BS astrocyte-related PET route whose interpretation depends on target-validation versus disease-context paper, quantification route, disease regime, and material cohort covariates. | Learning-associated astrocyte ensembles, minute-scale transmitter integration, recall-state astrocytes, and arbitrary memory-content readout. | Target-defined human astrocyte-related proxy route, not direct astrocyte-ensemble or memory-state ground truth. |
| human target-defined neuroimmune PET proxy Biechele et al., Wijesinghe et al., Horti et al., Ogata et al., Yan et al. |
A target-defined human neuroimmune PET route whose interpretation depends on whether the paper is a TSPO disease-context / validation-bounded route, a CSF1R route-setting route, or an enzyme-defined COX-2 route. | Route-free microglia-state truth, local immune-controller identity, synapse-specific maintenance, and arbitrary transfer across tracer families or disease regimes. | Target-defined human neuroimmune proxy route, not direct immune-controller or maintenance-state ground truth. |
| human CSF-mobility / net-flow transport proxy Hirschler et al., Lim et al. |
Region-specific CSF mobility or plane-specific net-flow / displacement under high-field MRI or 2D PC-MRI breathing manipulations. | Net whole-brain solute flux, segment-specific drainage responsibility, local immune effector, and synapse-specific maintenance. | Macro clearance-transport proxy, not local clearance / immune-controller ground truth. |
| human exercise-conditioned contrast route Yoo et al. |
Intravenous-contrast-based putative glymphatic influx and parasagittal meningeal-lymphatic size / flow changes after a 12-week exercise intervention. | Route-free natural-sleep baseline, endogenous protein efflux, segment-resolved drainage truth, local immune effector, and same-subject whole-brain maintenance identification. | Intervention-conditioned macro clearance-transport proxy, not a general baseline clearance meter. |
| human intrathecal / biomarker-efflux clearance proxy Eide et al., Dagum et al. |
Intrathecal tracer retention / CSF-to-blood clearance variables or model-based brain-to-plasma biomarker efflux under named pharmacokinetic or multicompartment models. | Route-free natural-sleep drainage truth, segment-specific responsibility, local immune effector, and synapse-specific maintenance. | Model-conditioned clearance-transport proxy, not local clearance / immune-controller ground truth. |
This distinction matters operationally. Shapson-Coe et al. (2024) push the fixed-tissue structural scaffold. Finnema et al. (2016), Naganawa et al. (2021), and Johansen et al. (2024) push a regional synaptic-density proxy. Hansen et al. (2022) and Goulas et al. (2021) push regional neuromodulatory priors. Wong et al. (2013) pushes occupancy-based target engagement. Koepp et al. (1998), Lippert et al. (2019), and Erritzoe et al. (2020) push challenge-limited release proxies. Shatalina et al. (2024) and Lucchetti et al. (2025) push parcel-level biochemical organization. Rzechorzek et al. (2022), Rogala et al. (2024), and Tan et al. (2025) push passive or task-linked macro thermometry, while Tan et al. (2024) and Inoue et al. (2025) push perturbation-conditioned human thermal routes. Ren et al. (2015), Karkouri et al. (2026), and Li et al. (2025) push distinct macro energetic proxy classes. Qian et al. (2012), Qian et al. (2025), and Forsberg et al. (2022) push a quantity-defined macro ionic proxy family. Arshad et al. (2017), Hagiwara et al. (2018), Baadsvik et al. (2024), Chen et al. (2025), and Galbusera et al. (2025) together push a quantity-defined macro-myelin proxy family rather than one interchangeable human myelin meter. Padrela et al. (2025), Morgan et al. (2024), and Chung et al. (2025) together push a quantity-defined macro BBB water-exchange / tracer-specific transport proxy family. Tallman et al. (2025) pushes a human local clinical-unit allocation route. Huber et al. (2013), Kuhn et al. (2016), Khatri et al. (2025), Fehér et al. (2026), and Zrenner et al. (2018) push perturbation-conditioned plasticity proxies. Villemagne et al. (2022), Villemagne et al. (2022), Hiraoka et al. (2025), Mesfin et al. (2026), Matsuoka et al. (2026), Tyacke et al. (2018), Livingston et al. (2022), and Best et al. (2026) push target-defined human astrocyte-related PET proxies with separate SMBT-1 target-validation, AD-context, brain-quantification, whole-body biodistribution, SL25.1188 disease / severity, and I2BS ceilings. Biechele et al. (2023), Wijesinghe et al. (2025), Horti et al. (2022), Ogata et al. (2025), and Yan et al. (2025) push a target-defined human neuroimmune PET proxy family with separate TSPO disease-context / validation-bounded, CSF1R route-setting, and COX-2 enzyme-defined ceilings. Hirschler et al. (2025), Lim et al. (2025), Yoo et al. (2025), Eide et al. (2023), and Dagum et al. (2026) push a macro clearance-transport proxy family with distinct mobility, plane-specific net-flow, intervention-conditioned contrast-influx, intrathecal-clearance, and biomarker-efflux ceilings. These are not interchangeable evidence classes.
Therefore, on this site, human synaptic-density PET is written as a tracer-defined regional synaptic-density proxy, human receptor / transporter atlas as a regional chemoarchitectural prior, human occupancy PET as a ligand- and dose-limited target-engagement proxy, human displacement PET as a challenge-limited release proxy, human metabolic connectome as a macro-biochemical scaffold, passive / task-linked human thermometry as a bounded macro thermal proxy, human heat- or focal-cooling studies as perturbation-conditioned thermal proxies, 31P metabolite / pH balance, 31P MT exchange-flux, 31P NAD-content mapping, localized functional 31P NAD-dynamics, deuterium metabolite-mapping / absolute quantification, and deuterium kinetic-rate imaging as separate macro energetic proxy classes, human sodium MRI and CSF ion assays as a quantity-defined macro-ionic proxy family whose quantity type may be tissue-sodium mapping, SQ+TQF-derived ISMF / ISC / ISVF, normalized sodium density-weighted, mono-/bi-T2 separation, short-component-sensitive sodium imaging, or CSF ion concentration depending on the assay, human myelin MRI as a quantity-defined macro-myelin proxy family whose quantity type may be myelin-water, MT-family, bilayer-sensitive, qT1 remyelination-sensitive, or T1w/FLAIR tissue-health-sensitive depending on the assay, human BBB water-exchange MRI and tracer-specific transport PET as a quantity-defined macro BBB water-exchange / tracer-specific transport proxy family, human clinical single-unit episodic-memory recordings as a local allocation-related readout, TMS-EEG / sleep plasticity routes as perturbation-conditioned proxies, human astrocyte PET as a target-defined astrocyte-related proxy whose reading still depends on whether the evidence is first-in-human target validation, AD-spectrum disease context, a named brain quantification route, a whole-body biodistribution route, or a particular cohort / covariate regime, human neuroimmune PET as a target-defined neuroimmune proxy family whose reading still depends on whether the evidence is TSPO disease-context / validation-bounded, CSF1R route-setting, or COX-2 enzyme-defined, and CSF mobility / net-flow / contrast-influx / intrathecal / efflux evidence as a macro clearance-transport proxy family. Human ECM evidence such as Boonen et al. (2022) remains mostly ex vivo pathology, and current transcriptional / chromatin state, current post-transcriptional RNA-state, current phospho-signaling / second-messenger state, plus branch-local proteostasis still lack a comparable in vivo whole-brain human route. It is therefore valid to use animal causal evidence to support the existence of these layers, but not to silently upgrade present human routes into cell-specific recovery controller, pericyte / endothelial controller identity, capillary recruitment ground truth, astrocyte-ensemble identity, local thermal-state, current synaptic efficacy, current chloride homeostasis, local immune controller, local mitochondrial state, current RNA-state controller, current phospho-controller, current ECM plasticity gate, or instantaneous whole-brain transmitter field ground truth.
The remaining weakness after adding route cards was subtler. This page already separated proxy class and, elsewhere on the site, operational maturity. But a third axis still remained undernamed: calibrator role. The primary literature does not show that every living-human proxy calibrates the same hidden-state family. Johansen et al. (2024) is a regional synaptic-density atlas route; Hansen et al. (2022) and Goulas et al. (2021) are receptor / transporter atlas routes; Wong et al. (2013) is an occupancy route; Koepp et al. (1998), Lippert et al. (2019), and Erritzoe et al. (2020) are challenge-linked release routes; Lucchetti et al. (2025) is a parcel-level biochemical similarity route; Li et al. (2025) is a kinetic energetic-rate route in a very small, high-burden cohort; Baadsvik et al. (2024) and Genc et al. (2025) constrain quantity-defined macro myelin / oligodendrocyte-linked burden; Padrela et al. (2025), Morgan et al. (2024), and Chung et al. (2025) constrain quantity-defined macro BBB water-exchange or tracer-specific transport routes under explicit measurement / kinetic models; Villemagne et al. (2022), Villemagne et al. (2022), Hiraoka et al. (2025), Mesfin et al. (2026), Matsuoka et al. (2026), Tyacke et al. (2018), Livingston et al. (2022), and Best et al. (2026) constrain target-defined astrocyte-related or tracer-burden routes with separate SMBT-1 target-validation, AD-context, brain-quantification, whole-body biodistribution, SL25.1188 disease / severity, and I2BS roles; and Hirschler et al. (2025), Lim et al. (2025), Yoo et al. (2025), Eide et al. (2023), plus Dagum et al. (2026) constrain macro clearance-transport routes rather than local immune-controller identity. Therefore, on this site, each human row must now say not only what class it belongs to and how mature it is, but also which latent maintenance-state family it safely calibrates.
| Human route | Safe calibrator role on this site | What it still does not calibrate |
|---|---|---|
| SV2A PET Finnema et al., Naganawa et al., Johansen et al. |
Regional synaptic-density proxy with explicit tracer / quantification route. | Momentary synaptic efficacy, tagged-synapse eligibility, branch-local plasticity capture, or arbitrary memory content. |
| Receptor / transporter atlas Hansen et al., Goulas et al. |
Regional neuromodulatory prior constrained by named receptor / transporter families and atlas construction choices. | Current receptor occupancy, endogenous release, laminar effect, or the individual's present transmitter field. |
| Occupancy PET Wong et al. |
Selected target-engagement route for a named receptor family under an administered ligand and bounded dose window. | Endogenous transmitter release, unsampled receptor families, or stable neuromodulatory identity outside the dosing window. |
| Displacement / release-sensitive PET Koepp et al., Lippert et al., Erritzoe et al. |
Challenge-limited release proxy for a named tracer / receptor family and scan window. | Whole-brain transmitter field, downstream causal consequence, or a task-general neuromodulatory controller identity. |
| 1H-MRSI metabolic connectome Lucchetti et al. |
Parcel-level biochemical similarity scaffold constrained by a named metabolite set and correction model. | Structural wiring, local ATP flux, cell-specific glial state, or current synaptic controller identity. |
| 31P metabolite / pH balance Ren et al. |
Macro energetic-balance proxy for ATP synthesis, phosphorus-metabolite burden, and pH under a named acquisition and fitting route. | Branch-local mitochondrial positioning, local ATP sufficiency at a tagged synapse, or cell-specific recovery controller identity. |
| Deuterium metabolite mapping / absolute quantification Karkouri et al. |
Macro deuterated-metabolite burden route under an explicit absolute-quantification pipeline and route-specific hardware burden. | Branch-local mitochondrial positioning, local ATP sufficiency at a tagged synapse, or cell-specific recovery controller identity. |
| Deuterium kinetic-rate imaging Li et al. |
Model-conditioned whole-brain glucose transport / metabolic-rate route under dynamic acquisition and blood-input assumptions. | Branch-local mitochondrial positioning, local ATP sufficiency at a tagged synapse, or cell-specific recovery controller identity. |
| Myelin MRI / oligodendrocyte-linked microstructure MRI Baadsvik et al., Genc et al. |
Macro myelin / oligodendrocyte-linked burden and developmental microstructure route. | Per-axon conduction timing, nodal microgeometry, or plasticity-complete restoration of a specific circuit. |
| BBB water-exchange MRI / tracer-specific PET Padrela et al., Morgan et al., Chung et al. |
Macro BBB water-exchange or tracer-specific transport-model route under named ASL or kinetic PET assumptions. | Cell-specific pericyte / endothelial controller identity, local capillary recruitment, or plasticity-ready BBB gate state in a specific circuit. |
| Sodium MRI / ionic proxy Qian et al. |
Macro ionic proxy for bounded whole-brain ion-state burden. | Local chloride set point, transporter balance, or inhibitory sign at a given synapse. |
| MRS thermometry / task-linked thermal mapping Rzechorzek et al., Rogala et al., Tan et al. |
Macro thermal proxy for whole-brain rhythm, task-linked thermal shift, or bounded voxel-level thermal burden. | Submillimeter thermal microstate, synapse-specific heating burden, or local thermal-controller identity. |
| Clinical single-unit hippocampal route Tallman et al. |
Local allocation-related readout linking relative firing increase at encoding to sparse episodic-memory coding in the hippocampus. | Pre-existing intrinsic excitability, AIS / channel controller identity, synaptic-drive contribution, or whole-brain allocation landscape. |
| TMS-EEG / sleep-plasticity proxy Huber et al., Kuhn et al., Zrenner et al., Khatri et al., Fehér et al. |
Perturbation-conditioned excitability / plasticity response route in bounded motor or corticospinal assays. | Direct measurement of the underlying cellular controller, synapse-specific allocation state, or stable long-horizon maintenance identity. |
| Astrocyte PET (MAO-B / I2BS brain routes) Villemagne et al. (SMBT-1 first-in-human / AD-spectrum); Hiraoka et al.; Tyacke et al.; Livingston et al.; Best et al. |
Target-defined astrocyte-related proxy with an MAO-B or I2BS brain PET route whose reading still depends on route role, quantification model, and disease / covariate regime. | Learning-associated astrocyte ensemble identity, recall-state astrocytes, or arbitrary-content memory readout. |
| Whole-body SMBT-1 biodistribution Mesfin et al. |
Whole-body tracer-distribution / organ-uptake route for a named MAO-B PET tracer family. | Regional brain astrogliosis burden, AD-context trajectory, or local astrocyte-controller identity. |
| CSF mobility / contrast-influx / net-flow / efflux routes Hirschler et al., Lim et al., Yoo et al., Eide et al., Dagum et al. |
Macro clearance-transport route for CSF mobility, intervention-conditioned contrast influx, plane-specific net flow, intrathecal clearance variables, or modeled brain-to-plasma efflux. | Cell-specific immune controller identity, synapse-specific clearance support, or local astrocyte / microglia mechanism assignment. |
The remaining weakness on this page was that metabolic connectome could still be read as if the field had obtained another connectome in the same sense as tractography or direct flux mapping. Lucchetti et al. (2025) defined the object more narrowly: pairwise correlations among five metabolites (tCr, tNAA, Glx, Ins, Cho) across gray-matter parcels in 51 healthy participants, with replication in 13 more participants at a different site. The same paper reported that overall metabolic similarity aligns only weakly with tractography-based structural connectivity and more closely with cytoarchitectonic similarity and gene co-expression. Therefore, this site reads the row first as a parcel-level biochemical similarity graph, not as axonal wiring or a local maintenance-state map.
The measurement model also remains part of the object. Bhogal et al. (2020) showed that in vivo MRSI still faces low SNR, partial-volume effects, extracranial lipid artifacts, and scan-time constraints; Wright et al. (2022) showed that averaged instead of voxel-specific metabolite T1 corrections can bias maps; and Baboli et al. (2024) showed that absolute quantification can shift when tissue-water and relaxation corrections are individualized. Lucchetti et al. also corrected 5 mm isotropic MRSI using partial-volume modeling and PSF deconvolution. On this site, an MRSI-derived metabolic connectome must therefore disclose the metabolite set, parceling unit, resolution plus PSF / partial-volume correction, water / lipid handling, spectral QC thresholds, and abstention boundary before its claim ceiling is interpreted.
A final correction is that static 1H-MRSI similarity is not the same object as rate imaging. Li et al. (2025) used dynamic deuterium MRSI plus a kinetic model to map glucose transport and metabolic rates such as CMRGlc, CMRLac, and VTCA. This site therefore does not let the phrase human metabolic connectome silently inherit claims about current glucose-flux, ATP-turnover, or energetic-rate imaging.
The remaining weakness on this page was that human synaptic-density PET could still collapse several different inferential objects into one bucket. The primary literature does not support that shortcut. Finnema et al. (2016) established a living-human SV2A PET route and showed sensitivity to synaptic loss in temporal-lobe epilepsy. Naganawa et al. (2021) showed that quantification depends on the tracer, arterial-versus-reference route, compartment model, and named scan window. Johansen et al. (2024) is a healthy-human atlas route calibrated against autoradiography. Shatalina et al. (2024) is a healthy-human task / cognition association route linking [11C]UCB-J DVRcs to task-related activity and cognition. Smart et al. (2021) showed that brief visual activation does not measurably change [11C]UCB-J binding even when tracer influx rises with blood flow, so the route is not a momentary synaptic-efficacy meter. Holmes et al. (2022) found no measurable overall SV2A change 24 h after ketamine despite symptom improvement, showing that intervention response and synaptic-density readout are not the same question. Therefore, this site now requires a SV2A / synaptic-density PET route card before a claim is promoted beyond a regional, explicitly named ceiling.
| Route-card field | What must be fixed explicitly | What goes wrong if omitted |
|---|---|---|
| Claim family | State whether the paper is about tracer / validation, healthy atlas construction, disease or risk-group contrast, task / cognition association, or longitudinal intervention / target-engagement. | Atlas papers, case-control contrasts, healthy correlation studies, and drug-response designs collapse into one phrase such as synaptic-density PET shows current synaptic state. |
| Tracer and target route | Name the ligand, target, selectivity / blocking context, and whether the route uses [11C]UCB-J, 18F-SynVesT-1, or another explicitly identified SV2A tracer. | A result obtained with one tracer or validation context is silently promoted to all SV2A PET implementations. |
| Quantification route | Disclose arterial versus reference-tissue route, kinetic model or validated simplified window, and the reported quantity such as VT, DVR, or BPND. | The site treats the modality label alone as sufficient and hides how much the conclusion depends on model choice and scan window. |
| Spatial unit / anatomy handling | Write whether the object is voxelwise, parcelwise, or ROI-based, together with anatomy registration, atrophy handling, and partial-volume correction or abstention. | Regional density estimates are overread as if anatomy, tissue mixing, and resolution burden were negligible. |
| Comparison design / cohort relation | State whether the result is a healthy normative atlas, a cross-sectional disease comparison, a risk-group contrast, a same-subject longitudinal intervention, or a drug-occupancy / displacement design, and name the cohort or sample relation explicitly. | A healthy atlas is silently promoted to disease mechanism evidence, or a same-subject drug study is silently promoted to a normative state map. |
| Functional target | Name the dependent claim precisely: regional synaptic-density gradient, pathology burden, risk enrichment, task-related association, or target engagement under an administered intervention. | A paper that supports one inferential target is promoted to a generic statement that current synaptic function or plasticity was measured. |
| Human observability ceiling | Fix the ceiling in one line: regional presynaptic vesicle-density proxy, not current release probability, postsynaptic receptor occupancy, branch-local plasticity state, or arbitrary memory-content readout. | Regional SV2A density is silently rephrased as current synaptic efficacy or rapid plasticity ground truth. |
| Abstention boundary | Write which variables remain latent, especially task-time synaptic efficacy, E/I balance, synaptic-tag capture, branch-specific stabilization, and the responsible cell-specific controller. | The site accidentally treats `human synaptic-density PET exists` as equivalent to synaptic-complete or maintenance-complete state capture. |
The need is multi-axis. On the measurement side, Naganawa et al. (2021) makes the tracer and quantification route part of the object. On the cohort side, Johansen et al. (2024) is a normative atlas, not one participant's current task-time state. On the association side, Shatalina et al. (2024) relates regional SV2A signal to task-linked activity and cognition, which is not the same claim as detecting momentary synaptic change. On the dynamics side, Smart et al. (2021) and Holmes et al. (2022) show why brief activation or rapid symptom improvement must not be silently rephrased as measurable synaptic-density change. Therefore, this site does not let atlas, disease, cognition, and intervention routes inherit one another's claim ceiling without a route-card audit.
Common misreadings and demotion rules on this site
| Dangerous Reading | Why is it dangerous | Handling on this site |
|---|---|---|
| If you know the cell-type label, the input-output rule is almost determined | Morpho-electric variability and channel-expression variability remain within the same type. | Do not write excitability fixed in cell-type alone, leave it as latent state. |
| If there is a spatial transcriptomic atlas or DEG list, the current memory-stabilization program is also fixed | Cell identity, transient experience-induced transcription, and locus-specific epigenetic control are different layers, and the latter is time-dependent and often destructive to measure. | Atlas-level transcriptomics is treated as identity prior or clue; memory-stabilization controller remains latent unless temporal or causal evidence is shown. |
| If gene-level transcript abundance is similar, the current isoform / m6A / RNA-editing controller is also fixed | Alternative splicing, m6A-dependent translation / degradation, and RNA-editing ratio are post-transcriptional state variables that can diverge on a similar gene-count background. | Gene-level abundance is treated as insufficient; post-transcriptional RNA-state remains latent unless directly measured, causally perturbed, or externally calibrated. |
| If the connectome / cell type is the same, AIS and channel-state are also almost the same | AIS length / position and Na+ channel distribution change according to activity, sensory input, and learning. | If there is no patch, perturbation, or AIS proxy, the gain / allocation / spike-initiation rule will remain in latent state. |
| Since the average firing rate returned, the internal state also returned to the same | The same rate may be achieved with a different conductance combination or a different controller. | rate only recovery, does not claim internal identity, requests perturbation and recovery logs. |
| If the daytime activity and decoder performance are similar, the overnight maintenance is also the same | Synaptic scaling during sleep, firing-rate homeostasis, and network regime recovery remain separately. | The cross-day stability claim is demoted if no sleep / wake annotations or next day recovery are issued. |
| If the current weight is known, the late-stabilization route is also basically fixed | Tagged spines and dendritic branches can still differ in PRP capture, local translation/degradation/autophagy balance, and the persistence of structural tag-state. | If no tag/capture/proteostasis route is measured or perturbed, late stabilization and reconsolidation stay in latent state. |
| If connectome, cell type, and nominal weights are the same, inhibitory sign and brain state are also almost fixed | Local chloride set point, transporter state, and extracellular K+ / Ca2+ / pH composition can still change EGABA, network gain, and sleep/wake state transitions. | If ionic / chloride route is not measured, perturbed, or externally calibrated, inhibitory-polarity and state-transition claims remain latent. |
| If connectome, nominal weights, and timing proxy are the same, temperature can be treated as fixed background | Modest temperature changes can still alter synaptic reliability, spike generation, field-potential amplitude, and sequence timing, so part of the apparent signal may come from thermal operating point rather than the intended mechanism. | If thermal-state is not measured, externally calibrated, or logged, timing-sensitive and field-potential-sensitive claims remain latent or are demoted to a bounded human thermal proxy rather than local thermal-state ground truth. |
| With the human metabolic connectome, the glial / transmitter maintenance-state was also directly visible | Parcel-level metabolic similarity is useful, but it does not directly provide cell-specific astrocyte ensemble or transmitter state. | Human MRSI is treated as a macro-biochemical scaffold and is not written as the ground truth of local maintenance-state. |
| Because a human metabolic connectome exists, we now have another connectome comparable to tractography or metabolic-rate maps | Lucchetti et al. (2025) built a five-metabolite gray-matter parcel-similarity graph and reported only weak overall alignment with tractography-based structural connectivity. Static 1H-MRSI similarity is also not the same object as dynamic rate imaging. | Treat it as a macro-biochemical similarity scaffold and require the metabolic-connectome route card before reading beyond that ceiling. |
| With human synaptic-density PET, the current synaptic efficacy or plasticity state was directly visible | Naganawa et al. (2021) showed that SV2A PET depends on tracer and quantification route, while Smart et al. (2021) and Holmes et al. (2022) showed that brief activation or rapid symptom change need not produce measurable SV2A change. | Require the SV2A route card and treat the result as a regional synaptic-density proxy, atlas, disease/risk contrast, association study, or intervention audit only. |
| With human myelin bilayer map and nap / TMS proxy, cell-specific maintenance controller could also be seen | Myelin bilayer map is a mm-class tissue proxy, and TMS-EEG/PAS is a perturbational readout. The question remains which axon, oligodendrocyte, astrocyte, or synapse was responsible for the change. | Human myelin / sleep / excitability data is specified as macro or perturbational proxy and is not uploaded to the ground truth of cell-specific controller. |
| Since human CSF mobility and glymphatic clearance were visible, local immune / clearance controllers were also identified | Human CSF / clearance-transport data is a macro transport-side proxy, and it remains independent of which microglia, meningeal lymphatic segment, astrocyte endfoot, or local synapse is responsible for the difference. | Human clearance evidence is written as macro transport-side proxy and does not increase to moment-to-moment neural truth or cell-specific immune controller. |
| If the delay is set as a constant, the myelin sheath and oligodendrocytes can be postponed | Adaptive myelination and axon-glia coupling are concerned with timing and long-term support. | In the timing-sensitive claim, the fact that myelin / conduction is not measured is clearly stated in the text. |
| If human 31P or deuterium imaging exists, we could directly see the local mitochondrial status | 31P metabolite / pH balance, 31P MT exchange-flux, whole-brain 31P NAD-content mapping, localized functional 31P NAD-dynamics, deuterium metabolite-mapping / absolute quantification, and deuterium kinetic-rate imaging are route-specific macro or localized proxies. They still do not tell in which branch or synapse the ATP reserve is insufficient or where mitochondria are positioned. | Human energetic routes are written as separate proxy classes with named quantity type and route burden, and none is elevated to the ground truth of cell-specific bioenergetic / mitochondrial state. |
| If the engrams and spike trains on the neuron side are similar, recall and stabilization after several days will be the same. | Astrocyte ensemble, lactate transport, and local transmitter integration are involved in memory recall, restabilization, and fear-state representation. | When dropping glial substrate-routing or astrocyte-state, limit the scope of application of plasticity, memory consolidation, recall, restabilization, and slow state. |
| If memory is to last long, the molecular state that must be preserved is static | Persistence is often the result of active maintenance and reconsolidation across turnover. | We do not claim the sufficiency of the molecular snapshot, but specify that the maintenance mechanism has not been determined. |
Practical rules adopted on this site
Rule
- In long-term claims, put maintenance-state in a separate column:Do not mix connectome / cell type / synapse with intrinsic excitability, activity-dependent transcription / chromatin state, post-transcriptional RNA-state, local proteostasis / synaptic tagging, sleep-homeostasis, myelin / oligodendroglial support, bioenergetic / mitochondrial state, glial / metabolic support, clearance / immune support.
- Do not collapse cell identity into current plasticity program:Static transcriptomic labels and current memory-stabilization state should be written in separate columns.
- Do not collapse gene-level abundance into post-transcriptional RNA-state:Write isoform choice, m6A-dependent translation / degradation, and RNA-editing controller separately when the claim depends on them.
- Do not collapse current weight into late-stabilization route:Tagged branch state and local proteostasis should be measured separately, or written with separate abstention reasons.
- Do not collapse transcription / chromatin into one bucket:Separate allocation eligibility, time-windowed response map, persistent stabilization program, and locus-specific causal editability, then attach the transcription / chromatin route card when the claim depends on them.
- Don't collapse intrinsic excitability into one line:Make relative excitability, AIS / channel state, and recovery controller separate columns.
- Do not collapse thermal-state into timing or bioenergetics:Write tissue temperature separately when field-potential amplitude, membrane kinetics, or sequence timing matters.
- Do not collapse ionic milieu into excitability or glia:Write chloride set point / transporter state and interstitial-ion composition separately when inhibitory sign, rhythm, or state transition matters.
- Do not collapse cargo transport into proteostasis or bioenergetics:Write branch/spine/bouton-specific delivery and retention separately when the claim depends on local receptor, RNA, organelle, or presynaptic component placement.
- If sleep / wake history is not measured, write it as not measured:Do not auto-complete overnight maintenance from same-day fit.
- If sleep architecture / replay-coupling is not measured, write it as not measured:Do not promote overnight retention to consolidation-mechanism evidence from duration alone.
- Do not reduce sleep to mean correction:Leaves the possibility of dropping down to synapse diversity or network regime.
- If we absorb delay with a constant, we write it as absorbed:Do not silently push timing state and axonal support into the model.
- Don't replace memory persistence with static storage: Leave open the possibility of reconsolidation and support mechanisms acrossturnovers.
- Focus on post-perturbation recovery:Keep a log of not only what happened, but also where you return and how you return across sleep.
- Write the limitations of proxy first:Do not write that maintenance-state is uniquely determined only by EEG / pupil / behavior.
- Do not mix human proxy classes:Do not collapse EM fragments, whole-brain MRSI, 31P metabolite / pH balance, 31P MT exchange-flux, 31P NAD-content mapping, localized functional 31P NAD-dynamics, deuterium metabolite-mapping / absolute quantification, deuterium kinetic-rate imaging, sodium MRI, myelin bilayer map, and sleep / TMS proxy into the same "human-seen" word.
- Do not misinterpret human MRSI as local ground truth:Write macro-biochemical scaffold and cell-specific maintenance-state separately.
- Do not misread human clearance-transport proxy as local controller:Write macro transport-side proxy and cell-specific immune / clearance state separately.
- Does not complement glia omission from neuron-only success:Recall, restabilization, and fear-state representation leave the astrocyte state separate.
| What you want to claim | Minimum required submissions |
|---|---|
| cross-day stability | Fixed model degradation curve, recovery time, sleep / wake annotations, state / trait / drift separation, firing-rate distribution and excitability proxy if possible. |
| gain / excitability claim | relative excitability or perturbation proxy, AIS / channel proxy if possible, ionic / chloride route or omission log if inhibitory sign matters, within-day / cross-day gain drift, omission log of unmeasured allocation / recovery controller. |
| Long-horizon memory / learning claim | Perturbation responses before and after learning, relative excitability or allocation proxy, time-stamped transcription / chromatin route or omission log, post-transcriptional RNA-state route or omission log if isoform / m6A / editing controller matters, local proteostasis / tag-capture route or omission log, thermal-state covariate or omission log if field-potential amplitude or sequence timing matters, ionic / chloride route or omission log if inhibition or rhythm matters, presence or absence of overnight renormalization, glial substrate-routing route or omission log, astrocyte-state route or omission log, clearance / immune covariate if possible, and list of unmeasured maintenance-states. |
| timing-sensitive claim | delay / phase error, myelin or conduction proxy, thermal / heating / cooling log or thermometry if available, timing support approximated by a fixed constant, unmeasured oligodendroglial or thermal state. |
| energetic-mechanism claim | Energetic proxy such as 31P metabolite / pH balance, 31P MT exchange-flux, 31P NAD-content mapping, localized functional 31P NAD-dynamics, deuterium metabolite-mapping / absolute quantification, or deuterium kinetic-rate imaging, fatigue / repeated-burst failure log if possible, bioenergetic state set to fixed background, unmeasured mitochondrial positioning / redox reserve. |
| Claim close to state-complete reconstruction | To what extent did you acquire connectome, cell type, synapse, transcription / chromatin state, post-transcriptional RNA-state, phospho-signaling / second-messenger state, local proteostasis / synaptic tagging, delay / myelin, thermal-state, ionic milieu / chloride homeostasis, bioenergetic / mitochondrial state, neuromodulation, glia / metabolic support, clearance / immune support, sleep-homeostasis, intrinsic excitability / homeostasis, or did you abstain as a latent? |
References
- Gouwens, N. W., et al. (2021). Phenotypic variation of transcriptomic cell types in mouse motor cortex. Nature, 598, 144-150. doi:10.1038/s41586-020-2907-3
- Schulz, D. J., Goaillard, J.-M., & Marder, E. (2006). Variable channel expression in identified single and electrically coupled neurons in different animals. Nature Neuroscience, 9(3), 356-362. doi:10.1038/nn1639
- Santoni, G., et al. (2024). Chromatin plasticity predetermines neuronal eligibility for memory trace formation. Science, 385(6716), eadg9982. doi:10.1126/science.adg9982
- Traunmüller, L., et al. (2025). Novel environment exposure drives temporally defined and region-specific chromatin accessibility and gene expression changes in the hippocampus. Nature Communications, 16, 7787. doi:10.1038/s41467-025-63029-6
- Guan, J. S., Haggarty, S. J., Giacometti, E., et al. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459(7243), 55-60. doi:10.1038/nature07925
- Gulmez Karaca, K., Kupke, J., Brito, D. V. C., et al. (2020). Neuronal ensemble-specific DNA methylation strengthens engram stability. Nature Communications, 11, 639. doi:10.1038/s41467-020-14498-4
- Bharadwaj, R., Peter, C. J., Jiang, Y., et al. (2014). Conserved higher-order chromatin regulates NMDA receptor gene expression and cognition. Neuron, 84(5), 997-1008. doi:10.1016/j.neuron.2014.10.032
- Coda, D. M., Watt, L., Glauser, L., et al. (2025). Cell-type- and locus-specific epigenetic editing of memory expression. Nature Genetics, 57, 2661-2668. doi:10.1038/s41588-025-02368-y
- Terceros, A., Chen, C., Harada, Y., et al. (2026). Thalamocortical transcriptional gates coordinate memory stabilization. Nature, 649, 1254-1263. doi:10.1038/s41586-025-09774-6
- Wang, J., Telese, F., Tan, Y., et al. (2015). LSD1n is an H4K20 demethylase regulating memory formation via transcriptional elongation control. Nature Neuroscience, 18(9), 1256-1264. doi:10.1038/nn.4069
- Dai, J., Aoto, J., & Südhof, T. C. (2019). Alternative splicing of presynaptic neurexins differentially controls postsynaptic NMDA and AMPA receptor responses. Neuron, 102(5), 993-1008.e5. doi:10.1016/j.neuron.2019.03.032
- Shi, H., Zhang, X., Weng, Y.-L., et al. (2018). m6A facilitates hippocampus-dependent learning and memory through YTHDF1. Nature, 563(7730), 249-253. doi:10.1038/s41586-018-0666-1
- Peterson, L. N., Kasper, J. M., Allgaier, J. A., et al. (2025). ADAR2-mediated Q/R editing of GluA2 in homeostatic synaptic plasticity. Science Signaling, 18(886), eadr1442. doi:10.1126/scisignal.adr1442
- Joglekar, A., Prjibelski, A., Mahfouz, A., et al. (2024). Single-cell long-read sequencing-based mapping reveals specialized splicing patterns in developing and adult mouse and human brain. Nature Neuroscience, 27(6), 1073-1088. doi:10.1038/s41593-024-01616-4
- Li, Y., Zhu, M., Li, X., et al. (2025). Enhanced Protein Synthesis and Hippocampus-Dependent Memory via Inhibition of YTHDF2-Mediated m6A mRNA Degradation. Advanced Science, 12(34), e14926. doi:10.1002/advs.202514926
- Giese, K. P., Fedorov, N. B., Filipkowski, R. K., & Silva, A. J. (1998). Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science, 279(5352), 870-873. doi:10.1126/science.279.5352.870
- Lee, H.-K., Barbarosie, M., Kameyama, K., Bear, M. F., & Huganir, R. L. (2003). Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Cell, 112(5), 631-643. doi:10.1016/S0092-8674(03)00122-3
- Rodrigues, S. M., Farb, C. R., Bauer, E. P., LeDoux, J. E., & Schafe, G. E. (2004). Pavlovian fear conditioning regulates Thr286 autophosphorylation of Ca2+/calmodulin-dependent protein kinase II at lateral amygdala synapses. Journal of Neuroscience, 24(13), 3281-3288. doi:10.1523/JNEUROSCI.5303-03.2004
- Tomita, S., Stein, V., Stocker, T. J., Nicoll, R. A., & Bredt, D. S. (2005). Bidirectional synaptic plasticity regulated by phosphorylation of stargazin-like TARPs. Neuron, 45(2), 269-277. doi:10.1016/j.neuron.2005.01.009
- Havekes, R., Park, A. J., Tolentino, R. E., et al. (2016). Compartmentalized PDE4A5 signaling impairs hippocampal synaptic plasticity and long-term memory. Journal of Neuroscience, 36(34), 8936-8946. doi:10.1523/JNEUROSCI.0248-16.2016
- Vierra, N. C., et al. (2023). Endoplasmic reticulum-plasma membrane junctions couple electrical activity to Ca2+-activated PKA signaling in neurons. Nature Communications, 14, 6040. doi:10.1038/s41467-023-40930-6
- Altas, B., Tuffy, L. P., Patrizi, A., et al. (2024). Region-specific phosphorylation determines Neuroligin-3 localization to excitatory versus inhibitory synapses. Biological Psychiatry, 96(10), 815-828. doi:10.1016/j.biopsych.2023.12.020
- Rodriguez, A. C., Kramár, E. A., Augustynski, A. S., et al. (2025). HDAC3 Serine 424 phospho-mimic and phospho-null mutants bidirectionally modulate long-term memory formation and synaptic plasticity in the adult and aging mouse brain. Journal of Neuroscience, 45(29), e1619242025. doi:10.1523/JNEUROSCI.1619-24.2025
- Biswas, D., et al. (2023). The landscape of the human brain phosphoproteome reveals region-specific phosphorylation events. Journal of Proteome Research, 22(4), 1390-1404. doi:10.1021/acs.jproteome.2c00244
- Frey, U., & Morris, R. G. M. (1997). Synaptic tagging and long-term potentiation. Nature, 385(6616), 533-536. doi:10.1038/385533a0
- Fonseca, R., Vabulas, R. M., Hartl, F. U., Bonhoeffer, T., & Nägerl, U. V. (2006). A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. Neuron, 52(2), 239-245. doi:10.1016/j.neuron.2006.08.015
- Govindarajan, A., Israely, I., Huang, S.-Y., & Tonegawa, S. (2011). The dendritic branch is the preferred integrative unit for protein synthesis-dependent LTP. Neuron, 69(1), 132-146. doi:10.1016/j.neuron.2010.12.008
- Shires, K. L., Da Silva, B. M., Hawthorne, J. P., Morris, R. G. M., & Martin, S. J. (2012). Synaptic tagging and capture in the living rat. Nature Communications, 3, 1246. doi:10.1038/ncomms2250
- Pandey, K., Yu, X.-W., Steinmetz, A., & Alberini, C. M. (2021). Autophagy coupled to translation is required for long-term memory formation. Autophagy, 17(9), 2489-2505. doi:10.1080/15548627.2020.1775393
- Thomas, M., Bogaciu, C.-A., Rizzoli, S. O., et al. (2025). Long-term potentiation-induced changes in actin dynamics and spine geometry persist on the timescale of the synaptic tag. Communications Biology, 8, 756. doi:10.1038/s42003-025-08459-0
- Grubb, M. S., & Burrone, J. (2010). Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability. Nature, 465(7301), 1070-1074. doi:10.1038/nature09160
- Kuba, H., Oichi, Y., & Ohmori, H. (2010). Presynaptic activity regulates Na+ channel distribution at the axon initial segment. Nature, 465(7301), 1075-1078. doi:10.1038/nature09087
- Jamann, N., Dannehl, D., Lehmann, N., et al. (2021). Sensory input drives rapid homeostatic scaling of the axon initial segment in mouse barrel cortex. Nature Communications, 12, 23. doi:10.1038/s41467-020-20232-x
- Fréal, A., Jamann, N., Ten Bos, J., et al. (2023). Sodium channel endocytosis drives axon initial segment plasticity. Science Advances, 9(37). doi:10.1126/sciadv.adf3885
- Benoit, C. M., Ganea, D. A., Paricio-Montesinos, R., et al. (2025). Axon initial segment dynamics during associative fear learning. Nature Neuroscience, 29(3), 535-542. doi:10.1038/s41593-025-02152-5
- Turrigiano, G. G., Leslie, K. R., Desai, N. S., Rutherford, L. C., & Nelson, S. B. (1998). Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature, 391, 892-896. doi:10.1038/36103
- O'Leary, T., Williams, A. H., Franci, A., & Marder, E. (2014). Cell types, network homeostasis, and pathological compensation from a biologically plausible ion channel expression model. Neuron, 82(4), 809-821. doi:10.1016/j.neuron.2014.04.002
- Hengen, K. B., Torrado Pacheco, A., McGregor, J. N., Van Hooser, S. D., & Turrigiano, G. G. (2016). Neuronal firing rate homeostasis is inhibited by sleep and promoted by wake. Cell, 165(1), 180-191. doi:10.1016/j.cell.2016.01.046
- Torrado Pacheco, A., et al. (2021). Sleep Promotes Downward Firing Rate Homeostasis. Neuron, 109(3), 530-544.e6. doi:10.1016/j.neuron.2021.04.004
- Diering, G. H., et al. (2017). Homer1a drives homeostatic scaling-down of excitatory synapses during sleep. Science, 355(6324), 511-515. doi:10.1126/science.aai8355
- de Vivo, L., et al. (2017). Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. Science, 355(6324), 507-510. doi:10.1126/science.aah5982
- Noya, S. B., et al. (2019). The forebrain synaptic transcriptome is organized by clocks but its proteome is driven by sleep. Science, 366(6462), eaav2642. doi:10.1126/science.aav2642
- Xu, W., et al. (2024). Sleep restores an optimal computational regime in cortical networks. Nature Neuroscience, 27, 972-980. doi:10.1038/s41593-023-01536-9
- Ngo, H.-V. V., Martinetz, T., Born, J., & Mölle, M. (2013). Auditory closed-loop stimulation of the sleep slow oscillation enhances memory. Neuron, 78(3), 545-553. doi:10.1016/j.neuron.2013.03.006
- Maingret, N., Girardeau, G., Todorova, R., et al. (2016). Hippocampo-cortical coupling mediates memory consolidation during sleep. Nature Neuroscience, 19, 959-964. doi:10.1038/nn.4304
- Latchoumane, C.-F. V., Ngo, H.-V. V., Born, J., & Shin, H.-S. (2017). Thalamic Spindles Promote Memory Formation during Sleep through Triple Phase-Locking of Cortical, Thalamic, and Hippocampal Rhythms. Neuron, 95(2), 424-435.e6. doi:10.1016/j.neuron.2017.06.025
- Whitmore, N. W., Bassard, A. M., & Paller, K. A. (2022). Targeted memory reactivation of face-name learning depends on ample and undisturbed slow-wave sleep. npj Science of Learning, 7, 1. doi:10.1038/s41539-021-00119-2
- Baxter, B. S., Mylonas, D., Kwok, K. S., Talbot, C. E., Patel, R., Zhu, L., Vangel, M., Stickgold, R., & Manoach, D. S. (2023). The effects of closed-loop auditory stimulation on sleep oscillatory dynamics in relation to motor procedural memory consolidation. Sleep, 46(10), zsad206. doi:10.1093/sleep/zsad206
- Schreiner, T., Petzka, M., Staudigl, T., & Staresina, B. P. (2021). Endogenous memory reactivation during sleep in humans is clocked by slow oscillation-spindle complexes. Nature Communications, 12, 3112. doi:10.1038/s41467-021-23520-2
- Schreiner, T., Petzka, M., Staudigl, T., et al. (2023). Respiration modulates sleep oscillations and memory reactivation in humans. Nature Communications, 14, 8351. doi:10.1038/s41467-023-43450-5
- Geva-Sagiv, M., Mankin, E. A., Eliashiv, D., et al. (2023). Augmenting hippocampal-prefrontal neuronal synchrony during sleep enhances memory consolidation in humans. Nature Neuroscience, 26, 1100-1110. doi:10.1038/s41593-023-01324-5
- Schreiner, T., Petzka, M., Staudigl, T., et al. (2024). Spindle-locked ripples mediate memory reactivation during human NREM sleep. Nature Communications, 15, 5367. doi:10.1038/s41467-024-49572-8
- Whitmore, N. W., Yamazaki, E. M., & Paller, K. A. (2024). Targeted memory reactivation with sleep disruption does not weaken week-old memories. npj Science of Learning, 9, 64. doi:10.1038/s41539-024-00276-0
- Deng, Z., Fei, X., Zhang, S., & Xu, M. (2025). A time window for memory consolidation during NREM sleep revealed by cAMP oscillation. Neuron, 113(12), 1983-1997.e7. doi:10.1016/j.neuron.2025.03.020
- Duan, W., Xu, Z., Chen, D., et al. (2025). Electrophysiological signatures underlying variability in human memory consolidation. Nature Communications, 16, 2472. doi:10.1038/s41467-025-57766-x
- Shin, G.-H., Kweon, Y.-S., Oh, S., et al. (2025). Personalized targeted memory reactivation enhances consolidation of challenging memories via slow wave and spindle dynamics. npj Science of Learning, 10, 47. doi:10.1038/s41539-025-00340-3
- Koukaroudi, D., Qiu, Z., Fransén, E., et al. (2024). Sleep maintains excitatory synapse diversity in the cortex and hippocampus. Current Biology, 34(16), 3836-3843.e5. doi:10.1016/j.cub.2024.07.032
- Yiu, A. P., et al. (2014). Neurons are recruited to a memory trace based on relative neuronal excitability immediately before training. Neuron, 83(3), 722-735. doi:10.1016/j.neuron.2014.07.017
- Hadzibegovic, N., et al. (2025). Early intrinsic excitability plasticity of neocortical engram neurons defines memory formation and precision. Nature Communications, 17, 291. doi:10.1038/s41467-025-66975-3
- Tallman, C. W., Siler, S. N., Lee, H., et al. (2025). Neuronal allocation and sparse coding of episodic memories in the human hippocampus. Scientific Reports, 15, 21967. doi:10.1038/s41598-025-21967-7
- Zrenner, C., Desideri, D., Belardinelli, P., & Ziemann, U. (2018). Real-time EEG-defined excitability states determine efficacy of TMS-induced plasticity in human motor cortex. Brain Stimulation, 11(2), 374-389. doi:10.1016/j.brs.2017.11.016
- Huber, R., Mäki, H., Rosanova, M., Casarotto, S., Canali, P., Casali, A. G., Tononi, G., & Massimini, M. (2013). Human cortical excitability increases with time awake. Cerebral Cortex, 23(2), 332-338. doi:10.1093/cercor/bhs014
- Kuhn, M., Wolf, E., Maier, J. G., Mainberger, F., Feige, B., Schmid, H., et al. (2016). Sleep recalibrates homeostatic and associative synaptic plasticity in the human cortex. Nature Communications, 7, 12455. doi:10.1038/ncomms12455
- Khatri, U. U., Pulliam, K., Manesiya, M., Vieyra Cortez, M., Millán, J. del R., & Hussain, S. J. (2025). Personalized whole-brain activity patterns predict human corticospinal tract activation in real-time. Brain Stimulation, 18(1), 64-76. doi:10.1016/j.brs.2024.12.1193
- Fehér, K. D., Henckaerts, P., Hirsch, V., Bucsenez, U., Kuhn, M., Maier, J. G., et al. (2026). A nap can recalibrate homeostatic and associative synaptic plasticity in the human cortex. NeuroImage, 327, 121723. doi:10.1016/j.neuroimage.2026.121723
- Gibson, E. M., et al. (2014). Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science, 344(6183), 1252304. doi:10.1126/science.1252304
- McKenzie, I. A., et al. (2014). Motor skill learning requires active central myelination. Science, 346(6207), 318-322. doi:10.1126/science.1254960
- Seidl, A. H., Rubel, E. W., & Barría, A. (2015). Tuning of Ranvier node and internode properties in myelinated axons to adjust action potential timing. Nature Communications, 6, 8073. doi:10.1038/ncomms9073
- Dutta, D. J., Woo, D. H., Lee, P. R., et al. (2018). Regulation of myelin structure and conduction velocity by perinodal astrocytes. Proceedings of the National Academy of Sciences USA, 115(46), 11832-11837. doi:10.1073/pnas.1811013115
- Cohen, C. C. H., Popovic, M. A., Klooster, J., et al. (2020). Saltatory conduction along myelinated axons involves a periaxonal nanocircuit. Cell, 180(2), 311-322.e15. doi:10.1016/j.cell.2019.11.039
- Micheva, K. D., Kiraly, M., Perez, M. M., & Madison, D. V. (2021). Conduction Velocity Along the Local Axons of Parvalbumin Interneurons Correlates With the Degree of Axonal Myelination. Cerebral Cortex, 31(7), 3374-3392. doi:10.1093/cercor/bhab018
- Dubey, S., Kuschmitz, S., Mezey, S. E., et al. (2022). Myelination synchronizes cortical oscillations by consolidating parvalbumin-mediated phasic inhibition. eLife, 11, e73827. doi:10.7554/eLife.73827
- van Blooijs, D., de Haan, A. M., Renaud, S., et al. (2023). Developmental trajectory of transmission speed in the human brain. Nature Neuroscience, 26, 828-838. doi:10.1038/s41593-023-01272-0
- Xin, W., Kaneko, M., Roth, R. H., Zhang, A., Nocera, S., Ding, J. B., Stryker, M. P., & Chan, J. R. (2024). Oligodendrocytes and myelin limit neuronal plasticity in visual cortex. Nature, 633, 856-863. doi:10.1038/s41586-024-07853-8
- Della-Flora Nunes, G., Osso, L. A., Haynes, J. A., et al. (2025). Incomplete remyelination via therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function. Nature Communications, 16, 732. doi:10.1038/s41467-025-56092-6
- Genc, S., Ball, G., Chamberland, M., et al. (2025). MRI signatures of cortical microstructure in human development align with oligodendrocyte cell-type expression. Nature Communications, 16, 3317. doi:10.1038/s41467-025-58604-w
- Looser, Z. J., et al. (2024). Oligodendrocyte-axon metabolic coupling is mediated by extracellular K+ and maintains axonal health. Nature Neuroscience, 27, 1598-1609. doi:10.1038/s41593-023-01558-3
- Hardingham, N. R., & Larkman, A. U. (1998). The reliability of excitatory synaptic transmission in slices of rat visual cortex in vitro is temperature dependent. The Journal of Physiology, 507(1), 249-256. doi:10.1111/j.1469-7793.1998.249bu.x
- Volgushev, M., Vidyasagar, T. R., Chistiakova, M., Yousef, T., & Eysel, U. T. (2000). Membrane properties and spike generation in rat visual cortical cells during reversible cooling. The Journal of Physiology, 522(1), 59-76. doi:10.1111/j.1469-7793.2000.00059.x
- Moser, E., Mathiesen, I., & Andersen, P. (1993). Association between brain temperature and dentate field potentials in exploring and swimming rats. Science, 259(5099), 1324-1326. doi:10.1126/science.8446900
- Long, M. A., & Fee, M. S. (2008). Using temperature to analyse temporal dynamics in the songbird motor pathway. Nature, 456, 189-194. doi:10.1038/nature07448
- Van Hook, M. J. (2020). Temperature effects on synaptic transmission and neuronal function in the visual thalamus. PLoS One, 15(4), e0232451. doi:10.1371/journal.pone.0232451
- Reig, R., Mattia, M., Compte, A., Belmonte, C., & Sanchez-Vives, M. V. (2010). Temperature modulation of slow and fast cortical rhythms. Journal of Neurophysiology, 103(3), 1253-1261. doi:10.1152/jn.00890.2009
- Owen, S. F., Liu, M. H., & Kreitzer, A. C. (2019). Thermal constraints on in vivo optogenetic manipulations. Nature Neuroscience, 22, 1061-1065. doi:10.1038/s41593-019-0422-3
- Boorman, L. W., Harris, S. S., Shabir, O., Lee, L., Eyre, B., Howarth, C., & Berwick, J. (2023). Bidirectional alterations in brain temperature profoundly modulate spatiotemporal neurovascular responses in-vivo. Communications Biology, 6, 185. doi:10.1038/s42003-023-04542-6
- Lazopulo, A., Emmenegger, Y., Đukanović, N., Hoekstra, M. M. B., & Franken, P. (2025). Brain temperature as proxy for brain state and oscillatory activity in the mouse. Scientific Reports, 15, 37301. doi:10.1038/s41598-025-21175-3
- Pizzorusso, T., Medini, P., Berardi, N., Chierzi, S., Fawcett, J. W., & Maffei, L. (2002). Reactivation of ocular dominance plasticity in the adult visual cortex. Science, 298(5596), 1248-1251. doi:10.1126/science.1072699
- Frischknecht, R., Heine, M., Perrais, D., Seidenbecher, C. I., Choquet, D., & Gundelfinger, E. D. (2009). Brain extracellular matrix affects AMPA receptor lateral mobility and short-term synaptic plasticity. Nature Neuroscience, 12(7), 897-904. doi:10.1038/nn.2338
- Gogolla, N., Caroni, P., Lüthi, A., & Herry, C. (2009). Perineuronal nets protect fear memories from erasure. Science, 325(5945), 1258-1261. doi:10.1126/science.1174146
- Chelini, G., Pantazopoulos, H., Durning, P., et al. (2024). Focal clusters of peri-synaptic matrix contribute to activity-dependent plasticity and memory in mice. Cell Reports, 43(7), 114112. doi:10.1016/j.celrep.2024.114112
- Jabłońska, K., Kaczor, K., Kółeczko, M., et al. (2024). Extracellular matrix integrity regulates GABAergic plasticity in the hippocampus. Matrix Biology, 136, 74-96. doi:10.1016/j.matbio.2024.11.001
- Boonen, M., Hellings, N., Hoedemaekers, T., et al. (2022). Reorganization of the brain extracellular matrix in hippocampal sclerosis. International Journal of Molecular Sciences, 23(15), 8197. doi:10.3390/ijms23158197
- Nguyen, P. T., Dorman, L. C., Pan, S., et al. (2020). Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. Cell, 182(2), 388-403.e15. doi:10.1016/j.cell.2020.05.050
- Lehner, A., Hoffmann, L., Rampp, S., et al. (2024). Age-dependent increase of perineuronal nets in the human hippocampus and precocious aging in epilepsy. Epilepsia Open, 9(4), 1372-1381. doi:10.1002/epi4.12963
- Alexander, G. M., Nikolova, V. D., Stöber, T. M., Gruzdev, A., Moy, S. S., & Dudek, S. M. (2025). Perineuronal Nets on CA2 Pyramidal Cells and Parvalbumin-Expressing Cells Differentially Regulate Hippocampal-Dependent Memory. Journal of Neuroscience, 45(6), e1626242024. doi:10.1523/JNEUROSCI.1626-24.2024
- Banovac, I., Prkačin, M. V., Kirchbaum, I., et al. (2025). Morphological and Molecular Characteristics of Perineuronal Nets in the Human Prefrontal Cortex-A Possible Link to Microcircuitry Specialization. Molecular Neurobiology, 62(1), 1094-1111. doi:10.1007/s12035-024-04306-1
- Mehak, S. F., Shivakumar, A. B., Jijimon, F., Gupta, A., Pillai, V. G., & Gangadharan, G. (2025). Targeting CA2 Perineuronal Nets Restores Recognition Memory and Theta Oscillations in Aged Mice. Aging Cell, 24(9), e70139. doi:10.1111/acel.70139
- Glykys, J., Dzhala, V., Egawa, K., Balena, T., Saponjian, Y., Kuchibhotla, K. V., Bacskai, B. J., Kahle, K. T., Zeuthen, T., & Staley, K. J. (2014). Local impermeant anions establish the neuronal chloride concentration. Science, 343(6171), 670-675. doi:10.1126/science.1245423
- Heubl, M., Zhang, J., Pressey, J. C., Al Awabdh, S., Renner, M., Gomez-Castro, F., Moutkine, I., Eugène, E., Russeau, M., Kahle, K. T., Poncer, J.-C., & Lévi, S. (2017). GABAA receptor dependent synaptic inhibition rapidly tunes KCC2 activity via the Cl-sensitive WNK1 kinase. Nature Communications, 8, 1776. doi:10.1038/s41467-017-01749-0
- Ding, F., O'Donnell, J., Xu, Q., Kang, N., Goldman, N., & Nedergaard, M. (2016). Changes in the composition of brain interstitial ions control the sleep-wake cycle. Science, 352(6285), 550-555. doi:10.1126/science.aad4821
- Huberfeld, G., Wittner, L., Clemenceau, S., Baulac, M., Kaila, K., Miles, R., & Rivera, C. (2007). Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. Journal of Neuroscience, 27(37), 9866-9873. doi:10.1523/JNEUROSCI.2761-07.2007
- Simonnet, C., Sinha, M., Goutierre, M., Moutkine, I., Daumas, S., & Poncer, J.-C. (2023). Silencing KCC2 in mouse dorsal hippocampus compromises spatial and contextual memory. Neuropsychopharmacology, 48(7), 1067-1077. doi:10.1038/s41386-022-01480-5
- Nakamura, K., Moorhouse, A. J., Cheung, D. L., Eto, K., Takeda, I., Rozenbroek, P. W., Inada, H., Housley, G. D., Wake, H., & Nabekura, J. (2019). Overexpression of neuronal K+-Cl- co-transporter enhances dendritic spine plasticity and motor learning. The Journal of Physiological Sciences, 69, 453-463. doi:10.1007/s12576-018-00654-5
- Forsberg, M., Olsson, M., Seth, H., Wasling, P., Zetterberg, H., Hedner, J., & Hanse, E. (2022). Ion concentrations in cerebrospinal fluid in wakefulness, sleep and sleep deprivation in healthy humans. Journal of Sleep Research, 31(3), e13522. doi:10.1111/jsr.13522
- Byvaltsev, E., Behbood, M., Schleimer, J.-H., Gensch, T., Semyanov, A., Schreiber, S., & Strauss, U. (2023). KCC2 reverse mode helps to clear postsynaptically released potassium at glutamatergic synapses. Cell Reports, 42(8), 112934. doi:10.1016/j.celrep.2023.112934
- Alfonsa, H., Chakrabarty, A., Vyazovskiy, V. V., & Akerman, C. J. (2025). Sleep-wake-related changes in intracellular chloride regulate plasticity at glutamatergic cortical synapses. Current Biology, 35(6), 1373-1381.e3. doi:10.1016/j.cub.2025.01.050
- Rangaraju, V., Calloway, N., & Ryan, T. A. (2014). Activity-driven local ATP synthesis is required for synaptic function. Cell, 156(4), 825-835. doi:10.1016/j.cell.2013.12.042
- Rangaraju, V., Lauterbach, M., & Schuman, E. M. (2019). Spatially stable mitochondrial compartments fuel local translation during plasticity. Cell, 176(1-2), 73-84.e15. doi:10.1016/j.cell.2018.12.013
- Divakaruni, S. S., Van Dyke, A. M., Chandra, R., et al. (2018). Long-term potentiation requires a rapid burst of dendritic mitochondrial fission during induction. Neuron, 100(4), 860-875.e7. doi:10.1016/j.neuron.2018.09.025
- Underwood, E. L., Redell, J. B., Hood, K. N., et al. (2023). Enhanced presynaptic mitochondrial energy production is required for memory formation. Scientific Reports, 13, 14431. doi:10.1038/s41598-023-40877-0
- Bapat, P., Nirschl, J. J., Wilkerson, J. R., et al. (2024). VAP stabilizes dendritic mitochondria to locally support synaptic plasticity. Nature Communications, 15, 742. doi:10.1038/s41467-023-44233-8
- Hu, H., Tang, J., Wu, Y., et al. (2025). Polarized ATP synthase in synaptic mitochondria induced by learning and plasticity signals. Communications Biology, 8, 166. doi:10.1038/s42003-025-08963-3
- Vishwanath, A. A., Comyn, T., Mira, R. G., et al. (2026). Mitochondrial Ca2+ efflux controls neuronal metabolism and long-term memory across species. Nature Metabolism, 8, 467-488. doi:10.1038/s42255-026-01451-w
- Park, M., Salgado, J. M., Ostroff, L., Helton, T. D., Robinson, C. G., Harris, K. M., & Ehlers, M. D. (2006). Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. Neuron, 52(5), 817-830. doi:10.1016/j.neuron.2006.09.040
- Correia, S. S., Bassani, S., Brown, T. C., Lisé, M.-F., Backos, D. S., El-Husseini, A., Passafaro, M., & Esteban, J. A. (2008). Motor protein-dependent transport of AMPA receptors into spines during long-term potentiation. Nature Neuroscience, 11, 457-466. doi:10.1038/nn2063
- Maas, C., Belgardt, D., Lee, H. K., Heisler, F. F., Lappe-Siefke, C., Magiera, M. M., van Dijk, J., Hausrat, T. J., Janke, C., & Kneussel, M. (2009). Synaptic activation modifies microtubules underlying transport of postsynaptic cargo. Proceedings of the National Academy of Sciences of the United States of America, 106(21), 8731-8736. doi:10.1073/pnas.0902304106
- Uchida, S., Martel, G., Pavlowsky, A., Takizawa, S., Hevi, C., Watanabe, Y., Alarcon, J. M., & Shumyatsky, G. P. (2014). Learning-induced and stathmin-dependent changes in microtubule stability are critical for memory and disrupted in ageing. Nature Communications, 5, 4389. doi:10.1038/ncomms5389
- Yin, X., Takei, Y., Kido, M. A., & Hirokawa, N. (2011). Molecular motor KIF17 is fundamental for memory and learning via differential support of synaptic NR2A/2B levels. Neuron, 70(2), 310-325. doi:10.1016/j.neuron.2011.03.026
- Zhao, J., Fok, A. H. K., Fan, R., Kwan, P.-Y., Chan, H.-L., Lo, L. H.-Y., Chan, Y.-S., Yung, W.-H., Huang, J., Lai, C. S. W., & Lai, K.-O. (2020). Specific depletion of the motor protein KIF5B leads to deficits in dendritic transport, synaptic plasticity and memory. eLife, 9, e53456. doi:10.7554/eLife.53456
- Swarnkar, S., Avchalumov, Y., Espadas, I., Grinman, E., Liu, X.-A., Raveendra, B. L., Zucca, A., Mediouni, S., Sadhu, A., Valente, S., Page, D., Miller, K., & Puthanveettil, S. V. (2021). Molecular motor protein KIF5C mediates structural plasticity and long-term memory by constraining local translation. Cell Reports, 36(2), 109369. doi:10.1016/j.celrep.2021.109369
- Nakayama, K., Ohashi, R., Shinoda, Y., et al. (2017). RNG105/caprin1, an RNA granule protein for dendritic mRNA localization, is essential for long-term memory formation. eLife, 6, e29677. doi:10.7554/eLife.29677
- Liau, W.-S., Zhao, Q., Bademosi, A., et al. (2023). Fear extinction is regulated by the activity of long noncoding RNAs at the synapse. Nature Communications, 14, 7616. doi:10.1038/s41467-023-43535-1
- Espadas, I., Wingfield, J. L., Nakahata, Y., et al. (2024). Synaptically-targeted long non-coding RNA SLAMR promotes structural plasticity by increasing translation and CaMKII activity. Nature Communications, 15, 2694. doi:10.1038/s41467-024-46972-8
- Wong, V. C., Houlihan, P. R., Liu, H., Walpita, D., DeSantis, M. C., Liu, Z., & O'Shea, E. K. (2024). Plasticity-induced actin polymerization in the dendritic shaft regulates intracellular AMPA receptor trafficking. eLife, 13, e80622. doi:10.7554/eLife.80622
- Aiken, J., & Holzbaur, E. L. F. (2024). Spastin locally amplifies microtubule dynamics to pattern the axon for presynaptic cargo delivery. Current Biology, 34(8), 1687-1704.e8. doi:10.1016/j.cub.2024.03.010
- de Queiroz, B. R., Laghrissi, H., Rajeev, S., Blot, L., De Graeve, F., Dehecq, M., Keleman, K., Ule, J., Hubstenberger, A., & Besse, F. (2025). Axonal RNA localization is essential for long-term memory. Nature Communications, 16, 2560. doi:10.1038/s41467-025-57651-7
- Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010). Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron, 68(3), 409-427. doi:10.1016/j.neuron.2010.09.043
- Kisler, K., Nikolakopoulou, A. M., Sweeney, M. D., Lazic, D., Zhao, Z., & Zlokovic, B. V. (2020). Acute ablation of cortical pericytes leads to rapid neurovascular uncoupling. Frontiers in Cellular Neuroscience, 14, 27. doi:10.3389/fncel.2020.00027
- Pandey, K., Bessières, B., Sheng, S. L., Taranda, J., Osten, P., Sandovici, I., Constancia, M., & Alberini, C. M. (2023). Neuronal activity drives IGF2 expression from pericytes to form long-term memory. Neuron, 111(23), 3819-3836.e8. doi:10.1016/j.neuron.2023.08.030
- Swissa, E., Monsonego, U., Yang, L. T., Schori, L., Kamintsky, L., Mirloo, S., Burger, I., Uzzan, S., Patel, R., Sudmant, P. H., Prager, O., Kaufer, D., & Friedman, A. (2024). Cortical plasticity is associated with blood-brain barrier modulation. eLife, 12, RP89611. doi:10.7554/eLife.89611
- Mai-Morente, S., Razvan, M., Lechuga-Sancho, A. M., Calvo-Flores Guzmán, B., Arrabal, S., Soria, B., & Gutiérrez-Juárez, R. (2025). Pericyte pannexin1 controls cerebral capillary diameter and supports memory function. Nature Communications, 16, 5912. doi:10.1038/s41467-025-61312-0
- Ohene, Y., Harrison, I. F., Nahavandi, P., Ismail, O., Bird, E. V., Ottersen, O. P., Nagelhus, E. A., Thomas, D. L., Lythgoe, M. F., & Wells, J. A. (2019). Non-invasive MRI of brain clearance pathways using multiple echo time arterial spin labelling: an aquaporin-4 study. NeuroImage, 188, 515-523. doi:10.1016/j.neuroimage.2018.12.026
- Morgan, C. A., Thomas, D. L., Shao, X., Mahroo, A., Manson, T. J., Suresh, V., Jansson, D., Ohene, Y., Günther, M., Wang, D. J. J., Tippett, L. J., & Dragunow, M. (2024). Measurement of blood-brain barrier water exchange rate using diffusion-prepared and multi-echo arterial spin labelling: Comparison of quantitative values and age dependence. NMR in Biomedicine, 37(12), e5256. doi:10.1002/nbm.5256
- Padrela, B. E., Slivka, M., Sneve, M. H., Garrido, P. F., Dijsselhof, M. B. J., Hageman, T., Geier, O., Grydeland, H., Mahroo, A., Kuijer, J. P. A., Konstandin, S., Eickel, K., Barkhof, F., Günther, M., Walhovd, K. B., Fjell, A. M., Mutsaerts, H. J. M. M., & Petr, J. (2025). Blood-brain barrier water permeability across the adult lifespan: A multi-echo ASL study. Neurobiology of Aging, 147, 176-186. doi:10.1016/j.neurobiolaging.2024.12.012
- Padrela, B. E., Tecelão, S., Kirsebom, B.-E., Geier, O., Tranfa, M., Masserini, F., Sneve, M. H., Slivka, M., Falch, E. S., Pålhaugen, L., Mahroo, A., Eickel, K., Thomas, D. L., Günther, M., Selnes, P., Bjørnerud, A., Walhovd, K. B., Fjell, A. M., Barkhof, F., Petr, J., Fladby, T., & Mutsaerts, H. J. M. M. (2026). Blood-brain barrier water exchange in relation to amyloid, cognition and cerebrovascular burden. NeuroImage: Clinical, 49, 103926. doi:10.1016/j.nicl.2025.103926
- Chung, K. J., Abdelhafez, Y. G., Spencer, B. A., Jones, T., Tran, Q., Chen, M. S. Jr., Sarkar, S., Lyo, V., Nardo, L., Medici, V., Badawi, R. D., Cherry, S. R., & Wang, G. (2025). Quantitative PET imaging and modeling of molecular blood-brain barrier permeability. Nature Communications, 16, 3076. doi:10.1038/s41467-025-58356-7
- Farinas, A., Rutledge, J., Bot, V. A., Western, D., Ying, K., Lawrence, K. A., Oh, H. S.-H., Yoon, S., Ding, D. Y., Tsai, A. P., Moran-Losada, P., Timsina, J., Le Guen, Y., Global Neurodegeneration Proteomics Consortium, Montgomery, S. B., Baker, D., Poston, K. L., Wagner, A. D., Mormino, E., Cruchaga, C., & Wyss-Coray, T. (2025). Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging. Nature Medicine, 31(8), 2578-2589. doi:10.1038/s41591-025-03831-3
- Suzuki, A., et al. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. Cell, 144(5), 810-823. doi:10.1016/j.cell.2011.02.018
- Silva, B., et al. (2022). Glial ketogenesis regulates memory maintenance during starvation. Nature Metabolism, 4, 1534-1547. doi:10.1038/s42255-022-00528-6
- Pavlowsky, A., et al. (2025). Neuronal fatty acid oxidation fuels memory after intensive learning in Drosophila. Nature Metabolism, 7, 2467-2483. doi:10.1038/s42255-025-01416-5
- Greda, A. K., et al. (2025). Interaction of sortilin with apolipoprotein E3 enables neurons to use long-chain fatty acids as alternative metabolic fuel. Nature Metabolism, 7, 2346-2365. doi:10.1038/s42255-025-01389-5
- Villemagne, V. L., Harada, R., Dore, V., et al. (2022). First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis. Journal of Nuclear Medicine, 63(10), 1551-1559. doi:10.2967/jnumed.121.263254
- Villemagne, V. L., Harada, R., Dore, V., et al. (2022). Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum. Journal of Nuclear Medicine, 63(10), 1560-1569. doi:10.2967/jnumed.121.263255
- Hiraoka, K., Mesfin, B., Wu, Y., et al. (2025). Kinetic and quantitative analysis of [18F]SMBT-1 PET imaging for monoamine oxidase B. Annals of Nuclear Medicine, 39(11), 1249-1257. doi:10.1007/s12149-025-02083-y
- Mesfin, B., Ishioka, Y., Ichinose, Y., et al. (2026). Whole-body biodistribution of [18F]SMBT-1: a novel PET tracer for monoamine oxidase B imaging in healthy humans. Annals of Nuclear Medicine, 40(4), 405-415. doi:10.1007/s12149-025-02144-2
- Matsuoka, K., Takado, Y., Kimura, Y., et al. (2026). Quantification of monoamine oxidase B expression with 11C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 53, 1142-1156. doi:10.1007/s00259-025-07542-2
- Tyacke, R. J., Myers, J. F. M., Venkataraman, A., et al. (2018). Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain. Journal of Nuclear Medicine, 59(10), 1597-1602. doi:10.2967/jnumed.118.208009
- Livingston, N. R., Calsolaro, V., Hinz, R., et al. (2022). Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 27(4), 2019-2029. doi:10.1038/s41380-021-01429-y
- Best, L. M., Truong, J., McCluskey, T., et al. (2026). MAO-B status in alcohol use disorder: a [11C]SL25.1188 PET imaging study of putative astrogliosis. Molecular Psychiatry, 31, 2191-2201. doi:10.1038/s41380-025-03355-9
- Jaisa-Aad, M., Muñoz-Castro, C., Healey, M. A., Hyman, B. T., & Serrano-Pozo, A. (2024). Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias. Acta Neuropathologica, 147(1), 66. doi:10.1007/s00401-024-02712-2
- Cahill, M. K., et al. (2024). Network-level encoding of local neurotransmitters in cortical astrocytes. Nature, 629, 146-153. doi:10.1038/s41586-024-07311-5
- Sun, X., et al. (2024). Spatial transcriptomics reveal neuron-astrocyte synergy in long-term memory. Nature, 627, 374-381. doi:10.1038/s41586-023-07011-6
- Mukamel, E. A., & Yu, X. (2025). False positives in study of memory-related gene expression. Nature, 642, E1-E3. doi:10.1038/s41586-025-08988-y
- Sun, X., et al. (2025). Reply to: False positives in study of memory-related gene expression. Nature, 642, E4-E6. doi:10.1038/s41586-025-08989-x
- Zimmerman, K. D., Espeland, M. A., & Langefeld, C. D. (2021). A practical solution to pseudoreplication bias in single-cell studies. Nature Communications, 12, 738. doi:10.1038/s41467-021-21038-1
- Williamson, N. R., et al. (2025). Learning-associated astrocyte ensembles regulate memory recall. Nature, 636, 445-454. doi:10.1038/s41586-024-08170-w
- Dewa, K., et al. (2025). The astrocytic ensemble acts as a multiday trace to stabilize memory. Nature, 648, 99-107. doi:10.1038/s41586-025-09619-2
- Bukalo, O., et al. (2026). Astrocytes enable amygdala neural representations supporting memory. Nature. doi:10.1038/s41586-025-10068-0
- Louveau, A., Smirnov, I., Keyes, T. J., et al. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature, 523, 337-341. doi:10.1038/nature14432
- Ahn, J. H., Cho, H., Kim, J.-H., et al. (2019). Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature, 572, 62-66. doi:10.1038/s41586-019-1419-5
- Hablitz, L. M., Vinitsky, H. S., Sun, Q., et al. (2019). Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Science Advances, 5(2), eaav5447. doi:10.1126/sciadv.aav5447
- Da Mesquita, S., Papadopoulos, Z., Dykstra, T., et al. (2021). Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature, 593, 255-260. doi:10.1038/s41586-021-03489-0
- Kim, J., et al. (2025). Meningeal lymphatics-microglia axis regulates synaptic physiology. Cell, 188(8), 2129-2148.e21. doi:10.1016/j.cell.2025.02.022
- Eide, P. K., & Ringstad, G. (2021). Sleep deprivation impairs molecular clearance from the human brain. Brain, 144(3), 863-874. doi:10.1093/brain/awaa443
- Lee, J.-C., Wang, C.-Y., Lin, C.-L., & Lu, H.-C. (2022). Synaptic memory survives molecular turnover. Proceedings of the National Academy of Sciences of the United States of America, 119(42), e2211572119. doi:10.1073/pnas.2211572119
- Shapson-Coe, A., Januszewski, M., Berger, D. R., et al. (2024). A petavoxel fragment of human cerebral cortex reconstructed at nanoscale resolution. Science, 384(6696), eadk4858. doi:10.1126/science.adk4858
- Finnema, S. J., Nabulsi, N. B., Eid, T., et al. (2016). Imaging synaptic density in the living human brain. Science Translational Medicine, 8(348), 348ra96. doi:10.1126/scitranslmed.aaf6667
- Naganawa, M., Nabulsi, N., Lin, S.-F., et al. (2021). First-in-human evaluation of 18F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. Journal of Nuclear Medicine, 62(4), 561-567. doi:10.2967/jnumed.120.249144
- Smart, K., Liu, H., Matuskey, D., et al. (2021). Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task. Journal of Cerebral Blood Flow & Metabolism, 41(5), 1067-1079. doi:10.1177/0271678X20946198
- Johansen, A., et al. (2024). An in vivo high-resolution human brain atlas of synaptic density. Journal of Neuroscience. doi:10.1523/JNEUROSCI.1750-23.2024
- Shatalina, E., et al. (2024). The relationship between SV2A levels, neural activity, and cognitive function in healthy humans. Imaging Neuroscience. doi:10.1162/imag_a_00190
- Holmes, S. E., Finnema, S. J., Naganawa, M., et al. (2022). Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry, 27(4), 2273-2281. doi:10.1038/s41380-022-01465-2
- Lucchetti, F., Céléreau, E., Steullet, P., et al. (2025). Constructing the human brain metabolic connectome with MR spectroscopic imaging reveals cerebral biochemical organization. Nature Communications, 16, 11344. doi:10.1038/s41467-025-66124-w
- Bhogal, A. A., Broeders, T. A. A., Morsinkhof, L., et al. (2020). Lipid-suppressed and tissue-fraction corrected metabolic distributions in human central brain structures using 2D 1H magnetic resonance spectroscopic imaging at 7 T. Brain and Behavior, 10(12), e01852. doi:10.1002/brb3.1852
- Wright, A. M., Murali-Manohar, S., & Henning, A. (2022). Quantitative T1-relaxation corrected metabolite mapping of 12 metabolites in the human brain at 9.4 T. NeuroImage, 263, 119574. doi:10.1016/j.neuroimage.2022.119574
- Baboli, M., Wang, F., Dong, Z., Dietrich, J., Uhlmann, E. J., Batchelor, T. T., Cahill, D. P., & Andronesi, O. C. (2024). Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging. Radiology, 312(3), e232401. doi:10.1148/radiol.232401
- Ren, J., Sherry, A. D., & Malloy, C. R. (2015). 31P-MRS of healthy human brain: ATP synthesis, metabolite concentrations, pH, and T1 relaxation times. NMR in Biomedicine, 28(11), 1455-1462. doi:10.1002/nbm.3384
- Ren, J., Sherry, A. D., & Malloy, C. R. (2017). Efficient 31P band inversion transfer approach for measuring creatine kinase activity, ATP synthesis, and molecular dynamics in the human brain at 7 T. Magnetic Resonance in Medicine, 78(5), 1657-1666. doi:10.1002/mrm.26560
- Guo, R., Yang, S., Wiesner, H. M., Li, Y., Zhao, Y., Liang, Z.-P., Chen, W., & Zhu, X.-H. (2024). Mapping intracellular NAD content in entire human brain using phosphorus-31 MR spectroscopic imaging at 7 Tesla. Frontiers in Neuroscience, 18, 1389111. doi:10.3389/fnins.2024.1389111
- Kaiser, A., Vind, F. A., Duarte, J. M. N., Jelescu, I., Lin, Y., Yu, X., Widmaier, M., Wenz, D., & Xin, L. (2026). Ultra-high field 31P functional magnetic resonance spectroscopy reveals NAD+ dynamics in brain energy metabolism during visual stimulation. Journal of Cerebral Blood Flow & Metabolism. doi:10.1177/0271678X261415784
- Qian, Y., Zhao, T., Zheng, H., Weimer, J., & Boada, F. E. (2012). High-resolution sodium imaging of human brain at 7 T. Magnetic Resonance in Medicine, 68(1), 227-233. doi:10.1002/mrm.23225
- Fleysher, L., Oesingmann, N., Brown, R., Sodickson, D. K., Wiggins, G. C., & Inglese, M. (2013). Noninvasive quantification of intracellular sodium in human brain using ultrahigh-field MRI. NMR in Biomedicine, 26(1), 9-19. doi:10.1002/nbm.2813
- Rodriguez, G. G., Yu, Z., O'Donnell, L. F., Calderon, L., Cloos, M. A., & Madelin, G. (2022). Repeatability of simultaneous 3D 1H MRF/23Na MRI in brain at 7 T. Scientific Reports, 12, 14156. doi:10.1038/s41598-022-18388-1
- Azilinon, M., Makhalova, J., Zaaraoui, W., et al. (2023). Combining sodium MRI, proton MR spectroscopic imaging, and intracerebral EEG in epilepsy. Human Brain Mapping, 44(2), 825-840. doi:10.1002/hbm.26102
- Qian, Y., Lin, Y.-C., Chen, X., Ge, Y., Lui, Y. W., & Boada, F. E. (2025). Single-quantum sodium MRI at 3 T for separation of mono- and bi-T2 sodium signals. Scientific Reports, 15, 27427. doi:10.1038/s41598-025-07800-1
- Rzechorzek, N. M., Thrippleton, M. J., Chappell, F. M., et al. (2022). A daily temperature rhythm in the human brain predicts survival after brain injury. Brain, 145(6), 2031-2048. doi:10.1093/brain/awab466
- Rogala, J., Dreszer, J., Sińczuk, M., Miciuk, Ł., Piątkowska-Janko, E., Bogorodzki, P., Wolak, T., Wróbel, A., & Konarzewski, M. (2024). Local variation in brain temperature explains gender-specificity of working memory performance. Frontiers in Human Neuroscience, 18, 1398034. doi:10.3389/fnhum.2024.1398034
- Tan, Y., Liu, W., Li, Y., Zhang, N., Wang, M., Sun, S., & Ma, L. (2025). Measurement of Healthy Adult Brain Temperature Using 1H Magnetic Resonance Spectroscopy Thermometry. Clinical Neuroradiology, 35(1), 159-164. doi:10.1007/s00062-024-01467-3
- Li, X., Zhu, X.-H., Li, Y., et al. (2025). Quantitative mapping of key glucose metabolic rates in the human brain using dynamic deuterium magnetic resonance spectroscopic imaging. PNAS Nexus, 4(3), pgaf072. doi:10.1093/pnasnexus/pgaf072
- Reimer, J., McGinley, M. J., Liu, Y., et al. (2016). Pupil fluctuations track rapid changes in adrenergic and cholinergic activity in cortex. Nature Communications, 7, 13289. doi:10.1038/ncomms13289
- Lohani, S., Moberly, A. H., Benisty, H., et al. (2022). Spatiotemporally heterogeneous coordination of cholinergic and neocortical activity. Nature Neuroscience, 25(12), 1706-1713. doi:10.1038/s41593-022-01202-6
- Neyhart, E., Zhou, N., Munn, B. R., et al. (2024). Cortical acetylcholine dynamics are predicted by cholinergic axon activity and behavioral state. Cell Reports, 43(10), 114808. doi:10.1016/j.celrep.2024.114808
- Hansen, J. Y., Shafiei, G., Markello, R. D., et al. (2022). Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. Nature Neuroscience, 25(11), 1569-1581. doi:10.1038/s41593-022-01186-3
- Goulas, A., Changeux, J.-P., Wagstyl, K., Amunts, K., Palomero-Gallagher, N., & Hilgetag, C. C. (2021). The natural axis of transmitter receptor distribution in the human cerebral cortex. Proceedings of the National Academy of Sciences USA, 118(3), e2020574118. doi:10.1073/pnas.2020574118
- Wong, D. F., Kuwabara, H., Hsu, D. J., et al. (2013). Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 229(2), 245-252. doi:10.1007/s00213-013-3103-z
- Koepp, M. J., Gunn, R. N., Lawrence, A. D., et al. (1998). Evidence for striatal dopamine release during a video game. Nature, 393(6682), 266-268. doi:10.1038/30498
- Lippert, R. N., Cremer, A. L., Edwin Thanarajah, S., et al. (2019). Time-dependent assessment of stimulus-evoked regional dopamine release. Nature Communications, 10, 336. doi:10.1038/s41467-018-08143-4
- Erritzoe, D., Ashok, A. H., Searle, G. E., et al. (2020). Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology, 45(5), 804-810. doi:10.1038/s41386-019-0567-5
- Baadsvik, E. L., Weiger, M., Froidevaux, R., Schildknecht, C. M., Ineichen, B. V., & Pruessmann, K. P. (2024). Myelin bilayer mapping in the human brain in vivo. Magnetic Resonance in Medicine, 91(6), 2332-2344. doi:10.1002/mrm.29998
- Arshad, M., Stanley, J. A., & Raz, N. (2017). Test-retest reliability and concurrent validity of in vivo myelin content indices: Myelin water fraction and calibrated T1w/T2w image ratio. Human Brain Mapping, 38(4), 1780-1790. PMC5342928
- Hagiwara, A., Hori, M., Kamagata, K., et al. (2018). Myelin Measurement: Comparison Between Simultaneous Tissue Relaxometry, Magnetization Transfer Saturation Index, and T1w/T2w Ratio Methods. Scientific Reports, 8, 10554. PMC6043493
- Chen, M., Tang, S., Chen, H., Zhou, Z., Rong, P., Lu, H., & Chen, W. (2025). Orientation-independent magnetization transfer imaging of brain white matter. NeuroImage, 309, 121456. doi:10.1016/j.neuroimage.2025.121456
- Galbusera, R., Weigel, M., Bahn, E., Schaedelin, S., Cagol, A., Lu, P.-J., et al. (2025). Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study. Brain Pathology, 35(5), e70010. doi:10.1111/bpa.70010
- Colaes, R., Radwan, A., Billiet, T., Cappelle, S., Peeters, R., Christiaens, D., et al. (2026). Evaluating the T1w/FLAIR ratio as a proxy for myelin: Associations with myelin water imaging, diffusion metrics, and cognition. Neuroradiology. doi:10.1007/s00234-025-03875-9
- Fultz, N. E., Bonmassar, G., Setsompop, K., Stickgold, R. A., Rosen, B. R., Polimeni, J. R., & Lewis, L. D. (2019). Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science, 366(6465), 628-631. doi:10.1126/science.aax5440
- Eide, P. K., Lashkarivand, A., Pripp, A. H., et al. (2023). Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders. Nature Communications, 14, 2084. doi:10.1038/s41467-023-37685-5
- Kim, D., Huang, Y., & Liu, J. (2025). Non-invasive MRI measurements of age-dependent in vivo human glymphatic exchange using magnetization transfer spin labeling. NeuroImage, 310, 121142. doi:10.1016/j.neuroimage.2025.121142
- Hirschler, L., et al. (2025). Region-specific drivers of cerebrospinal fluid mobility measured with MRI in humans. Nature Neuroscience, 28, 1115-1126. doi:10.1038/s41593-025-02073-3
- Lim, C., Chen, C., Zhang, C., et al. (2025). Human cerebrospinal fluid net flow enhanced by respiration during the awake state. Nature Communications, 16, 595. doi:10.1038/s41467-025-66548-4
- Yoo, R.-E., Kim, J.-H., Moon, H. Y., et al. (2025). Long-term physical exercise facilitates putative glymphatic and meningeal lymphatic vessel flow in humans. Nature Communications, 16, 3360. doi:10.1038/s41467-025-58726-1
- Dagum, P., et al. (2026). The glymphatic system clears amyloid-beta and tau from brain to plasma in humans. Nature Communications, 17, 715. doi:10.1038/s41467-026-68374-8